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CHAPTER I 
 
INTRODUCTION 
 
This dissertation describes the development of a self-contained biomarker 
extraction device designed to extract nucleic acids from patient samples in a format 
suitable for use in low resource settings.  The device relies on the dominance of surface 
tension forces over gravitational forces acting on fluids arrayed sequentially in a length 
of small diameter plastic tubing.  The surface tension holds these processing solutions in 
place while magnetic beads loaded with captured nucleic acids are pulled down the 
length of the tubing.   
The work is organized into seven chapters.  The first chapter summarizes the 
project’s specific aims.  The second chapter presents relevant background and 
significance for the project.  The third chapter details the initial proof-of-concept study for 
developing a low resource nucleic acid extraction device, “Development of a low 
resource RNA extraction cassette based on surface tension valves,” which was 
published in ACS Applied Materials and Interfaces in 2011.  The fourth chapter, “A 
magnetic bead-based method for concentrating DNA from human urine for downstream 
detection” was published in PLOS ONE in 2013, and describes the development of a 
patient sample-extraction cassette interface for recovering DNA from human urine 
samples.  The fifth chapter, “Automated extraction of nucleic acid and protein biomarkers 
using surface tension valves,” describes the development and testing of an automated 
biomarker extraction processor and is in the process of being submitted for publication.  
The sixth chapter evaluates the impact of magnetic bead surface functionalization on 
extraction simplicity, speed, and nucleic acid recovery and offers suggestions for 
choosing the ideal surface functionalization.  This chapter, “The effects of magnetic bead 
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surface functionalization on nucleic acid extraction and detection,” is in the process of 
being submitted for publication.  The seventh and final chapter provides the project’s 
conclusions and suggestions for future work. 
 
Specific Aim 1:  Optimize the RNA capture, wash and elution steps to improve 
RNA recovery efficiency.    
 
 
 
The goal of this aim is to evaluate the RNA-silica capture, processing, and elution 
steps to improve RNA recovery to levels comparable to the laboratory gold-standard 
RNA extraction kit.  In addition, the advantages of the silica-based RNA capture method 
are compared to an mRNA-specific, and nucleic acid-sequence specific capture method 
to evaluate their suitability for use in low resource settings.  RNA recovery, total 
processing time, assay simplicity and toxicity, and available downstream detection 
modalities are considered for each bead functionality tested. Based on these 
comparisons the optimal situation for each bead type is identified.  
 
Specific Aim 2:  Develop and incorporate a patient sample-extraction cassette 
interface for sample loading into the small diameter tubing.   
 
 
 
The goal of this aim is to develop a simplified interface for incorporating patient 
samples directly into the small diameter tubing for processing.  Nucleic acid-silica 
adsorption buffer and magnetic beads are lyophilized within the bulb of a polypropylene 
transfer pipette, which serves as a biomarker capture chamber.  The patient sample is 
collected with the transfer pipette and subsequently introduced into the extraction tubing 
following biomarker capture.  This device eliminates the need for pipettors and 
disposable pipette tips and reduces the total number of steps required to prepare the 
sample for introduction into the small diameter tubing of the extraction cassette. 
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Specific Aim 3:  Design a DNA extraction assay to recover DNA from human urine 
samples in the extraction cassette.   
 
 
 
The goal of this aim is to design and test a DNA extraction assay for processing 
human urine in the low resource extraction cassette.  The magnetic beads, small 
diameter tubing, and DNA capture, wash and elution steps are modified to maximize 
recovery of spiked Mycobacterium tuberculosis DNA from pooled TB negative human 
urine samples.  The patient sample-extraction cassette interface designed in Aim 2 is 
used to handle and transfer urine samples during processing.  The urine sample 
interface in combination with the small diameter tubing successfully recovered spiked TB 
DNA biomarkers from human urine samples. 
 
Specific Aim 4:  Evaluate an automated extraction cassette processor.  
 
 
  
The goal of this aim is to test an automated biomarker extraction cassette 
processor as an alternative to manual nucleic acid extractions performed in the small 
diameter tubing.  The automated processor was tested on a bank of well-characterized 
patient sample surrogates prepared by PATH including Escherichia coli infected human 
urine, Mycobacterium tuberculosis infected synthetic sputum, and Plasmodium 
falciparum infected human blood culture.  Nucleic acid and protein biomarkers were 
successfully recovered from the sample surrogates.   
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CHAPTER II 
 
BACKGROUND AND SIGNIFICANCE 
 
Infectious Disease Diagnosis in Low Resource Settings 
Accurate and rapid detection of disease biomarkers is essential for efforts to 
control the spread of infectious diseases [1].  At well-equipped clinics and hospitals, 
diagnostic technologies include culture of the organism-of-interest, microscopy, 
antibody-based antigen detection by ELISA, and nucleic acid amplification and detection 
by PCR.  However, often the highest infectious disease burden is found in low-income 
developing countries where the availability of electricity and clean water is, at best, 
intermittent.  In the poorest of these countries, over 50% of deaths are caused by 
infectious diseases [2].  Due to the poor infrastructure across these low income countries 
many patients find it difficult or impossible to reach centralized hospitals and clinics and 
instead rely on small health posts that serve rural villages and townships.  In all of these 
healthcare settings, basic laboratory supplies may be available, but workers often have 
little to no training and are incapable of maintaining or repairing sophisticated equipment.  
Often, infectious samples are handled by workers who have no personal protective 
equipment [2].  Due to the lack of basic resources, and the difficulty many patients have 
in reaching the nearest health center or hospital, there is a dire need for rapid, 
inexpensive, easy-to-use diagnostics that can be safely and effectively utilized under 
these conditions.   
 In an attempt to improve healthcare in low resource settings, there is a 
widespread effort to expand the utility of current clinical diagnostic modalities by 
adapting them to perform with minimal training, equipment, and other resources [1,3].  
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Nucleic acid amplification technologies such as PCR are ideal for this effort due to their 
inherent sensitivity, specificity, and relatively rapid time-to-answer [4].  Significant 
resources have been poured into adapting PCR-based detection strategies into a self-
contained point-of-care format for use in low resource settings [1,5,6].  One or more of 
these advantages are frequently sacrificed in other diagnostic modalities such as cell 
culture and ELISA.  Cell culture is often highly sensitive and specific, but requires cell 
growth periods several days to weeks long, highly trained technicians, and large 
quantities of disposable laboratory supplies.  ELISA and other antibody-based methods 
provide relatively short time-to-result, but offer a lower sensitivity compared to PCR.  
Antibodies also require consistent cold storage to maintain stability. 
 
Sample Preparation in Low Resource Settings 
Patient samples contain inhibitors that directly interfere with nucleic acid 
amplification and detection during PCR.  Therefore, PCR often cannot be performed 
directly on unprocessed patient samples [7-9].  The removal of PCR inhibitors present in 
patient samples represents a significant roadblock to the widespread use of PCR as a 
low resource diagnostic.  Sample preparation techniques that remove contaminants 
such as carbohydrates, proteins, and lipids from a variety of patient sample matrices 
must be adapted to work under less than ideal conditions.  These inhibitors can prevent 
the amplification or detection of target nucleic acid sequences [7,9-11].  Patient samples 
frequently contain nucleases which, over time reduce the number of target nucleic acids 
present in the samples [10].  Failure to consistently extract nucleic acids from complex 
sample matrices for downstream detection is one of the greatest limitations to the 
widespread use of genetic diagnostic modalities in low resource settings [1].   
In a laboratory setting, there are several effective methods for preparing patient 
samples for downstream PCR.  One traditional laboratory method uses a guanidinium 
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thiocyanate (GuSCN)-phenol-chloroform cocktail to extract nucleic acids [12].  During 
the extraction, the mixture separates into an upper aqueous phase containing RNA and 
a lower organic phase containing DNA.  This is an efficient technique for the selective 
extraction of nucleic acids, however, the protocol requires approximately an hour to 
obtain a purified sample [13].  Completion of the extraction also requires direct handling 
of toxic chemicals and specialized equipment.  Additionally phenol is a well-known 
inhibitor of PCR and must be subsequently removed from the sample prior to analysis. 
Solid phase nucleic acid extractions are used more frequently than traditional 
GuSCN-phenol-chloroform separations to extract nucleic acids from patient samples 
[13].  Silica and chitosan are two examples of solid phases useful for nucleic acid 
extractions.  Both silica and chitosan are used to selectively purify total nucleic acids 
from patient samples by relying on electrostatic interactions between nucleic acids and 
the solid phase.  For example, in the presence of a strong chaotropic agent such as 
GuSCN, nucleic acids selectively adsorb to silica surfaces via a salt bridge [14,15].  As a 
result of this interaction, silica-based surfaces are frequently used to capture nucleic 
acids from complex samples and subsequently elute them into a pure solution 
compatible with PCR. 
The relative simplicity of solid phase extractions is widely exploited in commercially 
manufactured kits that consistently extract nucleic acids in as little as 10-15 minutes.  
Kits such as the Qiagen RNeasy and DNeasy Mini Prep kit and Norgen Urine Extraction 
kit rely on silica matrices packed into centrifugation columns.  Other kits such as the 
Qiagen MagAttract Mini Prep kit and Dynabeads MyOne silane kit utilize silica-coated 
magnetic particles that can be easily manipulated in the required wash buffers using a 
magnetic field, applied either with a robot or by hand.  Despite their efficacy in laboratory 
settings, these commercially available kits are relatively expensive, requiring trained 
personnel with access to pipettors, large quantities of disposable supplies, and 
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specialized equipment such as laboratory centrifuges and automated robots.  
Additionally, all of the kits require multiple pipetting steps that potentially expose the 
technician to dangerous infectious agents.  This is particularly problematic in settings 
where the technician is untrained and appropriate personal protective equipment is in 
limited supply. 
 Recently there has been a growing interest in developing microfluidic 
technologies for sample preparation [16].  Microfluidic devices overcome many of the 
limitations of traditional, laboratory-based nucleic acid extraction kits.  These devices are 
self-contained, decreasing the chance for contamination of both the sample and 
operator.  The extractions are automated, reducing the skill required for operation.  
Additionally, many of these devices are suitable for integration with downstream nucleic 
acid amplification and detection technologies [17].  Many microfluidic devices rely on the 
selective adsorption of nucleic acids to a silica surface in the presence of chaotropic 
salts.  Groups have utilized silica-coated microchannels, posts, and embedded 
microparticles as the solid phase within the microchannels [18-20].  The sample and 
subsequent washing buffers are then flowed through the microchannels to complete the 
nucleic acid extraction. 
Though many of these technologies boast a high efficiency for nucleic acid 
extraction, microfluidic devices historically suffer from poor reproducibility and require 
bulky external equipment for operation [21].  The small diameter of the microfluidic 
channels results in a limited solid phase surface area available for nucleic acid 
adsorption, restricting the total sample volume that can be flowed through the chip.  This 
is problematic for processing samples greater than ~500 uL in volume [1]. 
Recently, several non-microfluidic approaches have been described.  Sur and 
coworkers developed a technique called ‘immiscible phase nucleic acid purification’ by 
which nucleic acids bound to magnetic particles are pulled from the nucleic acid capture 
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solution through a single layer of an immiscible hydrophobic liquid [22].  According to this 
report, the passage of particles through the fluid interface removes loosely bound 
contaminants.  The beads are pulled through the hydrophobic layer directly into an 
elution buffer.  The maximum patient sample volume that can be extracted is limited by 
the small size of the sample lysis/binding chamber and is ~200 uL.  This concept was 
more recently adapted to a horizontal channel format with multiple extractions performed 
in parallel on a microtiter plate [23].  However, sample volume is limited to 10 uL in this 
configuration, and the sample is exposed to the air increasing the likelihood of operator 
exposure.  
 
Prevalence of Tuberculosis in Low Resource Settings 
Improving sample preparation to better enable diagnostics in resource limited 
settings would positively impact global health and improve the burden of many infectious 
diseases.  Tuberculosis is one major infectious disease whose burden could be 
significantly reduced by the introduction of a rapid, easy to use diagnostic suitable for 
use in low resource settings.   In 2012 an estimated 8.6 million people developed TB 
resulting in 1.3 million deaths.  It is estimated that one third of the world’s population is 
infected with the latent form of TB, most of these infections occurring in low income 
countries in South-East Asia, Africa and the Western Pacific [24].  Though the incidence 
of drug resistant TB disease is increasing, particularly in Eastern Europe and Central 
Asia, the treatment for greater than 90% of TB cases has been widely available for 
decades.  Despite the availability of treatment, the high TB prevalence and mortality rate 
remain unacceptably high underscoring the dire need for low resource-appropriate 
diagnostics [25]. 
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Diagnosis of Tuberculosis in Low Resource Settings 
  Worldwide, the most common method for diagnosing TB infection is sputum 
smear microscopy, a technique developed over 100 years ago.  As a diagnostic, sputum 
smear microscopy offers low sensitivity and no means to determine drug susceptibility of 
the particular strain [25,26].  The smears are often prepared and handled by personnel 
with poor access to personal protective equipment, increasing the risk of spreading the 
infection.  Despite its status as the most common TB diagnostic, many countries with the 
highest TB burden have less than 1 microscopy center per 100,000 people [24].    
Mycobacterium tuberculosis culture is the worldwide reference standard for TB 
diagnosis.  However, due to the need for well-equipped laboratories and trained 
technicians, cell culture is not widely available in many of the areas with the highest TB 
burden.  Cell culture results take weeks to obtain, limiting its use in diagnosing patients 
who do not live in areas where they can conveniently return to health centers for their 
results, treatment, and monitoring of disease progression [5]. 
The Cephiad GeneXpert was developed as a self-contained module that 
performs nucleic acid extraction, amplification, and detection within a single cartridge 
inserted into the device.  The cartridges were designed specifically to extract 
Mycobacterium tuberculosis DNA from sputum samples [1].  To perform the assay, a 
technician thoroughly mixes the collected sputum sample with a proprietary sample 
treatment reagent to neutralize any live bacteria and incubates the sample at room 
temperature prior to inserting the cartridge into the GeneXpert.  M. tuberculosis lysis, 
and nucleic acid extraction, amplification, and detection are automatically performed 
within the GeneXpert without any further user intervention.  The GeneXpert has been 
fully endorsed by the World Health Organization (WHO) for use in low resource settings 
due to its excellent sensitivity and specificity, as well as its capability to identify multi-
drug resistant tuberculosis [27]. 
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 Despite the WHO endorsement, the GeneXpert still does not fully meet the 
requirements for use in low resource settings.  The instrument and disposable cartridges 
are both expensive.  Maintenance plans are also costly, and the complexity of the 
instrument leads to frequent, costly breakdowns.  In many cases, clinics and hospitals 
cannot afford the repairs, and the instrument goes unused.  Additionally, sputum is not 
an ideal patient sample matrix due to the high risk of spreading infection during its 
collection and subsequent processing.  It can also be difficult to obtain a useable sputum 
sample, particularly from children who are frequently incapable of producing sputum 
[26]. 
 
Transrenal DNA as a Biomarker for Tuberculosis Detection in Urine 
Despite the advantages offered by the Cephiad GeneXpert, scientists are still 
seeking alternative TB biomarkers and diagnostics.  One promising biomarker is TB 
DNA present in human urine, referred to as transrenal DNA (Tr-DNA).  The analysis of 
transrenal DNA (Tr-DNA) for diagnosis of TB is an attractive alternative to traditional 
diagnostic methods requiring sputum collection.    Urine is an ideal patient sample matrix 
due to the relative ease of collection and a significantly reduced risk for spreading 
infection.  Large volumes of urine can be collected during a single visit, and the use of 
urine is often more acceptable to the patient [28].   
Tr-DNA is thought to originate from cells and organisms that break down within 
the body.  Botezatu et al. injected mice with both radiolabeled DNA and irradiated 
human cancer cells and detected DNA from both sources in the animals’ urine using 
scintillation counting and PCR, respectively.  In the same study, the group detected male 
DNA in women transfused with male blood as well as women pregnant with male 
fetuses, suggesting the permeability of the kidney to short 10-150 bp DNA fragments is 
possible in both mice and humans [29].  The study results suggest that when circulating 
11 
 
nucleic acids present in the bloodstream due to cellular death within the body enter the 
kidney, there is some level of permeability to the smaller fragments.  These fragments 
are not filtered out, but subsequently pass through the kidney and are excreted in the 
urine [28-30].  The nucleic acid background in human urine has been shown to vary from 
~40-250 ng/mL [31].  Melkonyan et. al. used gel electrophoresis to demonstrate the 
presence of two populations of human DNA in urine.  The first was a population of large 
(>5000 bp) fragments likely from cells that died within the urinary tract.  The second 
population was generally shorter than 250 bp with the majority ranging from ~10-150 bp 
[32]. 
Based on the promise of a noninvasive urine diagnostic, scientists have studied 
the potential use of Tr-DNA for TB detection.  To date, several of these studies have 
been completed in an attempt to determine the frequency at which TB DNA can be 
detected.  These studies have suggested that human urine contains DNA fragments 
long enough to be of diagnostic value, and have detected TB-specific sequences in 
multiple studies [33-35].  Whether TB TR-DNA fragments are present in high enough 
concentrations to be consistently detectable is controversial despite the handful of 
studies that examine human urine for such fragments.  The majority of studies utilize 
PCR followed by gel electrophoresis to detect ~100 bp sequences cleaved from the 
1350 bp IS6110 insertion sequence of Mycobacterium tuberculosis which has been 
shown to repeat as many as 25 times per genome [36].  Both the sensitivity and 
specificity of biomarker detection range from 7-100% [26].  In many of the studies, the 
sample volume and storage conditions are never described, and several different nucleic 
acid extraction methods are utilized.  The most promising study, performed by Aceti et. 
al. with 13 urine samples, yielded 100% sensitivity and specificity [33].  However, a 
nucleic acid extraction method is not described, no starting urine volume is provided, 
and no figures supporting the results are shown.  Despite the potential benefit a TB Tr-
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DNA biomarker would yield in efforts to control TB in low resource settings, the lack of 
standardization in urine storage and testing across multiple studies has severely limited 
its use to date. 
Another controversial factor in the use of Tr-DNA for diagnostic purposes is the 
post-collection sample treatment required to protect the DNA from degradation.  Human 
urine has been shown to have DNase I and II activity which could degrade any DNA 
biomarkers present in the urine both before and after sample collection [37,38].  Despite 
the high potential for biomarker degradation, there is no standardized method for urine 
sample handling prior to biomarker extraction and detection.   Several groups have 
added EDTA to freshly collected urine samples in an attempt to inhibit nuclease activity 
and prevent nucleic acid degradation.  In many studies, the addition of EDTA appears to 
minimize nuclease activity [39-41].  However the samples are treated differently across 
the studies, including the use final EDTA concentrations ranging from 10-40 mM.  
Without a consistent sample handling treatment across multiple studies it is difficult to 
definitively identify the ideal urine sample handling conditions.   
The extreme day-to-day variability of human urine represents another significant 
roadblock to standardizing Tr-DNA analysis.  The composition of human urine varies 
depending on diet and hydration.  A normal adult produces 1-2 liters of urine in a 24 hr 
period, with a pH range between 4.6 and 8.  Typically, 95% of urine is composed of 
water.  The majority of the solid components of urine are urea and creatinine, though 
there are also varying concentrations of sodium, potassium, magnesium, and calcium.  
There can also be small amounts of enzymes, carbohydrates and hormones [42].  The 
high variability of human urine can make it difficult to compare studies performed in 
separate countries, or even in various settings within a single country.   
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Nucleic acid extraction using a self-contained cassette 
 Despite the controversy surrounding the use of Tr-DNA as a reliable biomarker 
for TB detection, it remains an attractive alternative to more complex diagnostic 
modalities such as Cephiad’s GeneXpert sputum processing.  As with many low 
resource diagnostics, the first major hurdle to developing a suitable TB diagnostic is the 
sample preparation step [1].  Without an initial nucleic acid extraction step, nucleic acids 
are not detectable in urine by PCR [43].  A sample preparation device with the flexibility 
to reliably extract nucleic acid biomarkers from a variety of patient sample matrices 
would greatly improve the potential impact nucleic acid-based diagnostics could make 
towards controlling infectious diseases in low resource settings.   For example, a 
technology that could efficiently extract both RNA and DNA biomarkers from a variety of 
biologically complex sample matrices with differing volumes would be a welcome 
improvement over expensive, complex technologies that are limited in their flexibility to 
detect more than a single pathogen.   
 Functionalized magnetic particles are an ideal tool for achieving the desired 
flexibility.  The particle surface can be functionalized with a variety of surface 
modifications to selectively capture the biomarker of choice.  For example, both DNA 
and RNA adsorb to silica-coated surfaces, while the poly A tails on mRNA will hybridize 
to surfaces functionalized with oligo (dT) DNA probes.  An additional advantage of using 
magnetic particles is that they can be easily manipulated using a magnetic field.  This 
ease of manipulation means magnetic beads can be used in a wide variety of formats.  
This additional flexibility makes magnetic beads the ideal choice for use in a low 
resource extraction technology. 
 We have developed a nucleic acid extraction device suitable for operation in low 
resource settings by taking advantage of the flexibility offered by magnetic beads in 
addition to the surface tension forces experienced by fluids arrayed in a length of small 
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diameter tubing.  When multiple liquids arrayed in small diameter tubing are separated 
from one another by small air valves, these liquid/air interfaces remain in place even as 
magnetic beads are pulled through them with an external magnet [43-46].  This 
phenomenon allows an inexpensive piece of small diameter plastic tubing to serve as a 
self-contained device inside which the entire nucleic acid extraction occurs.  An external 
permanent magnet is the only required processing equipment.  The process involves 
three simple steps:  1) Individual processing solutions required for each extraction are 
pre-arrayed within the small diameter tubing; 2) Nucleic acids are captured onto the 
surface of magnetic particles within an external chamber; 3) Captured nucleic acids are 
washed by pulling the magnetic particles through the arrayed wash solutions and eluted 
in the final chamber.   
 The flexibility of this design has been demonstrated by extracting viral RNA from 
nasopharyngeal swab samples [44] and DNA from urine samples [43].  Additionally, the 
advantages offered by changing of magnetic bead surface functionalization were 
identified by extracting viral RNA using magnetic beads designed to capture total RNA, 
mRNA, and respiratory syncytial virus (RSV) N gene mRNA.  Coupled with a low 
resource diagnostic device, the extraction cassette has the potential to improve the 
quality of healthcare available in poorly equipped areas by providing a user friendly 
method to quickly and effectively diagnose disease.   
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Abstract 
Nucleic acid-based diagnostics are highly sensitive and specific, but are easily 
disrupted by the presence of interferents in biological samples.  In a laboratory or 
hospital setting, the influence of these interferents can be minimized using an RNA or 
DNA extraction procedure prior to analysis.  However, in low resource settings, limited 
access to specialized instrumentation and trained personnel presents challenges that 
impede sample preparation.  We have developed a self-contained nucleic acid extraction 
cassette suitable for operation in a low resource setting.  This simple design contains 
processing solutions preloaded within a continuous length of 1.6 mm inner diameter 
Tygon tubing.  Processing solutions are separated by air gaps and held in place during 
processing by the surface tension forces at the liquid-air interface, viz. surface tension 
valves.  Nucleic acids preferentially adsorbed to silica-coated magnetic particles are 
separated from sample interferents by using an external magnet to transfer the nucleic 
acid biomarker through successive solutions to precipitate, wash and elute in the final 
cassette solution.  The efficiency of the extraction cassette was evaluated using 
quantitative reverse transcriptase PCR (qRT-PCR) following extraction of respiratory 
syncytial virus (RSV) RNA. RNA was recovered from TE buffer or from lysates of RSV 
infected HEp-2 cells with 55 and 33% efficiency, respectively, of the Qiagen RNeasy kit.  
Recovery of RSV RNA from RSV infected HEp-2 cells was similar at 30% of the RNeasy 
kit.  An overall limit of detection after extraction was determined to be nearly identical 
(97.5%) to a laboratory-based commercially available kit.  These results indicate that this 
extraction cassette design has the potential to be an effective sample preparation device 
suitable for use in a low resource setting.   
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Introduction 
Recent research has focused on the development of nucleic acid-based 
detection for low resource settings [1].  Nucleic acid-based detection systems, such as 
quantitative PCR (qPCR), are particularly attractive technologies for detection of 
pathogens because of their sensitivity, specificity and relatively rapid time-to-answer.  
The effectiveness of PCR is dependent on both the quality and quantity of nucleic acid 
template [2] and the absence of interferents [3].  For example, carbohydrates, proteins, 
lipids or other unidentified interferents present in clinical samples have all been shown to 
inhibit PCR and produce false negatives [4-6].  In addition to various interferents, patient 
samples also contain nucleases, which directly reduce the number of nucleic acid 
targets present [5].   
To minimize false negatives and maximize the efficiency of nucleic acid-based 
diagnostics, nucleic acids are extracted and concentrated into an interferent-free buffer 
prior to testing.  One classic laboratory method uses a phenol-chloroform cocktail [7].  
This method is highly effective, but is not as commonly utilized today because it is time 
consuming and requires the use of toxic organic chemicals.  Several solid phase 
extraction kits are commercially available to purify DNA or RNA from patient samples.  
Many of these kits rely on selective nucleic acid binding to silica-coated surfaces in the 
presence of ethanol and a chaotropic agent such as guanidinium thiocyanate (GuSCN) 
[8,9].  GuSCN also denatures protein contaminants including nucleases that may be 
present in the sample [10,11].  These kits are not cost effective for low resource use and 
often require the use of specialized laboratory equipment, such as a robot or centrifuge, 
and trained technicians that are unavailable in a low resource setting.  Additionally, 
many involve multiple steps that increase the chance of contamination of both the 
sample and operator. 
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Microfluidics is one promising format for low resource nucleic acid-based 
diagnostics.  Recently, there has been a growing interest in expanding microfluidic 
technologies for sample preparation [1,12].  Many of these devices are suitable for 
integrating with downstream nucleic acid amplification and detection technologies 
[13,14].  However, the small surface area of solid phase available for nucleic acid 
binding and the limited sample volume that can be flowed through the channels limit the 
total mass of nucleic acid recovered [1], and therefore negatively impact the limit of 
detection.   
We have developed an alternative nucleic acid extraction cassette suitable for 
operation in a low resource setting.  This self-contained extraction cassette is preloaded 
with processing solutions separated by air gaps, which we refer to as “surface tension 
valves.”  In proof-of-principle RNA extraction studies, RSV infected cells are lysed and 
viral RNA is selectively adsorbed to silica-coated magnetic particles in the presence of 
GuSCN and ethanol.  Individual processing solutions are preloaded into a single 
continuous length of Tygon tubing and are separated from one another and held in 
places by surface tension forces.  Removal of interferents is achieved by selective RNA 
adsorption to silica-coated magnetic particles which are then pulled through each 
processing solution using an externally applied magnetic field.  RNA is eluted from the 
surface of the magnetic particle in the final solution.  This report describes the general 
characteristics of this approach and compares its performance to laboratory-based 
commercial kits.   
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Materials and Methods 
 
Preparation of RSV N gene RNA standards.   
Because our laboratories have experience with respiratory syncytial virus (RSV) 
detection, we have chosen to develop our extraction cassette using RSV RNA.  
Escherichia coli DH5α transformed with the pGBKT7 vector containing RSV N gene was 
generously provided by the Crowe Laboratory at Vanderbilt University.  E. coli were 
grown for 18 hours on kanamycin agar plates at 37 °C.  A single colony was isolated and 
transferred into 25 mL of Miller’s LB broth with 50 ug/mL kanamycin antibiotics and 
grown overnight on a rotating rack at 37 °C to an optical density of 0.6-0.8 AU.  The 
plasmid was extracted using a Qiagen Spin Miniprep Kit and linearized using the BssHII 
restriction enzyme.  Linearization was confirmed by running both pre- and post-
linearized plasmids on a 1% agarose gel.  Linearized plasmid was recovered from the 
restriction digest by ethanol precipitation.  The plasmid was then transcribed into RNA 
using a T7 MEGAscript transcription kit (Ambion, Austin, TX), and treated with DNase I.  
The expected RNA length was confirmed on a denaturing 2%-formaldehyde-1.2% 
agarose gel.  The RNA was quantified by UV-Vis spectroscopy.   
 
Preparation of RSV infected and uninfected HEp-2 cell lysates.  
Uninfected HEp-2 cell lysates were prepared from a confluent monolayer of HEp-
2 cells from a T-150 flask. The cells were harvested by scraping from the T150 flask and 
centrifuging at 500 x g for 5 minutes. The pellet was resuspended into 8 mL denaturing 
solution (4 M guanidinium thiocyanate, 25 mM sodium citrate [pH 7.0] 0.5% N-
laurosylsarcosine [Sarkosyl], 0.1 M 2-mercaptoethanol) and passed through a pipette tip 
10 times. The cell lysates were stored at a concentration of approximately 3 x 106 lysed 
cells per mL in 1 mL aliquots at -80 °C. 
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Infected HEp-2 cell lysates were prepared by infecting confluent monolayer of 
HEp-2 cells in two T150 flasks with RSV strain A2. After 4 days, one flask was harvested 
as described above and used to perform RSV RNA extractions from HEp-2 lysates. A 
plaque assay was performed on the second flask to quantify the concentration of 
infectious particles.  To prepare the assay, cells were scraped from the T150 flask and 
centrifuged at 500 x g for 5 minutes.  The pellet was resuspended into 8 mL of media, 
and cells were lysed by 3 cycles of freezing in an ethanol and dry ice slurry and thawing 
in a 37 °C water bath. The cell lysate was centrifuged at 100 x g for 5 minutes, and the 
supernatant was stored at -80 °C in 1 mL aliquots.  
One hundred uL of the lysed cells was serially diluted, and each dilution added in 
triplicate to a confluent monolayer of HEp-2 cells in a 24-well plate. Plates were 
incubated at 37 °C for 1 hour.  One mL of sterile 0.75% methyl cellulose (w/v) was then 
added to each well and the plate was placed at 37 °C for an additional 4 days. The 
infected HEp-2 cells were fixed in 80% methanol at -20 °C for 1 hour, washed 3 times 
with PBS, and blocked with a 5% milk solution for 1 hour. One hundred fifty µL of 30 
µg/mL anti-F protein primary antibody in 5% powdered milk solution was added to each 
well. After 1 hour, wells were washed 3 times with PBS, and 150 µL of 0.5 µg/mL anti-
mouse IgG HRP conjugate secondary antibody (Promega, Madison, WI) in 5% 
powdered milk solution was added for 1 hour.  Wells were washed 5 times with PBS and 
150 µL of TrueBlue peroxidase substrate (KLP, Gaithersburg, MD) added for 20 minutes 
at room temperature.  Punctate blue plaques were counted and averaged, and the 
plaque forming units (pfus) were determined by multiplying by the dilution factor. 
 
Conversion of RSV N gene RNA copy number to pfu/mL reported in clinical literature.   
The number of pfu/mL of the RSV infected HEp-2 cell lysates was converted to 
RSV N gene copies/uL by comparing qRT-PCR and plaque assay results on each half of 
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a split culture of infected Hep-2 cells harvested 4 days post-infection, the point at which 
peak titers are reached.  The concentration of N gene RNA in copies/uL was determined 
by RT-PCR using a standard curve following RNA extraction with the RNeasy kit.  A 
calculated extraction efficiency of 18.1% (see section 3, Figure 4B) was assumed to 
determine the total number of RNA copies present in the sample prior to extraction.  The 
number of N gene copies/pfu was approximated by dividing the total number of RNA 
copies/uL by the number of pfu/mL and determined to be ~104 copies/pfu. 
 
Quantitative RT-PCR.   
An 82-bp fragment of the RSV N gene was amplified using forward primer 5’-
GCTCTTAGCAAAGTCAAGTTGAAATGA-3’ and reverse primer 5’-
TGCTCCGTTGGATGGTGTATT-3’ [15].  Reactions were performed in a 25 μL volume 
using 5 μL of RNA template and the Clontech one-step RT-PCR kit according to 
manufacturer’s instructions.  Thermal cycling consisted of 48 °C for 20 minutes to 
synthesize cDNA, 95 °C for 3 minutes to inactivate the reverse transcriptase and 
activate QTaq DNA polymerase, and 40 cycles of 95 °C for 15 s and 60 °C for 60 s using 
a Rotor-Gene Q thermal cycler (Qiagen, Germantown, MD).  Product specificity was 
confirmed using melting curve analysis and gel electrophoresis.  Data was collected and 
Ct values recorded by Rotor-Gene Q Software (Qiagen, Germantown, MD) and 
converted to number of copies of RNA per μL using a standard curve.   
 
RNA extraction using prototype capillary extraction cassette.   
A prototype extraction cassette (Figure 1) was constructed from glass capillary 
tubes and pipette tips.  Glass capillary chambers (2 mm i.d.) were cut from stock tubing 
into 80 mm lengths, and the ends were flared outward.  Six capillary chambers were 
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aligned linearly on the top of a horizontal aluminum stage using machined aluminum 
mounts. 
 
 
 
A 1000 μL pipette tip was placed as a spacer in between each capillary chamber with 
the wide end of the pipette tip around the preceding capillary chamber and the narrow 
end resting inside the flared region of the next capillary chamber.  Thus successive 
processing chambers were separated from one another by air spacers within the pipette 
tips.  The first capillary chamber was reserved for the RNA sample and was initially left 
empty.  The remaining chambers were preloaded with the processing reagents supplied 
in the MagAttract RNA Cell Mini M48 kit (Qiagen, Germantown, MD) as follows: 200 μL 
of “Buffer MW” wash buffer, 200 μL “Buffer RPE” wash buffer, 200 μL “Buffer RPE” wash 
 
Figure 1.  Design of the prototype extraction method showing the 
processing solutions held in place in glass tubing and separated 
by air-filled pipette tips.  RNA is adsorbed to silica-coated 
magnetic particles which are pulled left to right through 
successive processing chambers using an external magnet.  
Following processing, the RNA is eluted in a final water chamber. 
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buffer, 200 μL RNase/DNase free water, 30 μL RNase/DNase free water heated to 65 
°C for elution of RNA.  Thirty μL of sample was added to 150 μL of “Buffer RLT” and 
homogenized by passage through a 20-gauge needle five times.  Twenty μL of the 
MagAttract bead solution (Qiagen, Germantown, MD) was added to the homogenized 
sample, vortexed, and placed on a rotary mixer for 5 minutes at room temperature.  The 
sample was then pipetted into the first chamber, shown on the left in Figure 1.  A 2.54 
cm cube of grade 40 NdFeB magnet (National Imports, Vienna, VA) was placed adjacent 
to the first capillary chamber and slowly pulled parallel to the chambers at a rate of ~4 
mm/second to pull the magnetic beads through each of the processing chambers.  The 
total pull-through time was ~2 minutes.  After reaching the final elution chamber, the 
beads were held to one side by the magnet and the eluent was collected.   
This initial design was used to perform proof-of-principle studies using 14 frozen 
de-identified nasal wash samples provided by Dr. John Williams’ lab (Vanderbilt 
University Hospital, Nashville, TN).  Use of specimens was approved by Vanderbilt 
University’s IRB.  At the time of collection, nasal swabs were placed in opti-MEM media 
(Invitrogen, Oslo, Norway) and frozen at -80 °C.  Each sample was characterized by 
Williams’ lab for respiratory syncytial virus (RSV) using RT-PCR after an extraction using 
Roche Total Nucleic Acid Extraction Kit (Basel, Switzerland). RT-PCR was performed 
using Roche LC Magna Pure machine (Basel, Switzerland).  We obtained samples 
which tested positive for RSV as determined by a calculated cycle threshold (Ct).  We 
also obtained samples which tested negative for RSV as determined by no calculated 
cycle threshold value within the cycles that were performed.  Seven samples 
characterized as RSV positive and seven as RSV negative were selected at random.  
Frozen samples were briefly thawed, divided and refrozen as 100 µL aliquots to facilitate 
comparison across different RNA extraction methods. 
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The number of extracted RSV N gene RNA copies/μL was calculated for the 7 
RSV positive and 7 RSV negative nasal wash samples after 4 different extraction 
methods using a standard curve.  The recovery efficiency of RNA extraction was 
compared to the RNeasy Mini kit (Qiagen, Germantown, MD), Dynabeads mRNA Direct 
kit (Invitrogen, Oslo, Norway) used according to manufacturer’s protocols, as well as the 
MagAttract RNA Cell Mini M48 kit (Qiagen, Germantown, MD) performed manually 
instead of with the Qiagen M48 BioRobot which was unavailable for these studies. The 
results were also compared to the calculated copy numbers of RSV N gene RNA 
detectable in each sample directly amplified by RT-PCR prior to extraction.  For each 
extraction method utilized, RNA was eluted in a 50 μL volume to ensure that RT-PCR 
analysis was comparable across all extraction methods tested. 
 
RNA extraction from TE buffer and HEp-2 cell lysates using continuous tubing extraction 
cassette.   
 
The initial prototype design of Figure 1 was further simplified into a continuous 
tubing design shown in Figure 2. 
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In this design, 8 processing solutions were preloaded within ~61 cm length of Tygon 
tubing (1.6 mm i.d.).  These solutions were chaotropic wash buffer (300 μL of 4 M 
guanidine hydrochloride, 25 mM sodium citrate, pH 7.0), two sections containing RNA 
precipitation buffer (300 μL of 80% ethanol, 5 mM potassium phosphate, pH 8.5,), three 
sections containing a water wash (100 μL of molecular grade water), and RNA elution 
(50 μL of molecular grade water).  The 50 μL elution volume was chosen so that the RT-
PCR input would be comparable to other extraction methods such as the RNeasy kit.  
Each solution was separated from the next by an air gap ~2 mm in length. Three types 
of extraction test samples were prepared:  5 μL of RSV N gene standard RNA in TE 
buffer at a concentration of 1 x 106 copies/μL, 20 μL of HEp-2 cell lysates (2 x 103 
cells/μL) spiked with 5 μL of RNA standard, or 20 μL of RSV infected HEp-2 cell lysates.  
 
Figure 2.  Design of the continuous tubing extraction cassette 
showing individual processing solutions separated by surface 
tension valves.  An external magnet is used to pull RNA 
adsorbed to silica-coated magnetic particles through each 
processing solution.  Following processing, the RNA is eluted in 
a final water chamber. 
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Cell lysate samples were homogenized by passage through a 25 gauge needle five 
times.  Prior to extraction, samples were added to 230 μL of RNA-silica binding buffer 
(230 μL of 2 M guanidine thiocyanate, 25 mM sodium citrate, pH 7.0, 50% ethanol) and 
20 μL of silica-coated 1 μm diameter magnetic particles (3 x 106 particles/μL) (Bioneer 
Inc., Alameda, CA) and placed on a rotating mixer for 5 minutes at room temperature.  
After mixing, each sample was loaded into the tubing, and the tubing ends were capped.  
The particles were collected in the first chamber by the external magnet and pulled 
through the surface tension valves and each successive chamber at ~4 mm/second 
using ~5 cm diameter neodymium ring magnet (Emovendo LLC, Petersburg, WV) as 
depicted in Figure 2.  Particles were dispersed in the chaotropic wash and RNA 
precipitation solutions by rapidly moving the magnet back and forth before being 
recollected.  In the water wash solutions, the particles were moved at ~8 mm/second to 
minimize RNA loss by elution during the wash.  Finally, the particles were dispersed in 
the final elution chamber and incubated at room temperature for 5 minutes before 
removal.  Although it was utilized in the prototype design, the elution of RNA at 65 °C 
was not performed in this final design because it would be impractical in most low 
resource settings.  The final chamber contents were collected for RT-PCR analysis.  
Each RNA extraction was completed in ~15 minutes. 
 
Continuous tubing extraction cassette limit of detection.   
The extraction cassette limit of detection was determined by calculating the 
minimum quantity of target RNA that must be added to RSV negative cell lysates to be 
detectable by RT-PCR following extraction.  This value was compared to the limit of 
detection calculated for the RNeasy kit.  Twenty uL of uninfected HEp-2 cell lysate was 
spiked with 5 μL of RNA in TE buffer containing 0, 5 x 103, 5 x 104, 1 x 105, 5 x 105, 1 x 
106, and 5 x 106 copies of RSV N gene RNA standard and extracted by both methods as 
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described in section 2.6.  After extraction, the RNA was quantified by RT-PCR.  The limit 
of detection was defined as 3 s.d. above the mean value obtained for control extractions 
containing no RNA. 
 
Post-extraction RNA distribution analysis.   
Extraction test samples were prepared using 5 μL of RSV RNA standard in TE 
buffer added to 230 μL of silica binding buffer.  Twenty μL of magnetic particles were 
added to the sample and mixed for 5 minutes.  RNA was extracted using the extraction 
cassette as described in section 2.6.  After extraction, each chamber solution was 
removed by cutting the tubing with a razor blade and collecting in a separate tube.  Each 
solution was purified with the RNeasy Mini kit according to manufacturer’s protocol in 
order to remove PCR inhibitors.  To account for RNA loss during the secondary RNA 
purification step, a control containing 5 μL of RSV RNA standard was purified from TE 
buffer using the RNeasy kit.  The purified RNA was quantified by RT-PCR analysis and 
normalized to the TE buffer control to account for loss during this second extraction.  
RNA remaining on magnetic particles after extraction was determined by recollecting the 
particles post-elution in 100 μL of nuclease free water.  The particles were placed on a 
rotary mixer for 12 hours at 4 °C.  Particles were removed and RNA in solution was 
purified with the RNeasy Mini kit and quantified by RT-PCR. 
 
Results 
RNA extraction from aliquots of frozen nasal wash samples using the prototype 
extraction cassette, shown in Figure 1, recovered on average 510 ± 800 RSV RNA 
copies per μL (Figure 3 dark bars).  Using aliquots from the same sample, the 
commercial RNeasy Mini kit, Dynabeads mRNA Direct kit and MagAttract RNA Cell Mini 
M48 kit recovered 4,400 ± 10,000, 750 ± 1,300, and 940 ± 1,000 copies per μL, 
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respectively.  In an unextracted RSV positive nasal wash sample, 3 ± 3 RSV RNA 
copies were detected. In samples previously classified as RSV negative, an average of 
less than 1 copy of RSV RNA was detectable per μL for all methods (Figure 3, light 
bars).   
 
 
 
Motivated by these encouraging preliminary results using the relatively crude 
prototype shown in Figure 1, a more thorough study was undertaken using a simplified 
continuous tubing design shown in Figure 2.  Due to the high sample-to-sample 
variability and limited number of the frozen nasal wash samples available, further testing 
was done with RSV infected HEp-2 cell lysates, which unlike the unknown patient 
samples had no sample-to-sample variation.  Using the continuous tubing extraction 
cassette shown in Figure 2, extraction of an RSV N gene standard added to TE buffer 
 
Figure 3.  The number of copies of RNA per µL extracted from RSV 
positive (black bars) and RSV negative (gray bars) nasal wash 
samples using five extraction methods were compared.  Extractions 
were performed using prototype extraction cassette, RNeasy Mini kit, 
Dynabeads mRNA Direct kit, and the MagAttract RNA Cell Mini M48 
kit (mean ± s.d., n = 7).   
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was recovered at an efficiency of 22.5 ± 19% (1.1 ± 0.95 x 106 copies) (Figure 4A).  
Recovery efficiency was calculated by dividing the total number of copies extracted by 
the initial number of copies present in the sample and multiplying by 100%.  In TE buffer, 
the RNeasy kit recovered 41 ± 19% (2.1 ± 0.95 x 106 copies).  TE buffer does not 
contain PCR interferents so, as expected, the detection of unextracted standard RNA 
was 100% (Figure 4A, right bar). 
 
 
 
In the more complex uninfected HEp-2 cell lysate sample matrix, the recovery 
efficiency of RNA was 7.6 ± 4.8% (3.8 ± 0.24 x 105 copies) using the extraction cassette, 
and 18.1 ± 2.4% (9.1 ± 1.2 x 105 copies) using the RNeasy kit (Figure 4B). The spiked 
cell lysates evidently contained RT-PCR interferents since there was no amplification of 
the unextracted spiked sample by RT-PCR (Figure 4B, right bar).   
Using the continuous tubing extraction cassette, RSV RNA extracted from RSV 
infected HEp-2 cell lysates containing 4.6 x 105 pfu/mL recovered 3.6 ± 0.09 x 105 RNA 
copies per µL from the elution chamber compared to 1.2 ± 0.07 x 106 copies per µL 
 
Figure 4.  Comparison of the percent of RSV RNA recovered after addition to TE buffer (A) or 
HEp-2 cell lysates (B) using  the extraction cassette (left bars), RNeasy kit (middle bars), or no 
extraction (right bars) (mean ± s.d., n = 9).  The recovery efficiency of the cassette was 55% 
and 42% of the RNeasy kit from TE buffer and HEp-2 cell lysates, respectively. 
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using the RNeasy kit (Figure 5, black bars).  Less than 100 copies/μL was reported in 
extractions obtained from uninfected cell lysates (Figure 5, gray bars), and RNA was not 
detectable for infected or uninfected cell lysates which were not extracted prior to RT-
PCR (Ct > 40) (Figure 5, “Unextracted”). 
 
 
 
For all methods, RNA loss during extraction was significant.  A post-extraction 
examination of the distribution of RNA in the processing solutions was successful in 
accounting for some of this loss. In a separate series of experiments using the 
continuous tubing extraction cassette, we found that only 59.5% (3.0 x 106 copies) of 
RNA could be accounted for in a post-processing distribution analysis of RSV N gene 
standard added to TE buffer (Figure 6).  Similar to the results found in Figure 4A, 28 ± 
4.5% (1.4 ± 0.23 x 106 copies) of the RNA was recovered in the elution.  Significant RNA 
was recovered in the water wash solutions, which contained 21.7 ± 4.6% (1.1 ± 0.23 x 
106 copies) of the initial RNA.  An additional 7.8 ± 3.5% (3.9 ± 1.8 x 105 copies) of the 
 
Figure 5.  Comparison of RNA extracted from RSV infected (black 
bars) and uninfected (gray bars) HEp-2 cell lysates using the 
extraction cassette and RNeasy kit.  Unextracted samples failed to 
report RSV RNA in either sample (mean ± s.d, n = 3). 
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RNA was recovered from the silica particles after 12 hours of further elution at 4 °C.  
Less than 2% of the RNA was recovered in the RNA-silica binding, chaotropic wash, and 
RNA precipitation solutions.  The tube wall was also checked for RNA binding by 
washing with water post-extraction, and no detectable RNA could be recovered (data not 
shown).  Approximately 40.5% (2.0 x 106 copies) was either lost or degraded during 
processing.  
 
 
 
The post-extraction limit of detection was established for the continuous tubing 
extraction cassette by determining how many RSV RNA copies had to be added to a 
HEp-2 cell lysate to produce a detectable signal following RNA extraction and RT-PCR.  
Five thousand copies of RSV RNA spiked into HEp-2 cell lysates (e.g. 5 uL of RNA at 
1,000 copies/uL into 20 uL of cell lysate) was the lowest concentration detectable by RT-
 
Figure 6.  The post-extraction distribution of RNA in each processing 
solution after RNA extraction from TE buffer is shown.  Insignificant 
amounts were recovered in the first three steps, but the water wash 
and silica particles contained significant RNA (mean ± s.d., n = 3). 
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PCR after sample extraction using both the continuous tubing extraction cassette and 
RNeasy kit (Figure 7).  For the extraction cassette, 197 ± 8.5 copies were reported in 
the sample containing no RSV RNA, resulting in a 3 s.d. limit of detection of roughly 222 
copies.   Cell lysates spiked with 5,000 copies prior to extraction reported a value of 228 
± 58.5 copies per PCR reaction.    Similarly, 202 ± 9.5 copies were reported in the 
sample containing no RSV RNA, and 312 ± 26.8 copies from lysates spiked with 5,000 
copies and extracted with the RNeasy kit.   
 
 
 
  
 
Figure 7.  The limit of detection of RNA detectable by RT-PCR after extraction 
from HEp-2 cell lysates spiked with known amounts of RSV RNA using either 
the continuous tubing extraction cassette (•) or the RNeasy kit (о) (mean ± s.d, 
n=3).  When a sample containing no copies of RNA was extracted, 197 ± 8.5 
RNA copies were detected with the extraction cassette and 202 ± 9.5 copies 
were detected with the RNeasy kit.  The limit of detection is shown for the 
continuous tubing extraction cassette (dotted line).  Comparable data from 
Figs 4B (black triangle ⁮) and 5 (white triangle), which were performed at a 
single concentration are also included. 
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Discussion 
Preparation of patient samples is necessary to avoid false negative prior to 
nucleic acid-based testing [6].  Sample preparation techniques mirroring the simple low 
resource nucleic acid-based diagnostic devices currently being developed are necessary 
to make diagnosis practical at the point-of-care.  Unfortunately, the operation of most 
existing commercial kits appropriate for RNA extraction and concentration require 
specialized laboratory equipment and trained laboratory personnel not available in a low 
resource setting.   
In agreement with previous studies [6], we found that without an initial extraction 
step, only purified RNA in solutions containing no interferents (e.g. TE buffer) can be 
directly detected by RT-PCR (Figure 4A). Direct amplification of viral RNA by RT-PCR 
prior to RNA extraction failed to detect viral RNA in RSV infected clinical nasal wash 
samples (Figure 3), HEp-2 cell lysates spiked with RSV RNA (Figure 4B) and RSV 
infected HEp-2 cell lysates (Figure 5).  Therefore, RSV false negatives are likely to be 
obtained when the extraction step is omitted prior to RT-PCR, and sample preparation is 
necessary to make an accurate diagnosis.   
A post-extraction limit of detection study was performed using spiked cell lysate 
samples, and the results suggest that the proposed continuous tubing extraction 
cassette and the RNeasy kit have a similar limit of detection of ~200 copies per µL.  The 
limit of detection of current clinical diagnostics is ~104 pfu/mL [16].  By dividing an RSV 
infected culture into two parts and measuring pfu/mL by traditional methods and by 
copies/uL RT-PCR (see section 2.3), it was determined that 104pfu/mL corresponds to 
~105 copies/uL.  Therefore, RT-PCR following extraction yields ~50-fold improvement in 
the limit of detection.  In combination with a point-of-care nucleic acid-based diagnostic, 
the proposed extraction cassette would be ideal in a low resource setting, and with only 
a two-fold improvement in the extraction process or optimization of the RT-PCR, lower 
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limits at or below the RSV infectious dose 50 (dose that will infect 50% of subjects, or 
~100 copies per µL) [16] are likely achievable. 
Currently, there are no commercially available low resource nucleic acid 
extraction devices for comparison to the proposed method.  However, several 
laboratory-based commercial kits are available, and we compared the proposed low 
resource method to these approaches.  We have utilized a quantitative method for 
evaluating and directly calculating the efficiency of the extraction cassette in order to 
simplify comparison of the device to the other methods used in this study.  Despite its 
simplicity, the extraction cassette isolated between 30 and 55% of the Qiagen RNeasy 
kit.  Therefore, using RT-PCR, the Ct values for the extraction cassette would fall within 
~1 cycle of the RNeasy kit.  As shown in Figure 4, ~22.5% of the total RNA input is 
recovered by the current design under idealized conditions (spiked TE buffer).  More 
complex sample matrices such as cell lysates or nasal wash samples evidently contain 
components that inhibit RT-PCR and/or make RNA recovery more difficult.  All extraction 
methods tested had lower extraction efficiencies when used to extract RNA from cell 
lysates.  For example, compared to extraction from TE buffer, the recovery from spiked 
cell lysates using the extraction cassette was reduced by 65%. Similarly, the recovery 
using the RNeasy kit was reduced by 57%.  
The prototype design was tested with a small subset of previously collected de-
identified nasal wash samples.  These samples were labeled RSV positive or negative 
during the collection process (not part of this study) using a commercial laboratory RNA 
extraction process and RT-PCR.  The testing of these samples was not designed as a 
blinded study and served as a simple validation of the basic extraction design.  The 
evaluation of these samples with our prototype device indicated that the basic design 
performed similarly to commercially available kits (Figure 3), but in general recovered 
less than the other kits tested.  All of the extraction methods used correctly classified the 
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RSV positive and negative samples.  However, the amount of RSV RNA present in 
these samples was quite variable as indicated by the coefficient of variation (s.d./mean) 
obtained with all of the extraction methods. The coefficients of variation were 157% 
(extraction prototype), 227% (RNeasy), 173% (Dynabeads), and 106% (MagAttract).  
This high variation was the primary reason for using the HEp-2 cell lysates as a more 
controllable clinical sample analogue for further device development and testing.  The 
error obtained with known RNA input is more indicative of variation inherent in the 
methods themselves.  As Figure 5 indicates, under these more controlled conditions, 
the coefficient of variation is substantially reduced for both the extraction cassette at 6% 
and the RNeasy kit at 13%. 
The prototype design was refined into the extraction cassette by loading 
processing solutions into a single length of tubing. The surface tension in the small 
diameter tubing holds each solution in place, and individual solutions remain undisturbed 
when magnetic particles pass through the surface tension valves from one solution to 
the next.  This is an agreement with previous studies using a filament-antibody 
recognition assay which found that high capillary forces held solutions within small 
diameter capillary tubes even in the presence of a moving filament [17].  Other research 
groups have analogously demonstrated that an immiscible hydrophobic liquid can 
effectively separate nucleic acid processing solutions.  Work by Sur and coworkers 
demonstrated that silica-coated magnetic beads are able to carry nucleic acids through a 
lipophilic barrier floating on the surface of two separate processing solutions to isolate 
RNA from RT-PCR interferents [18].  Subsequently, Barry and coworkers adapted the 
idea to separate solutions in a horizontal format, relying on the surface tension forces at 
the immiscible interface to prevent the processing solutions from mixing while allowing 
the transport of magnetic beads through the lipophilic barrier [19].  For the development 
of a low resource RNA extraction device, the use of surface tension valves in a 
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continuous length of tubing offers several advantages over the reported nucleic acid 
isolation technologies using lipophilic barriers.  
 One of the advantages of the extraction cassette design is the inherent flexibility 
and simplicity which provides a unique format for the development of other sample 
processing cassettes.  The scale of the cassette is similar to that of laboratory-based 
commercially available kits and can be modified to incorporate relatively large sample 
volumes. The simple design also makes it suitable for large-scale manufacturing.  
Additionally, it is possible to adapt the cassette format to perform many other solid phase 
based assays.  By functionalizing the magnetic beads with the appropriate capture 
moiety and loading the cassette with the appropriate processing solutions, assays could 
be developed for low resource processing of a variety of biomarkers, including DNA, 
proteins or carbohydrates.  The cassette also has the potential to be coupled with 
downstream platforms for integrated sample preparation, signal amplification and 
detection.  For example, by simply coupling the end of the extraction cassette tubing 
onto a thermocycler tube or onto the input port of a thermocycler, it is possible to elute 
the RNA into a prepared RT-PCR buffer without extra handling or risk of contamination. 
The simple format of the extraction cassette also improves the reliability of the 
device. The utilization of surface tension valves in the continuous tubing design allows 
the extraction process to be fully self-contained.  Individual processing solutions are 
preloaded into the tubing during manufacturing, eliminating the need for sample handling 
and pipetting during the extraction process.  This is advantageous as it minimizes the 
potential for contamination of the wash solutions, the extracted RNA, or the operator. 
The continuous diameter of the tubing minimizes particle loss during sample pull-through 
by eliminating locations where the particles can become trapped, a limitation of the 
original prototype design shown in Figure 1.  The surface tension valves also minimize 
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interferent carryover by preventing diffusion down the tubing, and separating the water 
wash into three successive steps also helped to minimize carryover. 
Fluid stability and continued separation during processing are key to this design.  
The surface tension at the valve interface is affected by the surface properties of the 
tubing and the properties of the air/liquid interface.  Consequently, the overall stability of 
the solution chambers within the cassette is dependent on each of these surface 
properties [19].  Some preliminary studies have been performed to estimate liquid 
carryover of processing solution across a valve.  Each of the four processing solutions 
was mixed with sodium fluorescein to create a fluorescein concentration of 2.7 μM.  
Twenty μL of beads (approximately 5.6 x 107 beads) were transported from each of 
these labeled solutions across a valve into 80 μL of unlabeled water. The fluorescence 
of the water downstream of the valve was measured and a standard curve used to 
estimate the volume of solution transferred.  The volumes of processing solution carried 
over for the RNA-silica binding buffer, chaotropic wash buffer, RNA precipitation buffer 
and water wash were 7.61 μL ± 0.59, 9.88 μL ± 0.27, 5.03 μL ± 0.26, and 5.41 μL  ± 
0.39, respectively.  If we assume that each downstream chamber is perfectly mixed, 
then the final RNA elution could contain a maximum of ~8.0 x 10-4% ethanol and ~25 nM 
guanidine salt, two known RT-PCR contaminants.  These values are far below the 
amounts experimentally determined to affect RT-PCR, which we determined to be ~ 1% 
ethanol or ~ 100 μM guanidine salt (data not shown).  Further, ongoing studies are 
directed at better understanding these properties and the influence of magnetic particle 
properties such as diameter, density, magnetic susceptibility, and surface chemistry on 
particle transport through a surface tension valve.   
Nucleotide extractions from biologically relevant samples are never 100% 
efficient, neither in a lab laboratory environment, nor in low resource settings.  In fact, 
the gold standard RNeasy kit only recovered 18.1 ± 2.4% of the RSV N gene RNA 
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spiked into HEp-2 cell lysates.  The performance of the extraction cassette would be 
improved by reducing the overall loss of RNA during the extraction process.  Unlike 
commercially available extraction kits, all of the required components in this study are 
based on previously published strategies for RNA extraction.  It is likely that further 
modifications to individual processing solutions will lead to an increase in the recovery 
efficiency.  An estimation of the RNA distribution within each wash chamber allows us to 
identify variables for optimization (Figure 6).  Significant quantities of RNA were lost 
during the water wash steps, which are necessary to remove the ethanol in the absence 
of centrifugation.  For downstream RNA detection by RT-PCR, the ethanol must be 
removed prior to amplification; however, other nucleic acid-based detection strategies 
may not be inhibited by the presence of ethanol.  In these cases, the water wash 
chambers could be reduced or eliminated and the recovery efficiency of the extraction 
cassette improved.  Approximately 8% of the RNA still remained on the silica particles 
after a 5 minute elution in water.  By increasing the elution time, the overall yield of the 
device could be improved by up to 8% in 12 hours, but the total extraction time would be 
dramatically increased.  Future studies will explore potential methods to minimize this 
loss, including the possibility of direct amplification of the RNA bound to the bead 
surface without an elution step.  Minimal RNA was detected within the RNA-silica 
binding, chaotropic wash and RNA precipitation solutions.  The post-extraction RNA 
distribution in the processing solutions suggests that RNA may be irreversibly bound to 
tubing or particle surfaces, degraded during processing, or located on particles that 
become trapped in the surface tension valves during magnetic pull-through.  
The extraction cassette investigated here can potentially be utilized for sample 
preparation in a low resource setting.  It is relatively inexpensive to produce at less than 
$1.00 per extraction. A rough cost estimate based on current catalog prices of the 
chemicals and materials required for the continuous tubing design suggests that the 
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most expensive items are the magnetic particles (about $0.50) and the Tygon tubing 
(about $0.30).  In its current form, the recovery efficiency of this device is acceptable.  
However, the continuous tubing design can likely be further improved by solution and 
surface optimization studies.  Its major advantages are that, unlike other commercially 
available methods, it can be performed without a laboratory centrifuge or access to a 
pipetter and without the skills necessary to operate these laboratory devices.  Thus, this 
approach is an attractive low resource alternative to commercially available methods. 
 
Conclusions 
We have shown that our self-contained extraction cassette performs effectively 
and offers many advantages over similar reported devices and commercially available 
kits.  The simplicity and flexibility of the cassette make it an robust sample preparation 
tool suitable for use in low resource settings where nucleic acid-based diagnostics must 
be utilized without specialized equipment and/or trained personnel.  The extraction 
cassette is an ideal format for coupling with downstream nucleic acid amplification and 
detection modalities.  Additionally, the technology is readily adaptable for the isolation of 
other potential biomarkers of interest, including DNA, proteins or carbohydrates.   
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Abstract 
Due to the presence of PCR inhibitors, PCR cannot be used directly on most 
clinical samples, including human urine, without pre-treatment.  A magnetic bead-based 
strategy is one potential method to collect biomarkers from urine samples and separate 
the biomarkers from PCR inhibitors.  In this report, a 1 mL urine sample was mixed 
within the bulb of a transfer pipette containing lyophilized nucleic acid-silica adsorption 
buffer and silica-coated magnetic beads.  After mixing, the sample was transferred from 
the pipette bulb to a small diameter tube, and captured biomarkers were concentrated 
using magnetic entrainment of beads through pre-arrayed wash solutions separated by 
small air gaps.  Feasibility was tested using synthetic segments of the 140bp 
tuberculosis IS6110 DNA sequence spiked into pooled human urine samples.  DNA 
recovery was evaluated by qPCR. Despite the presence of spiked DNA, no DNA was 
detectable in unextracted urine samples, presumably due to the presence of PCR 
inhibitors.  However, following extraction with the magnetic bead-based method, we 
found that ~50% of spiked TB DNA was recovered from human urine containing roughly 
5x103 to 5x108 copies of IS6110 DNA.  In addition, the DNA was concentrated 
approximately ten-fold into water. The final concentration of DNA in the eluate was 
5x106, 14x106, and 8x106 copies/µL for 1, 3, and 5mL urine samples, respectively.  
Lyophilized and freshly prepared reagents within the transfer pipette produced similar 
results, suggesting that long term storage without refrigeration is possible.  DNA 
recovery increased with the length of the spiked DNA segments from 10±0.9% for a 
75bp DNA sequence to 42±4% for a 100bp segment and 58±9% for a 140bp segment.  
The estimated LOD was 77 copies of DNA/µL of urine. The strategy presented here 
provides a simple means to achieve high nucleic acid recovery from easily obtained 
urine samples which does not contain inhibitors of PCR.   
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Introduction 
Relative to many other types of patient samples, urine samples are easy to 
obtain.  Therefore, they are frequently analyzed for biomarkers of disease.  Urine 
biomarkers include sugars for the diagnosis of diabetes mellitus, proteins for the 
diagnosis of liver and kidney disorders, and bacteria for the diagnosis of urinary tract 
infections [1].  In addition, transrenal DNA (Tr-DNA) sequences have been shown to be 
applicable in pathogen detection.  As human cells and microorganisms break down 
within the body, small nucleic acid fragments are thought to circulate in the blood 
stream, and subsequently pass through the kidneys and into the urine [2,3].  In healthy 
individuals, these Tr-DNA fragments have been shown to be less than 250 bp in length 
[4].  Tr-DNA sequences specific to Mycobacterium tuberculosis [5-7], urinary tract 
infections [8], Plasmodium [9], and Schistosoma mansoni [10] have been recovered from 
urine, pointing to Tr-DNA as a promising new biomarker for urinalysis. 
 The noninvasive collection of urine samples is advantageous in low resource 
settings where lack of automated equipment and skilled technicians, cultural taboos, or 
patient age make more invasive sample collection difficult [11].  Compared to blood, 
sputum, or cheek swab samples, urine sample volume is large, typically 10 to 100 mL, 
which maximizes the availability of the biomarker of interest.  This is a distinct advantage 
when detecting a biomarker that is expected to be present at relatively low 
concentrations, like Tr-DNA.  However, urine contains inhibitors that interfere with 
downstream nucleic acid-based detection strategies such as PCR [11,12].  Additionally, 
isothermal PCR and other nucleic acid-based assays being developed for use in low 
resource settings are frequently tested using commercial nucleic acid extraction kits that 
may be inappropriate for use in these settings.  Thus, the need for nucleic acid 
extraction and concentration is a well-recognized roadblock to performing nucleic acid-
based detection in low resource settings [11,13,14]. 
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 In order for PCR or other nucleic acid-based assays to detect DNA in urine 
samples, the DNA must be separated from inhibitors contained in the sample.  Current 
methods to extract nucleic acids for nucleic acid-based assays are either not amenable 
to a large volume patient sample such as urine, are not appropriate to a low resource 
setting, or both.  Commercially-available extraction kits for use in laboratories, such as 
Exgene Clinic SV (Biomol, GmbH), Norgen Urine DNA Isolation kit (Norgen Biotek 
Corporation), and QIAmp DNA kit (Qiagen), utilize spin columns to selectively adsorb 
nucleic acids and remove potential inhibitors to downstream assays.  However, these 
columns require relatively expensive equipment (e.g. centrifuge), disposable laboratory 
supplies, and trained personnel.  Products such as InstaGene Matrix (Bio-Rad) also 
remove PCR inhibitors from patient samples but dilute the DNA instead of concentrating 
it.  Self-contained microfluidic devices embedded with silica beads or posts have been 
developed for one-step nucleic acid extractions [15].  However, the small diameter of 
microfluidic channels restricts the silica surface area available for biomarker adsorption 
as well as the maximum sample volume that can be flowed through the channels 
(typically < 500 µL) [14].  This limits the utility of microfluidic devices for processing large 
volume samples like urine.  We report here a means of extracting and concentrating 
DNA from up to 5 mL urine samples without pipetting and centrifugation steps necessary 
in commercial DNA extraction kits.   
Magnetic beads are an effective tool for extracting and concentrating biomarkers.  
Using this dispersed solid phase approach, magnetic beads are mixed with large 
volumes of patient sample to capture biomarkers.  The magnetic beads are then 
recollected magnetically, and the captured biomarkers are released from the bead 
surface into a more amenable reaction buffer.  This has led to their use in a number of 
bioassay applications [16-18].  The coating on the magnetic bead surface is one of the 
key factors to this approach.  The adsorption of nucleic acids to silica in the presence of 
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high concentrations of chaotropic salts is used extensively to extract nucleic acids from 
complex sample matrices into inhibitor-free solutions in bead-based methods as well as 
in a number of other formats.  Additionally, the mobility of magnetic beads allows 
transfer of adsorbed nucleic acids into smaller volumes and, therefore, leads to more 
concentrated solutions [19].   
The ideal nucleic acid extraction technology for a low resource setting would 
require minimal processing steps, enable the use of large sample volumes to maximize 
biomarker recovery, and be self-contained to limit operator exposure to samples during 
processing [14,20].  We have previously reported the development of a low resource 
“extraction cassette” for the purification of RNA [21] and protein [22] from small volume 
patient samples.  The extractions were performed in a single length of small diameter 
tubing pre-arrayed with processing solutions separated from one another by air gaps or 
mineral oil held in place by surface tension.  After biomarker capture on the bead 
surface, the magnetic beads were pipetted into the small diameter tubing, and an 
external permanent magnet was pulled along the length of the tubing to wash and 
release biomarkers into a final buffer for subsequent testing.   
In these prior assays, biomarker capture by magnetic beads was performed in a 
multi-step process using refrigerated reagents added to a centrifuge tube.  In this report, 
we eliminate the need for multiple pipetting steps, refrigerated reagents, and the precise 
volume transfer to the small diameter tubing.  In addition, we have modified the magnetic 
bead and tubing components of our “extraction cassette” design based on the 
optimization studies reported by Adams et. al. [23].  The end result is a simple means to 
collect DNA biomarkers present in large volume urine samples in a transfer pipette bulb 
and to concentrate the biomarkers into a small volume using our preloaded extraction 
cassette for subsequent nucleic acid-based detection.   
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Materials and Methods 
 
Preparation of pooled human urine samples.   
Twenty disease-negative urine samples were obtained from the Vanderbilt 
University Molecular Infectious Disease Laboratory as “on-the-shelf” samples that 
contained no patient information.  An IRB exemption was granted from the Vanderbilt 
University Institutional Review Board for use of these samples.  There were two ways to 
use the human urine samples.  They could either be individually spiked prior to 
extracting, or they could be pooled and aliquotted prior to spiking.  In these studies, the 
urine samples were pooled allowing us to minimize variability in the concentration of 
PCR inhibitors that would be expected between individual urine samples.  Fifteen 
milliliters of each sample were pooled, pipetted into 1 mL aliquots, and stored at -80°C.  
Immediately prior to use, the samples were thawed at room temperature and spiked, in 
most cases, with a 140 bp synthetic DNA target from the IS6110 sequence of M. 
tuberculosis (Integrated DNA technologies, Coralville, Iowa).  The one exception is the 
sequence length studies described below. 
 
Quantitative PCR.   
A 129 bp amplicon of the IS6110 sequence was amplified using forward primer 
5’-ACCAGCACCTAACCGGCTGTGG-3’ and reverse primer 5’-
CATCGTGGAAGCGACCCGCCAG-3’[7].  Amplification reactions were performed in a 
25 µL volume using 5 µL of DNA template and the Qiagen QuantiTect SYBR Green 
PCR kit (Qiagen, Germantown, MD) according to manufacturer’s instructions.  Thermal 
cycling consisted of 95°C for 15 minutes to activate the Taq DNA polymerase and 40 
cycles of 95°C for 15 s, 62°C for 30 s, and 72°C for 30 s using a Rotor-Gene Q thermal 
cycler (Qiagen, Germantown, MD).  Product specificity was confirmed using melting 
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curve analysis.  Data were collected and Ct values recorded by Rotor-Gene Q software 
and converted to number of DNA copies per µL using a standard curve.  The primer 
efficiency for each standard curve was also determined using the Rotor-Gene Q 
software. 
 
Preparation of urine collection pipettes.   
The urine collection pipettes were prepared by drawing 1 mL of DNA-silica 
adsorption buffer (4 M guanidine thiocyanate, 25 mM sodium citrate, pH 7.0) containing 
6 x 108 Dynabeads® MyOne™ Silane magnetic beads (Life Technologies, Grand Island, 
NY) into the bulb of a 5 mL, fine tipped transfer pipette (Samco Scientific, San Fernando, 
CA, cat. # 232-20S).  The contents of the transfer pipettes were frozen for 2 hours at -
80°C, after which the pipettes were transferred to a Labconco bulk tray dryer (Labconco, 
Kansas City, MO) and lyophilized for ~18 hours.  Following lyophilization, the transfer 
pipettes were stored at room temperature for up to twelve weeks until use. 
 
DNA extraction from pooled human urine samples.   
The two components of this magnetic bead-based approach are shown in Figure 
8.  Based on the optimization studies performed by Adams et. al. the previously 
described “extraction cassette” was modified by using fluorinated ethylene propylene 
(FEP) tubing in place of Tygon® R-3603 tubing [23].  The tubing was prepared by 
preloading a 60 cm length of 1.6 mm inner diameter (i.d.) FEP tubing (Saint-Gobain 
Performance Plastics, Akron, OH) with DNA precipitation buffer (300 µL of 80% ethanol, 
5 mM potassium phosphate, pH 8.5), DNA wash solution (300 µL of 70% ethanol), and 
DNA eluent (50 µL of molecular grade water).  Each solution was pipetted sequentially 
into the tubing and separated from the next by a 4 µL air gap (2 mm in length).  A 1 mL 
human urine sample was spiked with 5 µL of IS6110 DNA to a concentration of 5 x 105 
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copies/µL.  Prior to extraction, the samples were drawn into the bulb of the transfer 
pipette, which was shaken vigorously by hand for 30 s to dissolve the lyophilized salts, 
then gently for 30 s to allow DNA adsorption to the silica surfaces of the beads.  After 
mixing, the transfer pipette was squeezed to transfer the sample from the bulb to the tip 
of the pipette.  The end of the pipette was then inserted into the preloaded small 
diameter tubing and the sample was transferred into the tubing (Figure 8A).  Stainless 
steel #1 machine screws (McMaster Carr Supply Co, Elmhurst, IL, cat. # 90065A054) 
were threaded into both ends of the FEP tubing to establish an airtight seal.  A 2.5 cm 
cube-shaped neodymium magnet (Emovendo, Petersburg, WV) adjacent to the DNA-
silica adsorption chamber was used to collect the beads.  Although one bead is not 
visible to the naked eye, the quantity of beads used here (6 x 108 beads) is readily 
perceived as a dark brown clump.  The beads were pulled through the air gaps and each 
successive solution at ~4 mm/s (Figure 8B).  Beads were dispersed in the DNA 
precipitation buffer and DNA wash solution by rapidly moving the magnet back and forth 
along the chamber.  Beads were then collected and pulled into the next solution.  Finally, 
the beads were dispersed throughout the eluent for ~10 s, collected, and pulled back 
into the DNA wash chamber.  Each DNA extraction was completed in ~15 minutes.   
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DNA recovery was quantified by PCR.  To prepare the extracted sample for 
PCR, the elution chamber was excised from the small diameter tubing using a razor 
blade, and the eluate was collected by holding the tubing over a 500 µL centrifuge tube.  
Additional extractions were performed using the commercially available Norgen Biotek 
urine extraction mini kit (Thorold, Ontario, Canada), performed according to 
manufacturer’s instructions on a 1 mL urine sample.  PCR was also performed on 5 µL 
of an unextracted urine sample containing 5 x 105 copies/µL of IS6110 DNA.  DNA 
recovery was calculated by dividing the total number of copies extracted by the initial 
number of copies present in the sample and multiplying by 100%. 
 
  
 
Figure 8.  The two components of the magnetic bead-based extraction method:  A) 
DNA is adsorbed to silica-coated magnetic beads previously lyophilized with DNA-
silica adsorption buffer in the bulb of a transfer pipette.  After mixing, the beads are 
transferred directly into the small diameter tubing by depressing the bulb.  B) The 
small diameter tubing “extraction cassette” is shown with processing solutions 
separated by air gaps.  DNA adsorbed to silica-coated magnetic beads is pulled 
through each processing solution by an external magnet and eluted in the final 
water chamber. 
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Effect of urine sample volume on final DNA concentration in the eluate.   
The recovery of spiked DNA from 1, 3 and 5 mL urine samples, each containing 
5 x 105 copies/µL of spiked DNA, was determined following magnetic bead-based 
extraction.  Each sample was drawn into the bulb of the lyophilized urine collection 
pipette, which was shaken vigorously for 30 s to dissolve the lyophilized salts, then 
gently for 30 s to distribute the magnetic beads for nucleic acid adsorption.  To avoid 
transferring volumes greater than 1 mL into the small diameter tubing and to limit the 
total length of the small diameter tubing to 60 cm, the magnetic beads were collected to 
one side of the pipette bulb using a permanent magnet, and all but 1 mL of each sample 
was transferred into a waste container for disposal.  The remaining 1 mL urine sample 
containing all magnetic beads was then transferred into the small diameter tubing.  
Finally, the magnetic beads were processed using an external magnet, the eluate 
collected, and the DNA amplified and quantified by PCR as described above. 
 
Comparison of urine collection pipette to freshly prepared DNA-silica adsorption buffer 
for DNA capture.   
 
One milliliter pooled human urine samples were extracted as described above by 
capturing DNA onto silica-coated magnetic beads contained within the urine collection 
pipette, transferring the sample into the small diameter tubing, and processing the 
sample using an external magnet.  The extractions were performed using urine 
collection pipettes containing lyophilized DNA-silica adsorption buffer and magnetic 
beads that had been stored at room temperature for 0, 4, 8, or 12 weeks prior to use.  
For comparison, the DNA-silica adsorption step was performed in a 2 mL centrifuge tube 
with freshly prepared DNA-silica adsorption buffer and magnetic beads.  One milliliter of 
DNA-silica adsorption buffer and 6 x 108 silica-coated magnetic beads were pipetted into 
the centrifuge tube followed by a 1 mL DNA-spiked pooled human urine sample.  The 
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contents of the tube were gently shaken for 60 seconds to allow mixing and DNA 
adsorption to the silica beads.  Finally, the sample was transferred to the small diameter 
tubing by pipetting and processed as described above for DNA extraction.  After 
processing, the recovery of IS6110 DNA from each sample was calculated following 
PCR.  
 
Effect of spiked DNA concentration of DNA recovery.   
To determine the effect of spiked DNA concentration on DNA recovery from 
human urine samples, multiple concentrations of spiked DNA were extracted and 
analyzed by PCR.  One milliliter human urine samples were spiked with 5 µL of TE 
buffer containing 0, 5 x 103, 5 x 104, 5 x 105, 5 x 106, or 5 x 108 copies of TB IS6110 
DNA.  Following extraction the DNA was quantified by PCR.    
 
PCR limit of detection.   
The limit of detection was determined for the PCR protocol described above.  A 1 
mL urine sample containing no TB IS6110 DNA was extracted using the magnetic bead-
based method.  PCR was performed on the extracted sample, and the number of copies 
detected in the blank sample was determined by referencing a standard curve run in TE 
buffer.  The PCR LOD was defined to be 3 s.d. above the average number of calculated 
copies from the extracted unspiked urine sample. 
 The minimum concentration of DNA that must be spiked into a human urine 
sample to be detectable in the eluate following extraction with the magnetic bead-based 
method, given the LOD of the PCR protocol used in this study, was determined.  Five 
microliters of TE buffer containing 0, 5 x 103, 5 x 104, 5 x 105, 5 x 106, or 5 x 108 copies 
of TB IS6110 DNA were added to each 1 mL urine sample.  Following extraction with the 
magnetic bead-based method, the number of copies detected in the eluate of each 
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extracted sample was determined by PCR.  The approximate number of copies that 
must be spiked into the initial urine sample to be detectable in the eluate at the PCR 
LOD was determined as the point which intersects this PCR-concentration curve. 
 
Effect of DNA length on DNA adsorption to silica.   
The effect of DNA target length on recovery of DNA using magnetic bead-based 
extraction was studied to determine the limitations of DNA adsorption to the silica-coated 
magnetic beads.  Human urine samples (1 mL) were spiked with 5 x 108 copies of DNA 
that was 75, 100, or 140 bp in length.  The samples were extracted using the magnetic 
bead-based extraction, and the recovery of DNA for each sample was determined 
following PCR amplification by referencing a standard curve.  A 67 bp fragment of each 
target was amplified using forward primer 5’-ACCAGCACCTAACCGGCTGTGG-3’ and 
reverse primer 5’-GTAGGCGAACCCTGCCCAGGTC-3’ [7], with cycling conditions 
identical to those described above. 
 
Adsorption and elution kinetics of silica-coated magnetic beads.   
The optimum adsorption and elution times for DNA adsorption to and elution from 
silica-coated magnetic beads was determined by comparing the recovery of DNA for 
adsorption or elution times ranging from 30 to 210 s.  For adsorption studies, 5 x 108 
copies of TB IS6110 DNA were spiked into 1 mL human urine samples and drawn into a 
transfer pipette bulb containing DNA-silica adsorption buffer and magnetic beads as 
described above.  The pipette was shaken vigorously for 30 s to dissolve the salts, and 
then gently for an additional 0, 30, 60, or 180 seconds.  For elution studies, 5 x 108 
copies of TB IS6110 DNA were extracted from 1 mL human urine samples using the 
magnetic bead-based extraction with an adsorption time of 30 s.  After dispersal in the 
final elution chamber, the beads were incubated at room temperature for 30, 60, 90, or 
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210 seconds before being collected and removed from the chamber.  Each sample was 
collected and IS6110 DNA was amplified by PCR.  The extracted DNA was quantified by 
referencing a standard curve.  The recovery of DNA was determined by dividing the total 
number of extracted DNA copies by the input number of DNA copies and multiplying by 
100%. 
 
Effect of number of magnetic beads on DNA recovery.   
The recovery of spiked DNA from 1 mL urine samples was determined following 
magnetic bead-based extraction performed with different numbers of magnetic beads.  
For each extraction, a urine collection pipette was prepared with either 12 x 108, 6 x 108, 
3 x 108, or 1 x 108 magnetic beads, and the magnetic bead-based extraction was 
performed on each spiked 1 mL urine sample as described above. 
 
DNA extraction capacity of the silica-coated magnetic beads.   
The maximum mass of DNA that could be extracted with the silica-coated 
magnetic beads was determined by spiking 100 µL of TE buffer with increasing 
quantities of calf thymus DNA (Sigma Aldrich, St. Louis, MO) and quantifying the mass 
of DNA extracted.  One hundred µL of TE buffer was spiked with 2.5, 5, 7, 10, or 20 µg 
of calf thymus DNA.  Each sample was mixed with 300 µL of DNA-silica adsorption 
buffer and 6 x 108 silica-coated magnetic beads for 60 s.  The DNA was extracted in the 
small diameter tubing as described above.  The extracted DNA was quantified by 
measuring its absorbance at 260 nm using a NanoDrop ND-1000 spectrophotometer 
and referencing a standard curve. 
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Statistical analysis.   
All statistical analyses were performed in SigmaPlot 11.0.  Analysis of variance 
(ANOVA) was used to determine statistical significance for data containing 3 or more 
sample populations, and a T test used for data containing 2 sample populations.  A p-
value < 0.05 was considered significant. 
 
Results 
 
DNA extraction from pooled human urine samples.   
The magnetic bead-based extraction recovered 50 ± 5% of TB IS6110 DNA 
spiked into 1 mL aliquots of pooled human urine (Figure 9, left).  The commercially-
available Norgen Biotek urine extraction kit recovered 33 ± 6% of spiked DNA (Figure 9, 
middle).  No spiked DNA was detectable in the unextracted urine sample (Figure 9, 
right) due to the presence of PCR inhibitors in urine.  The primer efficiencies for samples 
extracted with the magnetic bead-based extraction and Norgen kit were 93% and 96%, 
respectively.  Using the magnetic bead-based extraction, the DNA spiked into urine at an 
initial concentration of 5 x 105 copies/µL was concentrated to 5 x 106 copies/µL of water 
as determined by comparison to the PCR standard curve run at the same time. 
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Effect of urine sample volume on final DNA concentration in the eluate.   
As shown in Figure 10, the final concentration of spiked DNA in the eluate 
following extraction of the 1 mL urine sample was 5.2 x 106 ± 7.5 x 105 copies/µL, 
corresponding to a recovery of 52%.  The DNA concentration was significantly higher in 
both the 3 mL and 5 mL samples at 13.8 x 106 ± 16.0 x 105 and 8.2 x 106 ± 7.6 x 105 
copies per µL.  These corresponded to a total recovery of 46% of spiked DNA from the 3 
mL sample and 17% from the 5 ml sample. 
 
 
Figure 9.  The DNA recovery for the magnetic bead-based extraction 
method and a commercially available laboratory-based kit are 
comparable.  Though both are significantly higher than the unextracted 
sample, which is undetectable by PCR, there is no statistical difference 
between the two extraction methods (mean ± s.d., n = 9); * denotes 
statistically higher recovery than unextracted sample. 
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Comparison of DNA capture by urine collection pipette and freshly prepared DNA-silica 
adsorption buffer.   
 
There was no significant difference in recovery of DNA from the small diameter 
tubing following DNA capture in the urine collection pipette, which was stored in a 
lyophilized state, compared to a centrifuge tube containing freshly prepared adsorption 
reagents.  The urine collection pipette method recovered 46 ± 6%, 52 ± 4%, 45 ± 3%, 
and 42 ± 9% of spiked DNA following urine collection pipette storage for 0, 4, 8, or 12 
weeks, respectively, compared to 53 ± 6% of spiked DNA using the freshly prepared 
DNA-silica adsorption buffer (Figure 11). 
 
 
Figure 10.  The final concentration of IS6110 DNA in the eluate following 
magnetic bead-based extraction of 3 and 5 mL spiked urine samples is 
significantly higher than the IS6110 DNA concentration in the eluate 
following the extraction of 1 mL samples (mean ± s.d., n = 3);  * denotes 
statistically different from 1 mL sample. 
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Effect of spiked DNA concentration on DNA recovery.   
As the initial number of copies spiked into the 1 mL human urine sample was 
increased from 5 x 103 to 5 x 108, the percentage of DNA recovery from human urine 
samples did not change significantly over the range tested (Figure 12).  DNA recovery 
was 28 ± 42%, 70 ± 68 %, 46 ± 19%, 41 ± 18%, and 50 ± 5% from urine spiked with 5 x 
103 copies DNA/mL,  5 x 104 copies DNA/mL, 5 x 105 copies DNA/mL, 5 x 106 copies 
DNA/mL, and 5 x 108 copies DNA/mL, respectively.   
 
 
Figure 11.  There is no significant difference in DNA recovery using the 
lyophilized urine collection pipette stored for 0, 4, 8, or 12 weeks (black 
circles) compared to freshly prepared adsorption reagents (white circle) 
(mean ± s.d., n = 3). 
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PCR limit of detection.   
The PCR LOD is a reflection of background fluorescence due to primer dimers 
and other PCR artifacts.  Following extraction of a 1 mL human urine sample using the 
magnetic bead-based method, fluorescence corresponding to 1300 ± 2500 copies of 
DNA were reported by the PCR reaction.  This resulted in a 3 s.d. PCR LOD of roughly 
8800 copies (Figure 13, dotted line).  It was determined that the concentration of IS6110 
DNA in the initial human urine samples must be at least 77 copies/µL (Figure 13, red 
circle) to be detectable in the eluate at the calculated PCR LOD. 
 
 
Figure 12.  The recovery efficiency of DNA from human urine samples 
using magnetic bead-based extraction does not change as the number of 
copies spiked into the 1 mL human urine sample is increased (mean ± 
s.d., n = 3).  The average DNA recovery efficiency of the magnetic bead-
based extraction method is shown as a dotted line.  The recovery 
efficiency of the Norgen kit is shown at an initial DNA concentration of 5 x 
10
5
 copies/mL (white circle).   
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Effect of DNA length on DNA adsorption to silica.   
Increasing the length of target DNA increased the recovery of the magnetic bead-
based extraction.  As shown in Figure 14, when spiked with a 75 bp DNA sequence, the 
magnetic bead-based extraction recovered 10 ± 0.9% of the sample from 1 mL of human 
urine.  When the length of the DNA sequence was increased to 100 or 140 bases, the 
recovery increased to 42 ± 4% and to 58 ± 9%, respectively.   
 
 
Figure 13.  The LOD of the PCR reaction is shown at 8800 copies (dotted 
line).  The lowest initial concentration of IS6110 DNA detectable at the LOD 
was determined to be 77 copies/µL at the point at which this intersects the 
PCR-concentration curve (red circle) (mean ± s.d., n = 3). 
67 
 
 
 
Adsorption and elution kinetics of silica-coated magnetic beads.   
The percentage of DNA recovered from pooled human urine samples does not 
increase with increased adsorption or elution times.  As shown in Figure 15, 54 ± 18% is 
recovered from extractions with 30 s of adsorption time (white circles), and 44 ± 5% of 
DNA is recovered from extractions with 30 s of elution time (black circles).  As both 
adsorption and elution times are increased from 30 to 210 s there is no significant 
increase in the percentage of DNA recovered.  In the ideal case, the black and white 
circles plotted at 30 s would be identical, because they have identical adsorption and 
elution times.  The resulting minimal difference between the two data sets could simply 
be due to variation in PCR or the fact that the adsorption and elution data sets were 
collected on two separate days.  As the error bars indicate, these points have a high 
degree of variation which masks any difference between them. 
 
 
Figure 14.  DNA recovery is significantly increased with increasing DNA 
sequence length (mean ± s.d., n = 3).   * denotes statistically different than 75 
bp sequence. 
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Effect of number of magnetic beads on DNA recovery.   
The percentage of DNA recovered from 1 mL urine samples increases as the 
number of magnetic beads is increased to 6 x 108 beads/mL of urine.  After this point, 
the recovery of DNA does not increase as additional beads are added.  As shown in 
Figure 16, 7.6 ± 1% of spiked DNA is recovered from extractions performed with 1 x 108 
beads/mL, 29 ± 3% from extractions performed with 3 x 108 beads/mL, 49 ± 5% from 
extractions performed with 6 x 108 beads/mL, and 45 ± 8% from extractions performed 
with 12 x 108 beads/mL.  
 
 
Figure 15.  There was no significant change in DNA recovery with 
increased adsorption (white circles) or elution (black circles) times (mean ± 
s.d., n = 3).  In each experiment, the adsorption time was held at 30 s 
while the elution time was varied (black circles), and the elution time was 
held at 30 s while the adsorption time was varied (white circles).  To more 
clearly illustrate the error bars on each data point, the adsorption data was 
plotted two seconds to the right at each time point. 
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DNA extraction capacity of silica-coated magnetic beads.   
The maximum quantity of total DNA that can be extracted from TE buffer with 6 x 
108 magnetic beads is 5.5 µg, or ~9 fg of DNA per bead.  The mass of extracted DNA 
increases proportionally with an increase in magnetic beads and then plateaus.  As 
shown in Figure 17, 1.8 ± 0.1 µg of DNA was recovered when the extracted sample was 
spiked with 2.5 µg of DNA.  The recovered DNA increased to 4.0 ± 0.3 µg when the 
sample was spiked with 5 µg of DNA and 4.9 ± 0.2 µg when spiked with 7 µg of DNA.  
As the quantity of spiked DNA was increased to 10 µg and subsequently to 20 µg, the 
quantity of extracted DNA was maximized at 5.5 ± 0.2 µg and 5.4 ± 0.1 µg, respectively.  
Based on the extraction capacity of the beads and an expectation of 250 ng DNA/mL of 
urine [24], this translates to a minimum of ~2.7 x 107 beads. 
 
 
Figure 16.  The percentage of DNA recovered from 1 mL urine samples 
increases as the concentration of magnetic beads increases to 6 x 10
8
 
beads/mL (mean ± s.d., n = 3). 
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Discussion 
When biomarkers are present in low concentrations within patient samples, a 
large volume sample, such as urine, can maximize the number of biomarkers available 
for use in a molecular diagnostic test.  However, processing large volumes is a 
challenge, as these large samples are difficult to interface with DNA extraction 
technologies such as microfluidic devices, particularly in a low resource setting.  In our 
approach, magnetic beads were distributed in a large volume for nucleic acid adsorption 
and then transferred directly into small diameter tubing.  Here, the beads were collected 
and the adsorbed nucleic acids concentrated in a format compatible with PCR.  The 
magnetic bead-based method for extracting DNA from urine had an average recovery of 
50% while concentrating the DNA ten-fold (Figure 9).  The high primer efficiency for the 
magnetic bead-based extraction calculated from the PCR reaction (93%) indicated that 
the extracted DNA was sufficiently separated from PCR inhibitors found in urine 
 
Figure 17.  As the mass of spiked DNA is increased the mass of DNA 
recovered using the magnetic bead-based method increases and then 
plateaus at 5.5 µg (mean ± s.d., n = 3). 
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samples.  In optimization studies of the device, the elution volume was varied from 25 to 
500 µL to determine its effect on DNA recovery.  Although increasing the elution volume 
increased the total recovery of DNA from each sample, the end result was a more dilute 
final product.  We chose a 50 µL elution volume because it yielded the highest final 
biomarker concentration. 
The DNA biomarkers present in up to 5 mL of urine were captured onto the 
surface of silica-coated magnetic beads pre-lyophilized with the chaotropic salts 
necessary for nucleic acid-silica adsorption in the bulb of a 5 mL transfer pipette (Figure 
8A).  This design streamlines the concentration of DNA from large volume samples by 
eliminating the need for additional sample handling and pipetting steps that were 
required in our previous reports [21,22].  Following adsorption of nucleic acids to the 
magnetic beads, the transfer pipette was used to directly introduce the sample into the 
small diameter tubing without additional pipettors or disposable supplies, an advantage 
in low resource settings.  The transfer pipette bulb was large enough to contain the 
entire sample and allowed the beads to be easily distributed throughout the volume for 
maximum nucleic acid adsorption.  For this study, the 1 mL sample containing the beads 
was introduced into the tubing resulting in a 60 cm length.  However, this step is not 
necessary, and the overall tubing length can be shortened to ~15 cm by disposing of the 
majority of the urine sample and transferring only the magnetic beads into the small 
diameter tubing.   
The lyophilized urine collection pipette appears to have some long-term storage 
advantages, since lyophilized and freshly prepared reagents within the transfer pipette 
produce similar results (Figure 11).  This is partially due to the fact that the adsorption 
buffer consists only of salt and magnetic beads, which would be expected to have a long 
shelf-life in an unhydrated state but are easily resuspended.  The transfer pipettes were 
prepared in batches of 50 and stored at room temperature for up to 12 weeks prior to 
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use.  Over the 12 week storage period, there was no reduction in device performance 
(Figure 11).  The benefits of long term storage may be advantageous in low resource 
settings where reliable temperature control is not readily available.  Furthermore, the 
composition of the lyophilized contents of the transfer pipette can be modified to target 
other biomarkers in additional sample matrices such as blood and saliva. 
Although 1 mL urine samples were used for the majority of this study, the 
capacity of the urine collection pipette allows a maximum of 5 mL of urine to be 
processed with the magnetic bead-based method.  This volume is ten-fold greater than 
the maximum volume that can be processed using a typical microfluidic extraction 
device.  As shown in Figure 10, processing larger volumes of urine containing the same 
starting concentration of spiked DNA as the 1 mL urine sample yields significantly higher 
DNA concentrations in the eluate, thus improving the likelihood of detecting any 
biomarkers of interest.  This is especially beneficial in cases, such as Tr-DNA, where the 
expected concentration of biomarkers has not been well characterized but is thought to 
be low.  Since urine can be easily obtained in these volumes, it would be possible to 
improve detection simply by increasing the sample volume used. 
There is a decrease in DNA concentration in the eluate of the 5 mL urine sample 
compared to the 3 mL urine sample.  Because the binding capacity of the beads limits 
the number of biomarkers that can be captured within a given sample, it is important to 
consider this when increasing the urine sample volume.  The maximum mass of DNA 
that can be extracted with the magnetic beads was found to be 5.5 µg DNA/6 x 108 
beads (Figure 17).  This is ~20 times more DNA than the 250 ng expected in a 1 mL 
urine sample, or ~4 times more than the 1.25 µg expected in a 5 mL urine sample [24]. 
Although there is ample DNA capacity on the beads for a pure DNA sample 
containing the equivalent amount of DNA as a 5 mL urine sample, the additional PCR 
inhibitors present in the larger urine sample could be one cause of the decreased 
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concentration.  However, the scalability of the magnetic bead-based extraction would 
allow us to optimize for a 5 mL sample to take advantage of the increased biomarkers in 
a larger sample.  As shown in Figure 16, increasing the number of magnetic beads 
increases DNA recovery up to a point.  Additionally, increasing the volumes of wash 
solutions to remove additional inhibitors may further improve the final DNA concentration 
in larger samples.  With further optimization and a higher capacity transfer pipette, the 
magnetic bead-based method could be adapted to extract biomarkers from increasingly 
large urine volumes as high as 20 mL.  This drastic increase in volume may require a 
longer adsorption step, but the opportunity to capture more biomarkers may be worth the 
trade-off in total processing time. 
Two factors limit the general utility of this approach for detection of disease 
biomarkers excreted in urine.  The first is the availability of biomarkers in urine.  
Relatively little is known about DNA excreted in urine, but there is evidence that a 
nucleic acid background of 40-250 ng/mL is normally present [24].  Using gel 
electrophoresis to visualize Tr-DNA extracted from human urine provided by healthy 
volunteers, Melkonyan et. al determined that the expected size of these DNA fragments 
in urine is less than 250 bp, with the majority of the fragments being between 10 and 150 
bp [4].  With respect to diagnosis of TB, the use of biomarkers in urine is controversial.  
Though some studies have successfully detected TB DNA in urine [6,7], others have 
achieved poor results [5,25,26].  This may be due to lack of standardization in sample 
collection and processing, secondary infections, medication, or differences in patient 
populations.  Active TB infection is the most likely disease state for detection, since in 
latent TB the bacteria are sequestered within the lungs [27], and one would expect much 
lower levels of TB DNA biomarker to be available in the blood and urine.  Perhaps the 
biomarker recovery strategy described here will enable more definitive studies of Tr-DNA 
as a potential TB diagnostic.  Additionally, there are other potential applications for which 
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our technology could be useful, including the extraction of carbohydrates for the 
diagnosis of TB using LAM, or the extraction of nucleic acid biomarkers for chlamydia, 
gonorrhea, and prostate cancer [28-30]. 
DNA segment length affects the binding properties of the silica-coated beads and 
is a second factor limiting the diagnostic utility of this approach.  We found that 
sequences as short as 75 bp can be extracted from human urine following adsorption in 
the transfer pipette bulb, and that the recovery of DNA increases as the sequence length 
is increased.  These results agree with previously reported data that suggest the 
minimum nucleic acid length that can be recovered using silica adsorption is 60 bp, and 
that the recovery of nucleic acid is lower near this limit [31].  As demonstrated in Figure 
14, the recovery of 100 and 140 bp DNA sequences is increased approximately four-fold 
and six-fold, respectively, compared to a 75 bp sequence. Although the recovery of DNA 
decreases as the sequence length decreases, the longer sequences tested fall within 
the expected size range for Tr-DNA as reported by Melkonyan et. al [4].   
In patient samples exhibiting expected patient variability, the relationship 
between TB Tr-DNA measurements and clinical diagnosis remains to be determined.  In 
this study, one large stock of pooled human urine samples was used in an effort to 
minimize sample-to-sample variability of PCR inhibitors and account for the expected 
difference in nucleic acid concentration between patient samples.  A single concentration 
of synthetic TB IS6110 biomarker was spiked into each sample to create a controlled 
surrogate patient sample for the validation of our device.  Using this approach, we found 
that DNA recovery from human urine samples remained constant as the number of 
copies of spiked DNA increased (Figure 12).  This is an advantage, because when 
biomarkers are present in low concentrations, the magnetic bead-based method can still 
be used to effectively extract a high percentage of the biomarkers.  As the concentration 
of spiked DNA was increased, the sample variance decreased.  This was an expected 
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trend since at low copy numbers the signal is more difficult to distinguish from noise, a 
characteristic not only of the extraction process, but also of the PCR. 
After determining the LOD of the PCR reaction used in this study, we found that 
77 copies/µL was the minimum concentration of IS6110 DNA that must be present in a 1 
mL human urine sample to be detectable by PCR following extraction with the magnetic 
bead-based method (Figure 13).  This reported value is a function of the PCR protocol, 
the sample preparation method, and the limited sample-to-sample variability of PCR 
inhibitors present in the pooled human urine samples.  There is currently no clinical data 
available to determine the expected initial human urine biomarker concentration that 
would be necessary to utilize Tr-DNA samples for TB diagnosis.  We expect that if the 
use of Tr-DNA for clinical diagnosis becomes standardized in the future, our reported 
biomarker concentration will be useful in this field of study.  We also anticipate that the 
minimum required biomarker concentration would be different for alternative downstream 
detection strategies. 
One of the attractive features of the magnetic bead-based extraction strategy is 
that it is amenable to low resource settings.  First, urine samples are easy to obtain 
noninvasively and can usually be obtained in much higher volumes than other samples.  
The use of urine also circumvents the cultural taboos and cross contamination concerns 
with using blood samples.  Second, because of the simplicity and storage capabilities of 
the urine collection pipette, the magnetic bead-based extraction does not require 
refrigeration or special handling, both of which are highly desirable in a low resource 
setting.  Third, the reagent costs are relatively low and are estimated to be less than $1 
per extraction.  Fourth, a short processing time is essential in low resource settings 
where patients often require an immediate diagnosis.  The rapid DNA adsorption and 
elution from the magnetic beads minimizes the processing time required to achieve 
maximum DNA recovery (Figure 15), thus reducing the overall time-to-diagnosis.  The 
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magnetic bead-based extraction recovers comparable DNA to the Norgen kit and can be 
completed nearly 3 times faster.  Finally, although PCR was used as the nucleic acid 
detection method to validate the work done in this study, the extracted nucleic acids are 
expected to be compatible with a variety of downstream detection strategies that may be 
better suited for use in low resource settings, such as isothermal PCR.  One of the long-
term goals of this research is to incorporate an isothermal PCR amplification and 
detection scheme directly into the small diameter tubing to identify biomarkers-of-interest 
after extraction. 
Because there is no comparable low resource urine extraction technology, we 
chose to validate our magnetic bead-based extraction by comparing its performance to 
the commercially available laboratory-based Norgen urine extraction kit.  Though it 
performs well, the Norgen kit requires multiple pipetting and centrifugation steps which 
make it unsuitable for use in a low resource setting.  The magnetic bead-based 
extraction presented here performs similar to or better than the Norgen kit.  However, in 
the field, the magnetic bead-based extraction would be available as a preloaded 
cassette containing all necessary processing solutions sealed within the tubing.  For 
each extraction, processing would require only a sample collection step within the urine 
collection pipette followed by the transfer of magnetic beads down the length of the small 
diameter tubing using an external magnet. 
The magnetic bead-based extraction method effectively captures nucleic acids 
from large volume urine samples and concentrates them for downstream detection.  The 
urine collection pipette in combination with the pre-arrayed solutions in the small 
diameter tubing achieves high nucleic acid recovery from easily obtainable clinical 
human urine samples.  This approach, therefore, has potential utility for urine-based 
diagnosis of active TB in low resource settings and other diagnostic applications found to 
be associated with 60-250 bp DNA fragments excreted in urine. 
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Abstract 
 Biomarkers oftentimes must be extracted from patient samples to eliminate 
inhibitors of downstream detection methods.  We present an automated biomarker 
extraction device based on the transfer of biomarker-loaded magnetic beads through a 
series of processing solutions arrayed in a length of small-diameter tubing and held in 
place by surface tension valves.  The tubing is coiled around a 12.5 cm diameter plastic 
cassette, and a motor rotates the cassette past a fixed permanent magnet to transfer 
magnetic beads down the length of tubing, effectively washing and eluting captured 
biomarkers.  The automated extraction device was validated using surrogate patient 
samples prepared by the Program for Appropriate Technology in Health (PATH) using 
clinically relevant concentrations of various pathogens corresponding to a low, medium, 
and high level of infection.  Extracted biomarkers included RNA from influenza A infected 
swabs; DNA from Escherichia coli infected urine, Mycobacterium tuberculosis (TB) 
infected sputum, and malaria infected blood; and protein from malaria infected blood. 
Quantification was completed post-extraction using qRT-PCR, qPCR, and ELISA, 
respectively.  The lowest concentration of pathogen infection was successfully detected 
in each sample tested.  RNA biomarker recovery was at least 7.3 copies/uL from the 
influenza A sample.  DNA biomarker recovery was at least 405 copies/uL from the E. coli 
samples, 0.22 copies/uL from the TB samples, and 167 copies/uL from the malaria 
samples.  Protein biomarker recovery was at least 2.7 pM from the malaria samples.  
The automated biomarker extraction device was determined to be effective for extracting 
both nucleic acid and protein biomarkers from complex biological samples. 
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Introduction 
 Biomarkers of infectious diseases are typically found in relatively low abundance 
compared to the host of human biomolecules present in biological samples. Some of the 
most sensitive and effective biomarker detection methods (i.e., polymerase chain 
reaction [PCR] for nucleic acids or enzyme-linked immunosorbent assay [ELISA] for 
proteins) require biomarkers to be captured and extracted from complex samples prior to 
amplification and detection. Nucleic acid and protein extraction methods are relatively 
complex, and generally require an extensive number of user steps to be completed. 
Therefore, there is demand for automated methods for nucleic acid and protein 
biomarker extraction. Due to the diverse nature of both patient samples and validated 
biomarkers, there is also demand for an automated extraction device that can recover 
more than one type of biomolecular target. However, biomarker capture and isolation 
procedures are generally highly specialized to individual classes of biomarkers. For 
example, nucleic acid biomarkers are commonly extracted using a silica-coated solid 
phase and require chaotropic salts and highly concentrated ethanol solutions for 
processing, whereas proteins are commonly extracted using an antibody-coated solid 
phase with buffered saline and detergent processing solutions. Consequently, individual 
biomarker extraction protocols are not easily adapted into a single automated format for 
extracting multiple biomarker classes from a variety of sample matrices. 
 The use of functionalized magnetic beads as a platform for solid phase 
biomarker extraction has facilitated automated extraction of many biomarker classes 
because magnetic beads enable simple and flexible handling due to their susceptibility 
to magnetic manipulation. Various research groups have developed automated 
biomarker extraction assays based on functionalized magnetic beads. In one approach 
developed by Sur et al., a simple motorized actuator is used to draw magnetic particles 
84 
 
through a single step extraction process [1]. This device is simple to operate and is 
sealed from external contaminants, while most manual magnetic bead-based extractions 
require the user to repeatedly open and close the system to the environment to 
introduce the biomarker-bound beads to the various processing solutions. Multiple 
nucleic acid isolations were performed with this device using plasma, whole blood, and 
urine samples, indicating that the device is adaptable for different sample matrices. The 
device is limited to running one sample at a time and may not perform well with samples 
that require more than a single-step processing protocol. In another approach developed 
by Berry et al. [2], antibodies captured on the surface of functionalized magnetic beads 
are extracted from a simple buffer solution using an automated sliding magnet 
configuration. The magnet is positioned under an array of processing solutions 
separated by oil. This device uses a custom made tray to process multiple samples 
simultaneously. The format is capable of handling sample sizes ranging from 2 L to 1 
mL. However, this open format may be susceptible to environmental contaminants, and 
was not tested using complex biological matrices. In a more complex approach, a high-
throughput robotic instrument was designed to extract nucleic acids from biological 
samples in a 96-well plate format [3]. The benefits of this design include minimal user 
interaction after the initial setup and the instrument’s high-throughput capabilities with 
reduced procedure time. However, this instrument contains complex movable parts for 
solution handling and magnetic bead manipulation, and the plates remain open to the 
environment within the instrument. Another disadvantage of this approach is the high 
initial cost of the robotic workstation. Other automated designs based on magnetic 
beads have been developed that span a wide range of complexity from microfluidic chips 
to robotic workstations, but none have yet emerged as a universal biomarker isolation 
technique [4,5]. Despite the success of these approaches, there is a still need for an 
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automated system capable of extracting multiple biomarker classes from complex 
samples in diagnostic laboratories. 
 In this report, we describe a simple yet effective automated device for 
multiplexed extraction of nucleic acid or protein biomarkers from complex biological 
samples. This device was based on our previously developed manual biomarker 
extraction format, which uses functionalized magnetic beads to extract RNA, DNA, and 
protein biomarkers within small diameter plastic tubing (1.6 mm i.d.) [6-9]. The tubing is 
pre-loaded with processing solutions separated by air or mineral oil surface tension 
valves. In this format, the magnetic beads capture the biomarker of interest and are then 
pulled through the various processing solutions using an external magnet. We describe 
the adaptation of this versatile format into an automated device by coiling the extraction 
tubing around a plastic disk and processing the magnetic beads through the various 
solutions by turning the disk past a fixed permanent magnet using a motor and 
programmable controller (Figure 18). The result is an automated device suitable for 
extracting nucleic acid or protein biomarkers from complex biological samples with a 
simple user interface and rapid extraction time. 
 
Materials and Methods 
 
Materials for device fabrication. 
 The Arduino UNO Rev3 programmable controller was purchased from Arduino 
(Cat # A000066). The stepper motor drive controller (Cat # STR4), stepper motor (Cat # 
HT23-401), and power supply (Cat # PS150A24) were purchased from Applied Motion 
Products. Cylindrical magnets were purchased from SuperMagnetMan (Cat # Cyl0360 
N40).  
 
86 
 
Design and operation of the automated biomarker extraction device. 
The automated biomarker extraction device was designed to transport magnetic 
beads through a series of processing solutions contained within 1.6 mm i.d. tubing by 
rotating an extraction cassette (i.e., a plastic disk with extraction tubing wrapped around 
the circumference) past a fixed magnet using a simple stepper motor (Figure 18). A 
roller-drive design was chosen over an axle-drive design to facilitate the loading of 
multiple independent cassettes onto the device. In this design, individual cassettes are 
placed onto a rotating shaft that drives the rotation of the cassette past a second shaft 
containing fixed magnets.  
 
 
 
The Arduino UNO Rev3 programmable controller was used to send logical input 
commands to the motor controller to regulate the direction, speed, and timing of the 
drive motor. The motor controller is controlled by the Arduino UNO and modulates the 
power to the motor from the power supply. The Arduino code was developed with 
respect to the ratio of the roller drive shaft and extraction cassette diameters, allowing 
 
Figure 18.  The automated biomarker extraction device is shown.  Extraction tubing is wrapped 
around the outer diameter of each extraction cassette.  A stepper motor rotates the roller which 
drives the rotation of the extraction cassette past an array of fixed permanent magnets for 
processing.  
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the operator to simply input desired rotational distance and velocity into the appropriate 
command line. A device schematic and the default commands used to operate the 
Arduino UNO controller are provided as supporting information. Two timing gears and a 
ribbed belt attach the motor to a roller on which the cassettes sit. As the roller rotates, 
friction between the roller and the cassettes causes the cassettes to rotate past a panel 
of fixed magnets. The rotation processes magnetic beads through the various solutions 
within the tubing.  
 
Materials for nucleic acid extraction and detection. 
 Influenza A, Esherichia coli (E. coli), Mycobacterium tuberculosis (TB), and 
Plasmodium falciparum (malaria) infected sample panels were provided by the Program 
for Appropriate Technology in Health (PATH).  Primers, probes, and reference standard 
templates were purchased from Integrated DNA Technologies.  SuperScript III 
RT/Platinum TAQ mix was purchased from Life Technologies (Cat # 11732-088).  
Quanta PerfectA 2x mastermix was purchased from VWR (Quanta Biosciences, Cat # 
84010).  Dynabeads MyOne Silane magnetic beads (Cat # 37002D) were purchased 
from Life Technologies.  Neodymium magnets were purchased from Emovendo LLC.  
Filtration swabs (Cat # 5001.02) were purchased from Salimetrics Inc. Ni-NTA Magnetic 
Agarose Beads (Cat # 36111) were purchased from Qiagen Inc. Antibodies for the 
pfHRP-II ELISA (Cat # ab9206 and ab30384) were purchased from Abcam Inc. 3,3′,5,5′-
tetramethylbenzidine (TMB) One solution (Cat # G7431) was purchased from Promega 
Corporation. Recombinant HRP-II (Cat # AGPF-55) was purchased from Immunology 
Consultants Laboratory Inc.  Hemato-Seal tube sealing compound (Cat # 02-678) was 
purchased from Fisher Scientific.  Fluorinated ethylene propylene (FEP) tubing was 
purchased from McMaster Carr (Cat # 2129T11 and # 9369T46).  Tygon R-3603 tubing 
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was purchased from Fisher Scientific (Cat # 14-169-1B). All other materials were 
purchased from Sigma Aldrich or Fisher Scientific. 
 
Optimization of automated extraction cassette processing. 
 Prior to extraction the extraction tubing was prepared in a 30 cm length of 1.6 
mm i.d. FEP tubing according to Bordelon et al [7].  Briefly, the tubing was loaded by 
pipetting 50 uL nuclease-free water, 300 uL 70% ethanol, and 300 uL DNA precipitation 
buffer (80% ethanol, 5 mM potassium phosphate, pH 8.0) into one end.  Each solution 
was separated from the next by a 6 mm air valve.  A 500 uL human urine sample spiked 
with 5 x 108 copies of a 140 nucleotide TB IS6110 DNA sequence was combined with 
500 uL DNA-silica adsorption buffer (4 M guanidine thiocyanate, 25 mM sodium citrate, 
pH 7.0) and 6 x 108 silica-coated magnetic beads (20 uL suspension) and placed on a 
laboratory rotisserie for 5 minutes.  Following nucleic acid adsorption, the tube contents 
were pipetted into the end of the prepared small-diameter tubing and both ends sealed 
with tube sealing compound.  The prepared tubing was processed one of three ways:  
manually as described by Bordelon and coworkers [7], using a continuous single-speed 
automated approach, or using a continuous multi-speed automated approach.   
For automated processing, the prepared tubing was loaded onto the extraction 
cassette and placed in the device.  During single-speed processing, the extraction 
device was programmed to rotate the cassette at a single fixed speed to continually pull 
the beads from one end of the tubing to the other with no mixing.  The bead procession 
rate was set to 5°/second, 10°/second, 15°/second, or 20°/second and the extraction 
was allowed to proceed until the magnetic beads exited the final chamber.  The tubing 
was removed from the cassette and the elution chamber excised for downstream 
quantification by PCR using a Rotor-Gene Q thermal cycler. 
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During multi-speed processing, the extraction device was programmed to rotate 
the cassette at two alternating speeds.  The first was designed to transport the beads 
down the length of the tubing, and the second to mix the beads within each processing 
solution.  The bead transfer step was set to 10° at a rate of 5°/second, and the bead 
mixing step was set to 705° at a rate of 150°/second with a 5 second pause to collect the 
beads before the transfer step was repeated.  The extraction was allowed to proceed 
until the magnetic beads exited the final chamber.  The tubing was removed from the 
cassette and the elution chamber excised for downstream quantification by PCR using a 
Rotor-Gene Q thermal cycler. 
 
Validated PATH surrogate sample panels. 
The efficacy of the automated biomarker extraction device was tested using 5 
sets of surrogate patient sample panels prepared and validated by PATH.  Each sample 
panel contained a surrogate patient sample spiked with 3 concentrations of pathogen 
corresponding to a biologically relevant low, medium, or high level of infection.  The 
sample panels tested are listed in Table 1.  Each sample panel was received frozen on 
dry ice and stored at -80°C until needed. 
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Extraction of Influenza A RNA from flocked swabs.   
Prior to extraction the extraction tubing was prepared in a 15 cm length of 1.6 
mm i.d. FEP tubing.  The tubing was loaded by pipetting 50 uL nuclease-free water, 300 
uL 70% ethanol, and 300 uL RNA precipitation buffer (80% ethanol, 5 mM potassium 
phosphate, pH 8.0) into one end.  Each solution was separated from the next by a 6 mm 
air valve.   
Influenza A virions were eluted from the swab by soaking in 180 uL of sterile PBS 
for 15 minutes in a 2 mL microcentrifuge tube.  The flocked swab was discarded, and the 
contents of the tube vortexed briefly.  The sample was combined with 300 uL RNA-silica 
adsorption buffer (5.7 M guanidine thiocyanate, 25 mM sodium citrate, 1% 2-
mercaptoethanol, pH 7.0) and 6 x 108 silica-coated magnetic beads (20 uL suspension) 
and vortexed thoroughly.  After the addition of 300 uL of ethanol, the tube was placed on 
a laboratory rotisserie for 5 minutes.  Following nucleic acid adsorption, the tube 
contents were pipetted into the end of the preloaded tubing and both ends sealed with 
tube sealing compound. 
Table 1.  Summary of validated PATH surrogate sample panels tested in this study.  The 
sample concentration for Influenza A is provided in approximate expected Ct value for RT-
PCR.  The concentration is provided in cells/mL for TB and E. coli sample panels, and percent 
parasitemia for malaria samples. 
Pathogen Analyte 
Matrix/ 
Biomarker 
Sample Concentration 
Negative Low Medium High 
Influenza 
A 
Virions 
Flocked 
Swab/ 
RNA 
0 35-37 Ct 26-29 Ct 17-21 Ct 
TB H37RV Cells 
Sputum/ 
DNA 
0 
1 x 10
3
 
cells/mL 
1 x 10
4
 
cells/mL 
1 x 10
5
 
cells/mL 
E. coli Cells 
Urine/ 
DNA 
0 
1 x 10
3
 
cells/mL 
1 x 10
4
 
cells/mL 
1 x 10
5
 
cells/mL 
Malaria Parasite 
Blood/ 
DNA 
0 
0.001% 
parasitemia 
1% 
parasitemia 
5% 
parasitemia 
Malaria Parasite 
Blood/ 
Protein 
0 
0.001% 
parasitemia 
1% 
parasitemia 
5% 
parasitemia 
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The prepared tubing was loaded on the extraction cassette and placed in the 
device for extraction.  The bead transfer step was set to 10° at a rate of 5°/second and 
the bead mixing step was set to 705° at a rate of 150°/second with a 5 second pause to 
collect the beads before repeating the transfer step.  The extraction was allowed to 
proceed until the magnetic beads exited the final chamber, resulting in a total assay time 
of 10 minutes including nucleic acid adsorption.  The tubing was removed from the 
cassette and the elution chamber excised for downstream quantification by RT-PCR 
using a Qiagen Rotor-Gene Q thermal cycler. 
 
Extraction of E. coli DNA from human urine. 
Prior to extraction the extraction tubing was prepared in a 10 cm length of 1.6 
mm i.d. FEP tubing.  The tubing was loaded by pipetting 50 uL nuclease-free water, 300 
uL 70% ethanol, and 300 uL DNA precipitation buffer (80% ethanol, 5 mM potassium 
phosphate, pH 8.0) into one end.  Each solution was separated from the next by a 6 mm 
air valve.   
A 1 mL E. coli spiked urine sample was centrifuged for 5 minutes at 10,000 x g in 
a 1.5 mL microcentrifuge tube and the supernatant was discarded.    The E. coli cells 
were lysed by adding 100 uL lysis buffer (50 mM Tris-HCl, 10 mM EDTA, 5% Triton X-
100, 100 mM NaCl) and 25 uL lysozyme solution (10 mg/mL).  The tube was vortexed 
briefly and placed on a laboratory rotisserie for 20 minutes.  The lysed cells were 
centrifuged for 5 minutes at 10,000 x g to remove cell debris, and the supernatant was 
retained for nucleic acid extraction.  The sample was combined with 300 uL DNA-silica 
adsorption buffer (4 M guanidine thiocyanate, 25 mM sodium citrate, pH 7.0) and 6 x 108 
silica-coated magnetic beads (20 uL suspension) and placed on a laboratory rotisserie 
for 5 minutes.  Following adsorption, the contents of the tube were pipetted into the end 
of the preloaded tubing and both ends sealed with tube sealing compound. 
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The prepared tubing was loaded on the extraction cassette and placed in the 
device for extraction.  The bead transfer step was set to 10° at a rate of 5°/second and 
the bead mixing step was set to 705° at a rate of 150°/second with a 5 second pause to 
collect the beads before repeating the transfer step.  The extraction was allowed to 
proceed until the magnetic beads exited the final chamber, resulting in a total assay time 
of 40 minutes including cell lysis and nucleic acid adsorption.  The tubing was removed 
from the cassette and the elution chamber excised for downstream quantification by 
PCR using a Qiagen Rotor-Gene Q thermal cycler. 
 
Extraction of Mycobacterium tuberculosis DNA from synthetic sputum. 
Prior to extraction the extraction tubing was prepared in a 70 cm length of 1.6 
mm i.d.  FEP tubing.  The tubing was loaded by pipetting 50 uL nuclease-free water, 300 
uL 70% ethanol, 300 uL RNA precipitation buffer (80% ethanol, 5 mM potassium 
phosphate, pH 8.0), and 300 uL chaotropic wash buffer (4 M guanidine hydrochloride, 25 
mM sodium citrate, pH 7.0) into one end.  Each solution was separated from the next by 
a 6 mm air valve.   
A 500 uL TB-infected synthetic sputum sample was combined with TB 
lysis/binding buffer (4 M GuSCN, 25 mM sodium citrate, 4.9% Triton X-100, 0.2% 
sodium dodecyl sulfate, pH 7.0) and 6 x 108 silica-coated magnetic beads (20 uL 
suspension) in a 2 mL microcentrifuge tube.  The tube was vortexed for 10 minutes on a 
Fisher Vortex Genie 2 set to speed 4 to lyse the bacterial cells and capture released 
nucleic acids.  Following adsorption, the contents of the tube were pipetted into the end 
of the preloaded tubing and both ends sealed with tube sealing compound. 
The prepared tubing was loaded on the extraction cassette and placed in the 
device for extraction.  The bead transfer step was set to 10° at a rate of 5°/second and 
the bead mixing step was set to 705° at a rate of 150°/second with a 5 second pause to 
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collect the beads before repeating the transfer step.  The extraction was allowed to 
proceed until the magnetic beads exited the final chamber, resulting in a total assay time 
of 20 minutes including cell lysis and nucleic acid adsorption.  The tubing was removed 
from the cassette and the elution chamber excised for downstream quantification by 
PCR using a Qiagen Rotor-Gene Q thermal cycler. 
 
Extraction of Plasmodium falciparum DNA from human blood culture. 
Prior to extraction the extraction tubing was prepared in a 43 cm length of 2.36 
mm i.d. FEP tubing.  The tubing was loaded by pipetting 50 uL elution buffer (10 mM Tris 
pH 8.0, 1 mM EDTA, 0.05% Tween-20), 300 uL 70% ethanol, and 300 uL chaotropic 
wash buffer (80% ethanol, 640 mM GuSCN, 1.6 mM Tris pH 8.0, 160 uM EDTA, 0.08% 
Triton X-100) into one end.  Each solution was separated from the next by a 6 mm air 
valve.   
A 100 uL sample of malaria-infected human blood culture (5% hematocrit) was 
combined with 300 uL lysis buffer (4 M GuSCN, 10 mM Tris HCl pH 8.0, 1 mM EDTA, 
0.5% Triton X-100) and incubated at room temperature for 10 minutes with occasional 
vortexing to lyse red blood cells.  The lysed samples were then filtered using one-fourth 
of a Salimetrics swab, and the sample was expressed from the swab by using a 5 mL 
plastic syringe. After the addition of 100 uL of 100% isopropanol and 7.5 x 108 silica-
coated magnetic beads (25 uL suspension) to the filtered sample, it was incubated for 3 
minutes at room temperature.  Following nucleic acid adsorption, the tube contents were 
pipetted into the end of the preloaded tubing and both ends sealed with tube sealing 
compound. 
The prepared tubing was loaded on the extraction cassette and placed in the 
device for extraction.  The bead transfer step was set to 10° at a rate of 4°/second and 
the bead mixing step was set to 705° at a rate of 80°/second with a 5 second pause to 
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collect the beads before repeating the transfer step.  The extraction was allowed to 
proceed until the magnetic beads entered the final chamber, at which point the cassette 
was removed from the extraction device and the beads allowed to elute for 3 minutes.  
The beads were then removed from the elution chamber using a magnet, and the elution 
chamber excised for downstream quantification by PCR using the Roche LightCycler 96 
thermal cycler.  The total assay time was approximately 20 minutes including cell lysis 
and nucleic acid adsorption.   
 
Extraction of Plasmodium falciparum HRP-II from human blood culture. 
Prior to extraction the extraction tubing was prepared in a 24 cm length of 1.6 
mm i.d. Tygon R-3603 tubing.  The rounded end of a 200 uL PCR tube was cut off, and 
the top of the cap was punctured with a 27 ½ gauge needle to serve as an air release 
valve. The modified tube was then inserted into one end of the Tygon tubing.  Ten 
microliters of elution buffer (50 mM potassium phosphate, pH 8.0, 300 mM NaCl, 1 M 
imidazole, 0.05% Tween-20) was pipetted into the opposite end of the tubing which was 
then sealed with tube sealing compound.  Mineral oil valves (25 uL mineral oil) were 
added alternately with three 100 uL wash chambers (50 mM phosphate buffer, pH 8.0, 
300 mM NaCl, 125 mM imidazole, 0.05% Tween-20) down the length of the tubing using 
a 27 ½ gauge syringe.  Finally, mineral oil was added between the final wash chamber 
and inserted PCR tube to seal off the tubing to air. 
A 100 uL sample of infected blood culture (5% hematocrit) was lysed with 100 uL 
of lysis buffer (100 mM potassium phosphate pH 8.0, 600 mM NaCl, 250 mM imidazole, 
2% Triton X-100) in a 1.5 mL microcentrifuge tube.  Following lysis, the sample was 
filtered through a 1 mL syringe fitted with glass wool to removed lysed cell debris.  The 
filtered sample was mixed with 1.5 x 103 magnetic Ni(II)NTA agarose beads (10 uL 
suspension) in the modified PCR tube, which was placed on a laboratory rotisserie for 
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10 minutes to ensure mixing of the beads throughout the sample.  After the incubation 
period, the PCR tube was reinserted into the extraction tubing and the beads were 
pulled into the adjacent mineral oil valve using a donut-shaped neodymium magnet.  
Finally, the PCR tube was removed and the extraction tubing sealed with tube sealing 
compound.   
The prepared tubing was loaded on the extraction cassette and placed in the 
device for extraction.  The bead procession step was set to 10° at a rate of 3°/second 
and the bead mixing step was set to 695° at a rate of 60°/second with a 5 second pause 
to collect the beads.  The extraction was allowed to proceed until the magnetic beads 
exited the final chamber, resulting in a total assay time of 40 minutes including cell lysis 
and nucleic acid adsorption.  The tubing was removed from the cassette and the elution 
chamber excised for downstream quantification by ELISA. 
 
Nucleic acid quantification by PCR and RT-PCR. 
 Nucleic acids extracted from panel samples were quantified by RT-PCR or PCR 
as appropriate according to protocols adapted by PATH from existing studies [10-13].  
The primer/probe sequences and cycling conditions for each individual nucleic acid 
biomarker are provided in Table 2.  Influenza A RNA was quantified via RT-PCR using 
the SuperScript III RT/Platinum Taq mix in 25 uL reaction volumes with a final primer 
concentration of 800 nM and a final probe concentration of 150 nM.  DNA from E. coli, 
TB, and malaria was quantified via PCR using Quanta PerfectA 2x mastermix in 25 uL 
reaction volumes. Final primer concentrations were 800 nM, 300 nM, and 800 nM for E. 
coli, TB, and malaria, respectively.  The final probe concentration was 150 nM for all 
reactions.  All thermal cycling was performed using the Qiagen Rotor-Gene Q or Roche 
LightCycler 96 thermal cycler as noted above.  Rotor-Gene Q or LightCycler software 
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was used to determine Ct values, and nucleic acids were quantified by referencing a 
standard curve. 
 
Protein quantification by ELISA. 
Extracted pfHRP-II protein was quantified by ELISA in 96-well Immulon 2 HB 
plates according to Davis et. al [9].  Once the plate was developed, absorbance was 
quantified at 450 nm using a BioTek Synergy H4 microplate reader, and the protein was 
quantified by referencing a standard curve.  
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Table 2.  The primer and probe sequences and thermal cycling conditions used for the 
quantification of nucleic acids extracted from validated panel samples are shown. 
Influenza A – RT-PCR [10]  
Forward Primer (5’3’) GACCRATCCTGTCACCTCTGAC 
Reverse Primer (5’3’) AGGGCATTYTGGACAAAKCGTCTA 
Probe (5’3’) 
FAM-
TGCAGTCCTCGCTCACTGGGCAC
G-BHQ1 
Cycling Conditions 
50°C – 30 minutes 
95°C – 2 minutes 
45 cycles of: 
          95°C – 15 seconds 
          55°C – 30 seconds 
 
TB H37RV – PCR [11]  
Forward Primer (5’3’) GGGTAGCAGACCTCACCTATG 
Reverse Primer (5’3’) AGCGTAGGCGTCGGTGA 
Probe (5’3’) 
FAM-TCGCCTACGTGGCCTTT-
MGBQ 
Cycling Conditions 
95°C – 3 minutes 
45 cycles of: 
          95°C – 15 seconds 
          60°C – 60 seconds 
 
E. coli – PCR [12]  
Forward Primer (5’3’) GCAAACTGATGTCTTCCGCAC 
Reverse Primer (5’3’) CGAGCGGAACAATCAGCAT 
Probe (5’3’) 
FAM-
TCAGCTGATCAACACCGTTCACGT
TGA-TAMRA 
Cycling Conditions 
95°C – 3 minutes 
45 cycles of: 
          95°C – 30 seconds 
          56°C – 60 seconds 
 
Malaria – PCR [13]  
Forward Primer (5’3’) ACATGGCTATGACGGGTAACG 
Reverse Primer (5’3’) TGCCTTCCTTAGATGTGGTAGCTA 
Probe (5’3’) 
FAM-
TCAGGCTCCCTCTCCGGAATCGA-
BHQ1 
Cycling Conditions 
95°C – 3 minutes 
45 cycles of: 
          95°C – 30 seconds 
          56°C – 60 seconds 
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Results and Discussion 
 In this report, we describe the development of an automated device capable of 
extracting nucleic acid and protein biomarkers from complex samples.  The device was 
designed to move biomarker-bound magnetic beads through a series of processing 
solutions separated by surface tension valves within 1.6 mm i.d. plastic tubing by 
rotating the tubing passed a fixed permanent magnet (Figure 18). This device features 
fewer user steps, increased throughput, and enhanced reproducibility when compared to 
the manual extraction developed in our laboratory [6,7,9] 
One significant challenge to automating the process was reproducing the 
magnetic bead washing steps required during each extraction.  This problem was 
approached with three alternative solutions to determine the optimal extraction cassette 
processing to maximize biomarker recovery.  The first automated program tested was a 
simple procession of the beads from one end of the tubing to another without dispersing 
the beads throughout the solution.  Using this approach, recovery of a spiked DNA 
biomarker decreased linearly with increasing cassette rotation speed (Figure 19A).  The 
maximum biomarker recovery was 2 ± 0.09 x 105 DNA copies, but the recovery was 
significantly lower than for a manual extraction which recovered 1.2 ± 0.5 x 107 copies 
(Figure 19B), indicating that the single-speed extraction process was relatively 
ineffective due to the lack of bead dispersion in each processing solution. 
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 To incorporate mixing steps into the automated program, a more complicated 
solution was a position-dependent program that repeatedly reversed the motor direction 
to disperse the beads throughout each chamber.  This method depended on precise 
extraction tubing preparation, and large quantities of magnetic beads were left behind 
with the slightest deviations in solution volume or position.  Additionally, this position-
dependent alternative required vastly different programming for each biomarker tested, 
and was not tolerant of variations in sample volume for a single biomarker.  This 
approach was quickly abandoned in favor of the final method. 
 Finally, we tested a position-agnostic program based on continuous-direction 
multi-speed processing.  In this approach, the motor spins slowly to move the beads 
forward ~10° then spins rapidly in the same direction for two complete turns.  During the 
rapid spin, the beads are not entrained by the magnet and become dispersed.  The 
beads are then collected with a short pause step, followed by an additional slow spin.  
The process repeats until the beads reach the elution chamber.  Using this approach, 
DNA biomarker recovery was 9 ± 2 x 107 copies, and was comparable to the manual 
 
Figure 19.  A.  DNA biomarker recovery decreases linearly with increasing rotational motor speed 
when the single-speed extraction process is utilized (n=3, mean ± s.d.).  B.  DNA biomarker recovery is 
significantly higher using a manual magnetic bead process and a multi-speed automated process 
compared to the continuous single-speed automated extraction (n=3, mean ± s.d.).  * denotes 
significantly lower DNA recovery compared to manual extraction. 
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extraction process (Figure 19B).  Variations in tubing contents, sample and wash buffer 
volumes, and surface tension valve lengths had no effect on biomarker recovery using 
this position-agnostic multi-speed processing method.  The consistently alternating 
speeds utilized in this program operate independently of extraction cassette alignment, 
allowing individual extraction cassettes to be added or removed from the device without 
disrupting the continuous roller.  One advantage of this design is that multiplex 
extractions are enabled.   
 The automated biomarker extraction device performed well on the sample panels 
tested, recovering detectable quantities of target biomarker for all high, medium, and low 
levels of infection.  In each sample panel tested there is a decrease in extracted 
biomarker concentration from high to low infection levels.  This was the expected trend 
because the starting pathogen concentration also decreased significantly from high to 
low infectivity (Table 1).  The concentration of recovered RNA from influenza infected 
swabs was 1.1 ± 0.6 x 105, 2.3 ± 0.4 x 103, and 7.3 ± 2 copies/uL for high, medium, and 
low levels of infection, respectively (Figure 20A).  Approximately 1.8 ± 0.6 x 104, 2.5 ± 
0.7 x 103, and 405 ± 48 copies/uL of DNA biomarkers were detected in high, medium, 
and low E. coli infected urine (Figure 20B), 463 ± 472, 69.2 ± 84, and 0.22 ± 0.3 
copies/uL in high, medium, and low TB infected sputum (Figure 20C), and 1.6 ± 2 x 106, 
1.2 ± 1.5 x 104, and 167 ± 129 copies/uL in high, medium, and low malaria infected 
blood (Figure 20D).  Finally, 7.2 ± 2.7 x 103, 512 ± 74, and 2.7 ± 1.9 pM HRPII protein 
biomarker was detected in high, medium, and low malaria infected blood (Figure 20E).   
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Figure 20.  Target biomarkers are detected at biologically relevant high, medium, and low levels of 
infection for all processed sample panels.  A.  RNA biomarker was detected by RT-PCR following 
extraction of influenza A infected flocked swabs (n=3, mean ± s.d.).  DNA biomarkers were detected by 
PCR following extraction of B.  E. coli infected human urine (n=3, mean ± s.d.),  C.  TB infected synthetic 
sputum (n=3, mean ± s.d.),  and D.  malaria infected human blood culture (n=9, mean ± s.d.).   E.  Protein 
biomarker was detected by ELISA following extraction of pfHRPII from malaria infected human blood 
culture (n=5, mean ± s.d.). 
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 One major hallmark of the automated biomarker extraction device is the flexibility 
to extract multiple classes of biomarkers using the same device.  In this study, the 
extraction of RNA, DNA, and protein biomarkers is demonstrated, representing a 
significant advantage over less flexible alternative extraction methods.  Theoretically, the 
automated biomarker extraction device could be used to recover any additional 
biomarker classes that could be captured on a surface-functionalized magnetic bead, 
such as whole cells.   
 In addition to its efficacy, the automated biomarker extraction device was also 
relatively rapid.  Each patient sample surrogate required less than 10 minutes for 
magnetic bead processing, and total extraction time ranged from 15 to 40 minutes 
including cell lysis and biomarker capture steps.  Additionally, the potential multiplex 
capabilities of the biomarker extraction device would further increase extraction 
throughput.  Biomarker extraction speed is an important consideration in laboratory 
sample preparation, particularly when relatively long detection schemes such as PCR 
and ELISA are utilized.   
 
Conclusions 
In conclusion, we successfully developed an automated biomarker extraction 
device that isolated multiple biomarker classes (RNA, DNA, and protein) from complex 
surrogate patient samples. The automated format was demonstrated to reduce user 
processing steps and increase extraction throughput without requiring complex robotics 
or fluid pumping.  Biomarker recovery using the automated device was comparable to 
the more complex and involved manual extraction.  The continuous roller format utilized 
in this device allows multiple cassettes to be processed simultaneously, and cassettes 
may be added to or removed from the device without interrupting the processing of other 
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cassettes. This automated device has the potential to simplify and shorten sample 
preparation for multiple biomarker classes in diagnostic settings. 
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Supporting Information 
 
Automated biomarker extraction processor Arduino code 
int i=0;  // variables to keep count for while loop 
int y=0; 
 
//Test Requirements 
int rot_1 = 705; //desired rotation for phase 1 (degrees) 
int rot_2 = 15; //desired rotation for phase 2 (degrees) 
int spd_1 = 150; //desired rotational velocity for phase 1 (deg/sec) 
int spd_2 = 5; //desired rotational velocity for phase 2 (deg/sec) 
int phase_gap = 5000; //desired delay time between phases (milliseconds) 
 
//Device Specifications 
double roller_dia = 0.75; //roller diameter in inches 
 
//Motor Specifications 
double step_deg = 0.18; //degrees per step 
 
//Cartridge Specifications 
double cart_dia = 5.5; //cartridge diameter in inches 
 
//Calculated Constants 
double ratio_eff_gear = cart_dia/roller_dia; 
int step_1 = rot_1/step_deg*ratio_eff_gear; 
int step_2 = rot_2/step_deg*ratio_eff_gear; 
int delay_1 = step_deg/spd_1*1000000/ratio_eff_gear; 
int delay_2 = step_deg/spd_2*1000000/ratio_eff_gear; 
 
void setup() {                 
  pinMode(12, OUTPUT);  
} 
void loop() { 
  while(i < step_1){ 
  digitalWrite(12, HIGH);   // set the PIN on 
  delayMicroseconds(delay_1);   // delay between steps 
  digitalWrite(12, LOW);    // set the PIN off 
  i++; 
  } 
  delay(phase_gap); 
   while(y < step_2){ 
  digitalWrite(12, HIGH);   // set the Pin on 
  delayMicroseconds(delay_2);    // delay between steps 
  digitalWrite(12, LOW);    // set the PIN off 
  y++; 
  } 
  i=0; 
  y=0; 
  } 
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Automated biomarker extraction processor wiring diagram 
 
 
 
 
 
  
 
Figure S1.  This schematic depicts the connections between individual automated biomarker 
extraction device components. 
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Abstract 
 Magnetic beads are convenient for extracting nucleic acids from samples 
preparatory to downstream molecular detection.  However, the appropriate bead surface 
functionality for each situation is not always apparent.  Factors such as the desired level 
of assay simplicity and speed, biomarker specificity, and molecular detection strategy 
must be considered when choosing the ideal surface functionalization.  The advantages 
and disadvantages of three magnetic bead surface chemistries – silica-coated, oligo (dT) 
and RSV sequence-specific – were evaluated.  Silica-coated and oligo (dT) beads 
recovered RNA with ~70% efficiency in less than 10 minutes.  Silica-coated beads 
recovered nucleic acids independent of sequence while oligo (dT) beads more 
selectively recovered mRNA.   RSV-specific beads mainly recovered RSV mRNA, but 
required an incubation time of 3 hours to reach 70% recovery.  Following a 10 minute 
incubation, the RSV-specific beads recovered ~7% of RSV mRNA.  Silica-coated bead 
are well-suited for applications that require nucleic acids other than mRNA, especially 
when background nucleic acid-tolerant detection such as PCR is to be used.  Oligo (dT) 
beads are ideal when mRNA is to be used as a biomarker.  They are rapid and efficient 
enough to work well with PCR but also enable detection strategies performed directly on 
nucleic acids hybridized to the bead surface.  RSV-specific beads may be too selective 
to be useful for detection strategies such as PCR.  They may be appropriate for 
detection schemes performed directly on captured sequences that are affected by high 
concentrations of background nucleic acid. 
 
  
110 
 
Introduction 
 Molecular detection of nucleic acids is an ideal diagnostic modality because of its 
inherent specificity, sensitivity and rapid time-to-diagnosis.  In patient samples, high 
concentrations of contaminants inhibit molecular detection.  Therefore, nucleic acids 
must first be extracted into a contaminant-free buffer to be detectable [1,2].   Nucleic 
acid capture using surface functionalized magnetic beads is one widely utilized 
technique for purifying nucleic acid biomarkers from patient samples.  Because magnetic 
beads can be easily manipulated with a magnetic field, they are a useful alternative to 
nucleic acid extraction using phase separation or centrifugation columns.  Once nucleic 
acids are captured onto the magnetic bead surface, the beads can quickly and easily be 
washed and nucleic acids eluted to complete the extraction.  For this reason, magnetic 
bead-based purification is readily adaptable to a variety of formats, including manual 
extraction performed on a magnetic rack [3], microfluidic chips [4,5] and other self-
contained formats [6-8], as well as automated robotic processing [9,10]. 
The class of nucleic acid biomarkers captured is dependent on the magnetic 
bead surface functionalization.  For example, a silica-coated surface nonspecifically 
recovers both DNA and RNA, while a DNA probe-coated surface recovers only 
complementary nucleic acids that hybridize to the probes.  Prior to extracting nucleic 
acids from a sample, a choice must be made as to what surface chemistry will best suit 
both the desired biomarker and downstream detection modality.   
In many cases, the desired biomarkers can be extracted using a variety of 
surface functionalities.  PCR and RT-PCR are tolerant of the high levels of background 
nucleic acids extracted using silica-coated magnetic particles [3,6,7].  PCR is also used 
following extraction with oligo (dT) functionalized beads which selectively recover mRNA 
[11,12] or with sequence-specific beads which recover complementary nucleic acid 
sequences [13,14].  In many of these cases, it is not always clear why a particular 
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surface functionality was chosen, because when using PCR, total nucleic acid extraction 
is likely sufficient to achieve the desired end result.   
Conversely, some downstream detection schemes are dependent on the capture 
of particular nucleic acid sequences or subsets and benefit from a reduction in 
nonspecific background nucleic acids.   Many of these assays rely on hybridization to 
captured nucleic acids.  For example, following extraction with oligo (dT) magnetic 
beads, captured mRNA has been detected on the bead surface using the isothermal 
amplification strategy quadruplex priming amplification [15].  The bio-barcode assay 
developed by Nam et. al. relies on the detection of specific nucleic acid sequences by 
hybridizing complementary DNA-coated gold nanoparticles to captured nucleic acids 
[16,17].  Alternatively, when extracting with silica-coated magnetic beads, nucleic acids 
are precipitated onto the bead surface and unavailable for hybridization.  In these 
applications, choosing the appropriate magnetic bead surface functionality is essential to 
obtaining the desired results. 
In this manuscript we have identified the advantages and disadvantages of three 
magnetic bead surface functionalities (silica, oligo (dT) and sequence-specific) that 
extract increasingly specific classes of nucleic acids to enable downstream detection. 
 
Materials and Methods 
 
RSV N gene detection by RT-PCR.   
A 277-bp fragment of the RSV N gene was amplified using forward primer 5’-
GGAACAAGTTGTTGAGGTTTATGAATATGC-3’ and reverse primer 5’-
CTTCTGCTGTCAAGTCTAGTACACTGTAGT-3’ [18].  PCR reactions were performed in 
a 20 μL volume using 5μL of RNA template and the Power SYBR Green RNA-to-CT 1-
Step Kit (Applied Biosystems, Grand Island, NY) according to manufacturer’s 
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instructions.  Thermal cycling consisted of 48°C for 30 minutes to synthesize cDNA, 
95°C for 10 minutes to inactivate the reverse transcriptase and activate QTaq DNA 
polymerase, and 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds using a 
Rotor-Gene Q thermal cycler (Qiagen, Germantown, MD).  Product specificity was 
confirmed using melting curve analysis.  Data were collected and Ct values recorded by 
Rotor-Gene Q Software (Qiagen, Germantown, MD) and converted to number of copies 
of RNA per μL using a standard curve. 
 
Preparation of RSV-specific functionalized magnetic beads.   
Dynabeads M-270 Amine magnetic beads (Life Technologies, Grand Island, NY) 
were functionalized with a 22 base DNA probe specific for the N gene of respiratory 
syncytial virus (RSV) according to the protocol developed by Hill, et. al. [16].  The 
thiolated DNA probe consisted of a 9 base A linker sequence followed by 22 bases 
complementary to the RSV N gene as follows:  5’ - /5ThioMC6-D/AAA AAA AAA ATC 
ATG TAA AAG CAA ATG GAG TA - 3’.  The probe sequence was attached to the 
amine-coated beads by SMCC coupling according to Hill, et. al.   
 
Characterization of RSV-specific and oligo (dT) magnetic beads using fluorescently 
labeled complementary and scrambled DNA sequences.   
 
A study comparing recovery of complementary and scrambled fluorescent probes 
was performed to determine whether the laboratory-synthesized RSV-specific beads 
were comparable to the commercially-available Dynabeads Oligo(dT) magnetic beads 
(Life Technologies, Grand Island, NY).  Twenty-two base DNA sequences 
complementary to the probes on each bead were purchased with a 5’ Cy5 dye to 
facilitate quantification.  In addition, a scrambled control probe was purchased to confirm 
113 
 
that probe hybridization was sequence-specific.  The three probe sequences are shown 
in Table 3. 
 
 
 
Extraction of complementary probes was adapted from the manufacturer’s 
protocol for mRNA extraction provided with the oligo (dT) beads.  To compare 
fluorescent probe recovery, 5 x 108 oligo (dT) or RSV-specific beads were washed with 
500 uL of lysis/hybridization buffer (100 mM Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM 
EDTA, 1% LiDS, 5 mM dithiolthreitol (DTT)) in a 1.5 mL centrifuge tube.  The wash was 
removed while the beads were held to one side of the tube with a magnet.  For 
hybridization, 300 uL of lysis/hybridization buffer was added to the beads along with 400 
ng complementary probe and 400 ng scrambled control probe.  The beads were then 
placed on a laboratory rotisserie for 45 minutes to enable fluorescent probe 
hybridization.  Following hybridization, the beads were washed once using 300 uL wash 
buffer A (10 mM Tris-HCl, pH 7.5, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS) and once with 
300 uL wash buffer B (10 mM Tris-HCl, pH 7.5, 0.15 M LiCl, 1 mM EDTA) according to 
the manufacturer’s instructions.  Finally, 50 uL of nuclease-free water was added to the 
beads, and the hybridized probes were released by heating each tube to 65ºC for 2 
minutes.  The eluate was collected while the beads were held to one side of the tube 
with a magnet.   
Table 3.  Fluorescent DNA probes for determining magnetic bead hybridization specificity of 
oligo (dT) and RSV-specific magnetic beads. 
Probe Name Sequence 
Oligo (dT) complementary probe 5’ Cy5 – AAA AAA AAA AAA AAA AAA AAA A 3’ 
RSV N gene complementary 
probe 
5’ Cy5 – TAC TCC ATT TGC TTT TAC ATG A 3’ 
Scrambled control probe 5’ HEX – AGA TGA GAG AAT AGT TTC CAA A 3’ 
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Fluorescent probe recovery was quantified by measuring the fluorescence of 
each eluate on a NanoDrop 3300 Fluorospectrometer (Thermo Scientific, Inc., 
Wilmington, DE).  The samples were excited using a white light source, and the 
emission was collected at 665 nm for Cy5 and 556 nm for HEX.  The relative 
fluorescence was obtained for each eluate and converted to concentration in uM using a 
standard curve.  Finally, the hybridization efficiency was calculated by dividing the total 
number of extracted probes by the total number of input probes and multiplying by 
100%. 
 
Preparation of RSV N gene-spiked HEp-2 cell lysates.   
HEp-2 cell lysates were prepared from a confluent monolayer of HEp-2 cells 
grown in a T-150 flask. The cells were harvested by scraping from the flask and 
centrifuging at 500 x g for 5 minutes. The cell pellet was resuspended into 8 mL 
denaturing solution (4 M guanidinium thiocyanate, 25 mM sodium citrate [pH 7.0] 0.5% 
N-laurosylsarcosine [Sarkosyl], 0.1 M 2-mercaptoethanol) and passed through a pipette 
tip 10 times. The cell lysates were stored at a concentration of approximately 3x106 
lysed cells per mL in 1 mL aliquots at -80°C until ready for use.  Full length RSV N gene 
mRNA sequences were synthesized by Bio-Synthesis, Inc. (Lewisville, TX).  Spiked 
HEp-2 cell lysates were prepared by adding 5 uL of RSV N gene mRNA (1 x 106 
copies/uL) to 20 uL of HEp-2 cell lysate.  The resulting 25 uL samples were used 
immediately following preparation. 
 
Optimization of magnetic capture hybridization protocol for oligo (dT) and RSV-specific 
magnetic beads.   
 
The effect of eliminating magnetic bead wash steps from the oligo (dT) and RSV-
specific magnetic bead extractions was determined in an effort to further simplify the 
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extraction procedure.  Because the oligo (dT) and RSV-specific beads performed 
similarly when tested with complimentary nucleic acid biomarkers as described above, 
the optimization was performed only with oligo (dT) beads.  5 x 108 oligo (dT) beads 
were washed with 500 uL of lysis/hybridization buffer in a 1.5 mL centrifuge tube.  After 
washing, nucleic acid capture was performed by adding 25 uL of RSV N gene-spiked 
HEp-2 cell lysates with 300 uL of lysis/hybridization buffer to the washed beads and 
placing on a laboratory rotisserie for 5 min.  Following nucleic acid capture, the 
lysis/hybridization buffer was removed by pipetting while holding the magnetic beads to 
one side of the tube with a magnet.  The beads were then washed according to the 
manufacturer’s protocol with 300 uL of wash buffer A followed by 300 uL of wash buffer 
B.  Alternatively, both wash steps were omitted from the extraction.  Finally, 50 uL of 
nuclease-free water was added to the beads, and the hybridized probes were released 
by heating the tube to 65°C for 2 minutes.  The eluate was collected, and extracted RSV 
N gene mRNA was quantified by RT-PCR as described above. 
 
RNA extraction capacity of silica-coated, oligo (dT), and RSV-specific magnetic beads.   
 
To ensure the silica-coated, oligo (dT), and RSV-specific beads were compared 
equally, the RNA extraction capacity was determined for each bead type.  In all 
subsequent experiments, the extraction capacity was equivalent for each bead surface 
functionality. 
The maximum mass of background RNA that could be extracted using the silica-
coated magnetic beads was determined by spiking 20 uL of TE buffer with increasing 
quantities of mouse universal RNA (SABiosciences, Valencia, CA) and quantifying the 
mass of RNA extracted.  Twenty microliters of TE buffer was spiked with 200, 400, 600, 
800, or 1000 ng of mouse RNA.  The samples were combined with 300 uL of RNA-silica 
adsorption buffer (5.7 M guanidine thiocyanate (GuSCN), 25 mM sodium citrate, 1% 2-
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mercaptoethanol) and 1 x 108 Dynabeads MyOne Silane magnetic beads (Life 
Technologies) and vortexed thoroughly.  Three hundred microliters of ethanol was 
added, and the sample was placed on a laboratory rotisserie for 5 minutes to enable 
RNA adsorption.  Following adsorption, the solution was removed by holding the beads 
to one side of the tube with a magnet and pipetting out the liquid.  The beads were then 
washed in 300 uL precipitation buffer (80% ethanol, 5 mM potassium phosphate, pH 8.0) 
followed by a 300 uL 70% ethanol wash.  Finally, 50 uL of nuclease-free water was 
added to the beads to elute captured nucleic acids.  The beads were vortexed for 15 
seconds, and the eluate was collected.  The extracted RNA was quantified by measuring 
absorbance at 260 nm using a NanoDrop ND-1000 spectrophotometer and referencing a 
standard curve.   
The maximum mass of complementary RNA that could be extracted using the 
oligo (dT) and RSV-specific magnetic beads was determined by spiking 20 uL of TE 
buffer with increasing quantities of full length RSV N gene mRNA and quantifying the 
mass of mRNA extracted.  Twenty microliters of TE buffer was spiked with 200, 400, 
600, 800, or 1000 ng of mouse RNA.  The samples were combined with 300 uL of 
lysis/hybridization buffer and 1 x 108 oligo (dT) or RSV-specific magnetic beads in a 1.5 
mL centrifuge tube, vortexed thoroughly, and placed on a laboratory rotisserie for 5 
minutes.  Following hybridization, the solution was removed by holding the beads to one 
side of the tube with a magnet and pipetting out the liquid.  Finally, 50 uL of nuclease-
free water was added to the beads, and they were heated to 65°C for 2 minutes to elute 
captured mRNA.  The extracted RNA was quantified by measuring absorbance at 260 
nm using a NanoDrop ND-1000 spectrophotometer and referencing a standard curve.   
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RNA capture kinetics using silica-coated magnetic beads.   
The optimal adsorption time for RNA to silica-coated magnetic beads was 
determined for extraction of RSV N gene-spiked HEp-2 cell lysates following 
quantification using RT-PCR.  Three hundred microliters of RNA-silica binding buffer and 
5 x 108 silica-coated magnetic beads were added to 25 uL of RSV spiked HEp-2 cell 
lysates and vortexed thoroughly.  Three hundred microliters of ethanol was added, and 
the sample was placed on a laboratory rotisserie for 1, 3, 5, 30, 60, 120, or 180 minutes.  
Following adsorption, the solution was removed by holding the beads to one side of the 
tube with a magnet and pipetting out the liquid.  The beads were then washed in 300 uL 
precipitation buffer followed by a 300 uL 70% ethanol wash.  Finally, 50 uL of nuclease-
free water was added to the beads to elute any captured nucleic acids.  The beads were 
vortexed for 15 seconds, and the eluate was collected.  Extracted RSV N gene RNA was 
quantified by RT-PCR as described above. 
 
RNA capture kinetics using oligo (dT) and RSV-specific beads.   
The optimal hybridization time for RNA to oligo (dT) and RSV-specific magnetic 
beads was determined following extraction of RSV N gene-spiked HEp-2 cell lysates and 
quantification using RT-PCR.  For both bead surface functionalities, 6.7 x 108 magnetic 
beads were washed in 500 uL of lysis/hybridization buffer.  For hybridization, 300 uL of 
lysis/hybridization buffer was added to the beads along with 25 uL of N gene-spiked 
HEp-2 cell lysates.  The beads were then placed on a laboratory rotisserie for 1, 3, 5, 30, 
60, 120, or 180 minutes.  Following hybridization, the solution was removed by holding 
the beads to one side of the tube with a magnet and pipetting out the liquid.  Fifty 
microliters of nuclease-free water was added to the beads, and the hybridized probes 
were released by heating the centrifuge tube to 65°C for 2 minutes.  The eluate was 
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collected, and extracted RSV N gene mRNA was quantified by RT-PCR as described 
above. 
 
Ratio of RSV biomarkers to background RNA following extraction with silica-coated, 
oligo (dT), and RSV-specific beads.   
 
The quantity of extracted RSV mRNA was compared to a background of tRNA 
and mRNA for extraction with the silica-coated, oligo (dT), and RSV-specific beads.  A 
mixed RNA sample was prepared by combining 1000 ng background RNA (yeast tRNA, 
Ambion), 30 ng background mRNA (Influenza A matrix protein gene mRNA synthetically 
prepared by Bio-Synthesis), and 0.003 ng full length RSV N gene mRNA.  This ratio of 
background nucleic acid, background mRNA, and viral RNA is approximately equivalent 
to what would be expected in a population of RSV infected cells collected from a patient 
[19].  The RNA sample was extracted using the methods described above for the silica-
coated, oligo (dT), and RSV-specific beads.  Extracted RSV N gene mRNA was 
quantified following RT-PCR as described above.  The presence of extracted 
background DNA was confirmed by measuring the eluate absorbance at 260 nm on a 
NanoDrop ND-1000 spectrophotometer and comparing the absorbance to a blank 
sample containing no RNA.   
Background mRNA was quantified by amplifying a 106 bp region of the influenza 
A matrix protein gene using forward primer 5’ GACCRATCCTGTCACCTCTGAC 3’ and 
reverse primer 5’ AGGGCATTYTGGACAAAKCGTCTA 3’ [20].  Twenty-five microliter 
RT-PCR reactions were prepared using the Power SYBR Green RNA-to-CT 1-step kit, 
and cycling conditions were as follows:  30 minutes at 48⁰C to synthesize cDNA, 95°C 
for 10 minutes to inactivate the reverse transcriptase and activate QTaq DNA 
polymerase, and 40 cycles of 95°C for 15 seconds and 55°C for 60 seconds using a 
Rotor-Gene Q thermal cycler (Qiagen, Germantown, MD).  Product specificity was 
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confirmed using melting curve analysis.  Data were collected and Ct values recorded by 
Rotor-Gene Q Software (Qiagen, Germantown, MD) and converted to number of copies 
of RNA per μL using a standard curve. 
 
Self-contained RSV RNA extraction using silica-coated magnetic beads.   
The preparation of the self-contained extraction tubing was adapted from our 
RNA extraction cassette [6].  A 15 cm section of 2.36 mm inner diameter (i.d.) fluorinated 
ethylene propylene (FEP) tubing (McMaster Carr, catalog # 9369T24) was prepared by 
pipetting 50 uL of nuclease-free water, 300 uL of 70% ethanol, and 300 uL of RNA 
precipitation buffer into one end of the tubing.  Each solution was separated by pipetting 
a 6 mm long air valve between each subsequent addition.  A 1.5 mL centrifuge tube was 
prepared with 25 uL of RSV RNA spiked HEp-2 cell lysate, 300 uL of RNA-silica binding 
buffer, 5 x 108 silica-coated magnetic beads, and 300 uL of ethanol as described above.  
The tube was placed on a laboratory rotisserie for 5 min. to enable nucleic acid 
adsorption.  Following nucleic acid capture, the contents of the tube were pipetted into 
the 15 cm piece of tubing, and both ends of the tubing were capped with clay tube 
sealant (Figure 21A).  A 2.5 cm cubic neodymium magnet was used to gather the 
magnetic beads from the RNA-silica binding buffer and pull them through the first air 
valve into the RNA precipitation buffer.  The magnet was then moved rapidly back and 
forth down the length of the RNA precipitation chamber to disperse the magnetic beads.  
Beads were collected and pulled through the next air valve into the RNA wash chamber, 
where they were dispersed by again moving the magnet back and forth.  Finally, beads 
were collected, pulled into the water chamber and dispersed for 10 seconds to elute 
captured nucleic acids.  The beads were then collected and removed from the water 
chamber.  A razor blade was used to excise the water chamber from the remainder of 
the tubing, and the eluate was collected by holding the excised tubing section over a 0.5 
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mL centrifuge tube.  Extracted RSV mRNA was quantified by RT-PCR as described 
above. 
 
 
 
Self-contained RSV RNA extraction using oligo (dT) and RSV-specific beads.  
A 10 cm length of 2.36 mm i.d. FEP tubing was prepared by pipetting 50 uL of 
nuclease-free water into one end.  A 6 mm air valve was added to the tubing adjacent to 
the water chamber.  A 1.5 mL centrifuge tube was prepared by washing 6.7 x 108 oligo 
(dT) or 6.7 x 108 RSV-specific beads with 500 uL of lysis/hybridization buffer.  The wash 
buffer was removed, and 300 uL of lysis/hybridization buffer and 25 uL of RSV mRNA 
spiked HEp-2 cell lysates were added to the washed beads.  The samples were placed 
on a laboratory rotisserie for 5 minutes to capture any complementary nucleic acids 
present in the sample.  Following nucleic acid capture, the contents of the tube were 
pipetted into the small diameter tubing after the 6 mm air valve.  Both ends of the tube 
 
Figure 21.  A) Total nucleic acids were captured on silica-coated 
magnetic beads and extracted by pulling the beads through a series 
of processing solutions using a permanent magnet.  B)  Sequence-
specific nucleic acids were captured on oligo (dT) or RSV-specific 
beads and extracted by pulling the beads directly into nuclease-free 
water to elute. 
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were capped with tube sealant (Figure 21B).  The magnetic beads were collected from 
the lysis/hybridization buffer using a 2.5 mm cubic neodymium magnet and transported 
through the air valve into the water chamber.  The magnet was rapidly moved back and 
forth on the outside of the water chamber to disperse the beads.  A razor blade was 
used to excise the water chamber, and the water containing dispersed magnetic beads 
was collected by holding the excised tubing section over a 1.5 mL centrifuge tube.  The 
tube was then heated to 65⁰C for 2 minutes on a heating block.  After heating, the eluate 
was pipetted out of the tube while holding the magnetic beads to one side of the tube 
with a magnet.  Extracted RSV mRNA was quantified by RT-PCR as described above. 
 
Statistical Analysis.   
All statistical analyses were performed in SigmaPlot 11.0. Analysis of variance 
(ANOVA) was used to determine statistical significance for data containing 3 or more 
sample populations, and a T test used for data containing 2 sample populations. A p-
value <0.05 was considered significant. 
 
Results 
 
Characterization of RSV-specific and oligo (dT) beads using fluorescently-labeled 
complementary and scrambled DNA sequences.   
 
Both the oligo (dT) and RSV-specific beads recovered ~70% of the 22 base 
complementary fluorescent probe and ~2% of a scrambled fluorescent probe, indicating 
that the laboratory-synthesized RSV-specific beads were comparable to the 
commercially-available oligo (dT) beads.  The oligo (dT) beads recovered 69 ± 13% of 
complementary probe 5’ Cy5 – AAA AAA AAA AAA AAA AAA AAA A 3’, and the RSV-
specific beads recovered 74 ± 15% of complementary probe 5’ Cy5 – TAC TCC  ATT 
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TGC TTT TAC ATG A 3’ (Figure 22, black bars).  Additionally, the oligo (dT) and RSV-
specific beads recovered 2.4 ± 0.3 and 1.9 ± 0.5%, respectively, of a scrambled DNA 
probe (Figure 22, gray bars). 
 
 
 
Optimization of magnetic capture hybridization protocol for oligo (dT) and RSV-specific 
magnetic beads.  
  
There is a ~50% decrease in mRNA recovery when wash steps are excluded 
from the oligo (dT) extraction protocol, though this decrease in yield is not statistically 
significant.  When performed according to manufacturer’s instructions, the oligo (dT) 
beads recovered 83 ± 22% of RSV N gene mRNA from 25 uL of spiked HEp-2 cell 
lysates (Figure 23).  When no wash steps were included, and the magnetic beads were 
eluted into water directly following nucleic acid capture, 39 ± 30% of spiked RSV N gene 
was detectable following RT-PCR. 
 
Figure 22.  Characterization of oligo (dT) and RSV-specific magnetic 
beads.  The recovery of a complementary DNA probe was equivalent for 
the oligo (dT) and RSV-specific beads (black bars).  Both oligo (dT) and 
RSV-specific beads recovered less than 3% of a nonspecific scrambled 
probe (gray bars) (mean ± s.d., n=3) 
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RNA extraction capacity of silica-coated, oligo (dT), and RSV-specific magnetic beads. 
 
The mass of RNA extracted using silica-coated magnetic beads increases to 
~400 ng and then plateaus as the mass of spiked RNA is increased to 1000 ng.   A 
similar trend is seen when using oligo (dT) and RSV-specific magnetic beads.  As the 
quantity of full length RSV N gene mRNA is increased from 200 to 1000 ng, the mass of 
mRNA recovered plateaus at ~300 ng.  The maximum quantity of mouse total RNA that 
can be extracted from TE buffer using 1 x 108 silica-coated magnetic beads is ~400 ng or 
4 fg/bead (Figure 24, black circles).  The maximum quantity of full length RSV N gene 
mRNA that can be extracted using 1 x 108 oligo (dT) (Figure 24, white circles) and RSV-
specific magnetic beads (Figure 24, gray circles) is ~300 ng or 3 fg/bead.  This 
corresponds to an oligo (dT) and RSV-specific magnetic bead extraction capacity of 
~3800 RSV N gene mRNA copies/bead.  To keep the extraction capacity similar when 
comparing silica-coated, oligo (dT), and RSV-specific beads, a total extraction capacity 
 
Figure 23.  RSV mRNA is detectable by RT-PCR when wash steps are 
eliminated from the oligo (dT) extraction protocol (mean ± s.d., n=3). 
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of 2000 ng was used for each bead type.  Equivalent extraction capacity was achieved 
using 5 x 108 silica-coated magnetic beads and 6.7 x 108 oligo (dT) or RSV-specific 
beads. 
 
 
 
RNA capture kinetics using silica-coated, oligo (dT), and RSV-specific beads.   
Magnetic bead capture kinetics are dependent on bead surface functionalization.  
The percentage of RSV N gene recovered from HEp-2 cell lysates remains relatively 
constant as nucleic acid capture time is increased using the silica-coated and oligo (dT) 
beads but increases exponentially when using RSV-specific beads.  As shown in Figure 
25, 75 ± 9% of spiked RSV N gene mRNA is recovered using the silica-coated beads 
(black circles) and 71 ± 26% recovered using the oligo (dT) beads (white circles) 
following a 1 min nucleic acid capture step.  As the nucleic acid capture time is 
increased from 1 minute to 3 hours this recovery does not increase further.   
 
Figure 24.  As the mass of spiked RNA is increased, the mass of RNA 
recovered using silica-coated (black circles), Oligo (dT) (white circles), or 
RSV-specific beads (gray circles) increases and then plateaus once the 
RNA extraction capacity of the beads is reached (mean ± s.d., n=3). 
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The percentage of RSV N gene recovered using the RSV-specific beads 
increases exponentially as nucleic acid capture time is increased from 1 minute to 3 
hours.  After 1 minute, the recovery of RSV N gene is 7.4 ± 6%, and increases to 77 ± 
12% after a 3 hour capture step.  Following the 3 hour incubation, the recovery of RSV N 
gene using RSV-specific magnetic beads is similar to the recovery using silica-coated 
and oligo (dT) beads following a 1 minute capture step. 
 
  
 
Figure 25.  RSV N gene mRNA recovery remains relatively constant as 
nucleic acid capture time is increased from 1 min to 3 h using silica-coated 
(black circles) and oligo (dT) (white circles) magnetic beads.  RSV N gene 
mRNA recovery using RSV-specific beads (gray circles) increases 
exponentially as RNA capture time is increased to 3 hours (dotted line). 
(mean ± s.d., n=3). 
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Ratio of RSV biomarkers to background RNA following extraction with silica-coated, 
oligo (dT), and RSV-specific beads.   
 
Background yeast tRNA was detectable by absorbance in the eluate following 
extraction with silica-coated magnetic beads, but not oligo (dT) or RSV-specific beads.  
As shown in Figure 26A, the absorbance measured in eluate collected with silica-coated 
magnetic beads was 0.016 ± 0.002.  The absorbance was 0.002 ± 0.001, and 0.004 ± 
0.001 for the oligo (dT) and RSV-specific beads, respectively.  These values were 
equivalent to the blank sample with a measured absorbance of 0.001 ± 0.001. 
 
 
 
A spiked control mRNA was detectable in the eluate from all three bead types, 
but was significantly lower for the RSV-specific beads than for the silica and oligo (dT) 
beads.  Similarly, the RSV N gene mRNA was detectable in all three eluates, but was 
15-fold lower in the RSV-specific bead extraction.  As shown in Figure 26B, 2 ± 0.05 x 
    
Figure 26.  A) Background yeast tRNA recovery was confirmed by measuring absorbance on 
each eluate.  Significant amounts of yeast tRNA were detected in the eluate following 
extraction with silica-coated magnetic beads.  The absorbance on eluate following extraction 
with oligo (dT) and RSV-specific magnetic beads was below the limit of detection of the 
spectrophotometer (mean ± s.d., n=3). * denotes detectable quantities of tRNA compared to a 
blank sample. B) The recovery of background mRNA (black bars) and RSV N gene mRNA 
(gray bars) was measured following RT-PCR.  The recovery of background mRNA is 
significantly lower in the eluate recovered using the RSV-specific beads than the silica-coated 
and oligo (dT) beads.  The recovery of RSV N gene mRNA is comparable for all three bead 
chemistries tested (mean ± s.d., n=3).  # denotes significantly fewer background mRNA copies 
detected than silica-coated and oligo (dT) beads.  % denotes significantly fewer RSV mRNA 
copies detected than silica-coated and oligo (dT) beads.  
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1010  copies of spiked control mRNA were detected following extraction with silica-coated 
magnetic beads, 7 ± 0.3 x 1010  copies detected following extraction with oligo (dT) 
beads, and 8 ± 0.9 x 108  copies detected following extraction with RSV-specific beads.  
Additionally, 2.5 ± 0.2 x 106, 2.8 ± 1 x 106, and 1.7 ± 0.3 x 105  copies of spiked RSV N 
gene mRNA were detectable following extraction with the silica-coated, oligo (dT), and 
RSV-specific beads, respectively. 
 
Self-contained RSV RNA extraction using silica-coated, oligo (dT), and RSV-specific 
beads. 
 
Using the self-contained extraction, ~80% of RSV N gene biomarkers were 
recovered using silica-coated and oligo (dT) magnetic beads and ~10% were recovered 
using RSV-specific magnetic beads.  Following a 5 minute nucleic acid capture step the 
silica-coated and oligo (dT) beads recovered 84 ± 48 and 78 ± 38% of spiked RSV N 
gene mRNA from HEp-2 cell lysates, respectively.  The RSV-specific beads recovered 
8.9 ± 5.4% of spiked RSN N gene mRNA (Figure 27). 
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Discussion 
In this report, we present a thorough analysis of three magnetic bead 
functionalities for nucleic acid extraction.  Due to their simplicity, speed, flexibility, and 
compatibility with a variety of downstream detection formats, oligo (dT) beads appear to 
be the best choice for applications that require purified mRNA.  One useful application of 
the oligo (dT) surface functionality is the detection of pathogens that are actively 
replicating and producing mRNA [21]. 
Oligo (dT) beads selectively capture nucleic acid sequences which have poly(A) 
tails available for hybridization to the poly(T) probes.  As a result, samples processed 
with the oligo (dT) magnetic beads contain mainly mRNA.  In an extracted sample 
containing no background nucleic acids or other potential contaminants, oligo (dT) beads 
recover over 70% of complementary poly(A) sequence, while recovering less than 3% of 
a nucleic acid sequence not complementary to the poly(T) probe attached to the 
 
Figure 27.  The RSV N gene mRNA recovery from HEp-2 cell lysates is 
shown for the silica-coated, oligo (dT), and RSV-specific magnetic beads 
used in the self-contained extraction (mean ± s.d., n=6). 
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magnetic beads (Figure 22).  In a more complex sample containing both mRNA and 
large quantities of background tRNA, the oligo (dT) beads again recovered minimal 
amounts of the non-complementary sequences (Figure 26A).  This reduction in 
background RNA may not be necessary in a background-tolerant diagnostic such as RT-
PCR.  However, using the oligo (dT) beads, the captured mRNA sequences are 
available for amplification or detection strategies performed directly on the mRNA 
sequences while they are still attached to the beads.  This advantage enables strategies 
such as quadruplex priming amplification to be performed on the extracted biomarkers 
directly on the magnetic bead surface [15]. 
Total extraction time is an important consideration when preparing a sample for 
downstream detection.  In diagnostics involving RT-PCR, amplification time is frequently 
greater than 2 hours.  In such cases, it is ideal to reduce the total time-to-diagnosis for 
the patient by reducing other processing steps prior to detection.  This is particularly 
important in settings where the patient has traveled many hours to reach a clinic and 
may not be willing or able to return for their results.  The long 3’ poly(A) tails on mRNA 
rapidly hybridize to the poly(T) probes attached to the oligo (dT) magnetic beads, 
resulting in a total extraction time less than 10 minutes (Figure 25, white circles).  The 
rapid mRNA loading minimizes the total nucleic acid extraction time, which proves useful 
in minimizing a patient’s time-to-diagnosis.   
Because the oligo (dT) beads depend solely on nucleic acid hybridization to 
capture and extract nucleic acids, the hybridization step contains a significantly lower 
concentration of toxic salts (6 mg lithium chloride/extraction) compared to the silica-
based extractions (200 mg GuSCN/extraction).  The reduction in toxic chemicals leads 
to an extraction process that is safer for the user.  This is especially useful in settings 
where the technician has little to no personal protective equipment or where hazardous 
waste is not managed safely. 
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The simplest extraction should have a minimum number of processing steps to 
decrease the likelihood of operator error and risk of contamination.  The oligo (dT) bead 
manufacturer recommends a simple protocol including two magnetic bead wash steps 
prior to nucleic acid elution.  However, the oligo (dT) processing was further simplified by 
eliminating the wash steps and immediately eluting extracted mRNA following capture.  
The resulting 50% reduction in recovered mRNA is not statistically significant.  More 
importantly, the self-contained extraction is simplified to a single step (Figure 23).  In 
settings where simplicity is the highest priority in a sample preparation process, the one-
step extraction may be worth any potential loss in yield.  Additionally, the single step 
makes the oligo (dT) surface chemistry an attractive choice for a variety of simple 
nucleic acid extraction formats.  The oligo (dT) beads were evaluated in our self-
contained device, which relies on surface tension valves to separate solutions during 
processing (Figure 21B).  The single step oligo (dT) extraction was easily adaptable to 
the self-contained format, performing similarly to the silica-based extraction (Figure 27) 
and recovering ~70% of spiked RSV mRNA biomarker.    
Silica-coated beads are useful when there is no need for a specific subset of 
nucleic acids, or when mRNA is not the biomarker of interest.  The silica-coated 
magnetic beads are a useful alternative to oligo (dT) beads.  They are rapid, easy to 
use, and nonspecifically capture nucleic acids present in the sample independent of 
sequence (Figure 26).  Because silica-based extractions are not selective for specific 
nucleic acid sequences, they are well-suited for detection strategies that are tolerant of 
high background nucleic acids, such as PCR and RT-PCR.  Furthermore, using these 
strategies, eluate from a single extraction could potentially be used to detect DNA, RNA, 
or biomarkers of multiple diseases.   
The silica-coated magnetic beads rely on electrostatic interactions to 
nonspecifically capture nucleic acids when they come into contact with the beads.  This 
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process occurs rapidly, and results in a total extraction time of less than 10 minutes, an 
advantage in settings where short time-to-diagnosis is important (Figure 25, black 
circles).  One disadvantage is that these interactions require the presence of high 
concentrations of a strong chaotropic agent, in this case 5.7 M GuSCN.  In laboratory 
settings, GuSCN has been relied on for decades as a rapid, dependable method for 
extracting nucleic acids.  However, GuSCN is a potent inhibitor of RT-PCR, and must be 
washed away during the extraction.  Additionally, GuSCN is a highly toxic substance 
which can be dangerous in settings where the operator does not have the training or 
personal protective equipment to properly handle and dispose of this chemical.  This 
toxicity should be considered when choosing the appropriate magnetic bead 
functionalization. 
Extractions performed with silica-coated magnetic beads are relatively simple to 
complete.  The silica-coated beads require thorough washing with ethanol to remove 
traces of GuSCN that could inhibit downstream processes such as RT-PCR.  Even with 
these additional wash steps compared to the oligo (dT) beads, silica-based extractions 
using magnetic beads have been adapted to a variety of formats due to their relative 
simplicity compared to alternative methods such as phase separation and centrifugation 
columns.  The silica-based extraction method was successfully adapted to our self-
contained tubing format to extract both RNA and DNA from patient samples [6,7].  The 
silica-coated magnetic beads performed well in the self-contained format shown in 
Figure 21A, recovering ~70% of spiked RSV mRNA biomarker (Figure 27). 
The RSV-specific magnetic beads are simple to use and capture nucleic acids 
specific to the species-of-interest (Figure 22), but they may require too much processing 
time to be more advantageous than silica-coated or oligo (dT) beads in many cases.  
One distinct advantage is that they enable detection strategies that are inhibited by high 
concentrations of background nucleic acids or that rely on hybridization to the biomarker 
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while it remains hybridized to the magnetic bead.  For example, the bio-barcode assay 
developed by Nam, et. al. uses DNA-functionalized gold nanoparticles to hybridize to 
captured nucleic acids and subsequently detect their presence downstream [17]. 
The RSV-specific magnetic beads recover RSV RNA complementary to the 
probes attached to the bead surface.  There is minimal nonspecific nucleic acid 
extracted, and background nucleic acids are not recovered at a high enough 
concentration to be detectable by spectrophotometer (Figure 26A).  The extraction is 
performed similarly to the oligo (dT) extraction, and requires a low concentration of toxic 
salt rather than the high concentration required for silica-based extraction.  As a result, 
the RSV-specific extraction can also be simplified to require no wash steps following 
nucleic acid capture, reducing the process to a single step.  Like the silica-coated and 
oligo (dT) beads, the RSV-specific beads performed reasonably well when tested in the 
self-contained tubing format (Figure 21B).  The recovery was ~15 fold lower than the 
other beads tested using a 5 minute nucleic acid capture step (Figure 27).   
Should the sequence-specific beads be chosen, the tradeoff between total 
extraction time and biomarker yield would be an important consideration.  The long 
extraction time is likely required because the sequence-specific probes must come into 
contact with a short 25 base complementary sequence from RSV N gene sequences 
present in the sample.  Due to the high selectivity of the probes, RSV-specific capture 
beads require a binding time approaching 3 hours to maximize biomarker recovery 
(Figure 25).  A 3 hour binding time results in a total nucleic acid extraction time longer 
than many detection strategies, including RT-PCR.  Because RT-PCR is typically not 
affected by background nucleic acids, sequence-specific magnetic beads are probably 
not an ideal choice for applications which rely on RT-PCR as the final detection strategy.  
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Conclusions 
 In choosing the appropriate magnetic bead surface functionality for nucleic acid 
extractions, the advantages and disadvantages of each must be considered.  There are 
often trade-offs between assay effectiveness, simplicity, speed, and compatibility with 
the desired downstream detection strategy.  Oligo (dT) beads offer the benefits of 
simplicity, speed, and the flexibility to perform additional detection schemes directly on 
captured nucleic acids.  However, they are not useful when mRNA is not the biomarker 
of interest.  Silica-coated beads are also rapid and simple, though they require a high 
concentration of toxic salt and additional detection cannot be performed on captured 
nucleic acids still adsorbed to the bead surface.  RSV-specific beads are simple and 
specific, enabling downstream detection directly on the captured nucleic acids.  
However, there is a significant trade-off between speed and nucleic acid recovery 
efficiency which must be considered with these beads. 
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CHAPTER VII 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 This dissertation comprises four manuscripts which describe the development of 
a biomarker extraction device designed to simplify nucleic acid extractions in resource-
limited settings.  The self-contained extraction device effectively recovers nucleic acid 
biomarkers from complex patient samples, enabling downstream molecular detection 
strategies such as PCR.  The self-contained extraction device offers significant 
advantages over similar reported devices and commercially available extraction kits.  
These include a simple design and the flexibility to process different biomarkers and 
patient sample matrices by modifying the tubing contents.   
The proof-of-concept design presented in Chapter III relies on silica-coated 
magnetic particles and surface tension valves to extract RSV RNA biomarkers from 
complex sample matrices with a recovery efficiency of ~10%.  One limitation of this 
design was the requirement for a multi-step nucleic acid capture process prior to sample 
introduction into the device.  This drawback was addressed through the introduction of a 
patient sample-extraction tubing interface, described in Chapter IV.  The transfer pipette 
interface was included to enable the extraction of DNA from large-volume human urine 
samples.  Short TB DNA biomarkers were recovered with an efficiency of ~50% and a 
limit of detection of ~75 DNA copies/uL.  This approach has the potential to improve TB 
diagnosis in resource-limited settings by enabling urine-based biomarker detection, and 
may also be useful for other diagnostic applications found to be associated with short 
DNA fragments excreted in urine.   
The self-contained extraction device was further improved with the design of an 
automated extraction processor, presented in Chapter V.  A circular extraction cassette 
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holds the loaded small-diameter tubing, effectively reducing the tubing footprint to a 12.5 
cm disk.  A continuous processing program rotates each loaded cassette past a fixed 
permanent magnet to transfer magnetic beads from one end of the tubing to the other.  
The automated biomarker extraction device extracted detectable quantities of nucleic 
acid and protein biomarkers from well-characterized patient sample surrogates 
containing clinically-relevant high, medium, and low concentrations of infectious 
organisms.  The successful detection of influenza A, E. coli, TB, and malaria biomarkers 
extracted with the automated extraction processor demonstrates the flexibility of the self-
contained extraction device.   
 The magnetic beads are one of the major enabling technologies of the surface 
tension-based extraction device, and three surface functionalities are studied in Chapter 
VI.  When choosing a magnetic bead surface functionality for performing nucleic acid 
extractions, the advantages and disadvantages of each available magnetic bead type 
must be considered.  There are often trade-offs between assay effectiveness, simplicity, 
speed, and compatibility with the desired downstream detection strategy.  Of the 
magnetic bead surface functionalities studied, oligo (dT) beads offer the benefits of 
simplicity and speed.  Oligo (dT) beads also enable additional detection schemes 
performed directly on the bead surface.  Silica-coated beads are also useful for rapid, 
simple nucleic acid extractions, though they require a high concentration of toxic salt.  
Additionally, adsorbed nucleic acids are not available for downstream detection directly 
on the bead surface.  RSV-specific beads enable simple and specific extractions.  
However, there is a significant trade-off between assay speed and nucleic acid recovery 
efficiency which must be considered when choosing these beads. 
 Future studies should focus on incorporating the patient sample-extraction tubing 
interface into the automated processor design.  In its current iteration, magnetic bead 
transfer into the small-diameter tubing for automated processing requires pipetting the 
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entire prepared sample into the tubing using the transfer pipette interface, or manually 
transferring the magnetic beads down the transfer pipette stem and into the tubing.  
Eliminating this initial step would decrease user involvement and bring the extraction 
closer to a fully automated process.  Incorporating the patient sample loading into the 
automated device would require a custom-made device that not only fit seamlessly into 
the end of the plastic tubing, but was also developed to snap into the circular cassette.  
This design would allow the magnetic beads to be captured by the fixed magnets and 
transferred into the tubing using the same process that conveys the beads down the 
tubing during the extraction.   
 Validating the improved biomarker extraction device on clinical TB-infected urine 
samples would further strengthen the promising DNA extraction data presented in 
Chapter IV.  A small retrospective study performed on TB positive urine samples 
(Appendix A) revealed some limitations of analyzing patient samples collected and 
stored under uncontrolled conditions.  In a prospective study, urine sample collection 
and storage would be well-controlled, and nuclease activity could be eliminated by the 
addition of the chelating agent EDTA immediately upon sample collection.   
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APPENDIX 
 
 
EXTRACTION OF TRANSRENAL DNA FROM STORED URINE SAMPLES OBTAINED 
FROM PERU AND SOUTH AFRICA 
 
 
 
Introduction 
One promising application of the automated extraction cassette processor is the 
extraction of Mycobacterium tuberculosis Tr-DNA biomarkers from patient urine 
samples.  We sought to detect a short segment of the TB IS6110 sequence in the 
eluates of patient urine samples processed with the automated extraction cassette 
processor.  The study was completed in two separate phases.  During the first phase, 
previously frozen urine samples were shipped to the lab from collaborators at the 
University of Cayetano in Lima, Peru for processing.  During the second phase, a bank 
of previously frozen urine samples were made available from a collaborator at the 
University of Cape Town (UCT) in Cape Town, South Africa.  Due to regulations in South 
Africa, the samples could not be shipped to the United States, and were instead 
processed at UCT. 
One critical problem when processing clinical samples is the incorporation of 
appropriate controls to reduce false negatives.  A positive extraction control was 
included in the device to confirm the automated device was working as expected during 
each extraction. 
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Materials and Methods 
 
Incorporation of a positive extraction control. 
 A control DNA sequence was incorporated into the automated extraction device 
and co-extracted along with any nucleic acids present in the processed clinical urine 
samples.  A 120 bp sequence from the Mus musculus GAPDH gene was selected as the 
positive control.  PrimerBank, an online resource containing primers designed for mouse 
genes was used to select this sequence.  The segment was chosen because the PCR 
cycling conditions were equivalent to those of the IS6110 TB gene and the two 
sequences could be amplified and detected during the same PCR run.  The 
incorporation and detection of the positive control sequence are described below.    
 
Urine samples from Lima, Peru. 
Frozen urine samples from 20 TB positive and 20 TB negative patients were 
obtained from the University of Cayetano in Lima, Peru.  One milliliter of each sample 
was provided.  All 40 samples were from HIV negative patients.  TB infection had been 
confirmed using both sputum smear microscopy and chest X-Ray.  Multiple freeze-thaw 
cycles were suspected for each sample, though the storage conditions following urine 
collection were not provided. 
 
Urine samples from Cape Town, South Africa. 
The Blackburn Lab at UCT provided 110 previously frozen human urine samples 
stored in 50 mL centrifuge tubes.  The samples were stored at -20°C prior to our arrival, 
but had been freeze-thawed multiple times.  Following an unknown sample storage 
history, 18 of the samples had been supplemented with 10 mM EDTA to inhibit nuclease 
activity.  The majority of these samples were provided in volumes greater than 10 mL.  
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However, 6 samples had volumes between 100 uL and 3 mL.  These were 
supplemented with nuclease free water to bring the total volume up to 5 mL for 
processing. 
The Dheda Lab at UCT provided 48 samples that were frozen immediately upon 
collection and had not been thawed prior to processing.  Of the 48 samples, 34 were 1 
mL urine samples and 14 were 1 mL serum samples.  These 48 samples were 
supplemented with 4 mL of nuclease free water to bring the volume up to 5 mL for 
processing. 
 
Preparation of urine collection pipettes for 1 mL Peru samples. 
The urine collection pipettes were prepared by drawing 1 mL of DNA-silica 
adsorption buffer (4M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0) 
containing 6 x 108 Dynabeads MyOne silane magnetic beads, and 5 x 106 copies of a 
120 bp segment of the Mus musculus GAPDH gene (which served as a positive 
extraction control) into the bulb of a 5 mL, fine tipped transfer pipette (Samco Scientific, 
catalog # 232-20S).  The contents of the transfer pipette were frozen at -80°C for 2 
hours, after which the pipettes were transferred to a Labconco bulk tray dryer and 
lyophilized for ~18 hours.  Following lyophilization, the transfer pipettes were stored at 
room temperature prior to use. 
 
Preparation of urine collection pipettes for 5 mL South Africa samples. 
The urine collection pipettes were prepared by drawing 5 mL of DNA-silica 
adsorption buffer containing 1.8 x 109 silica-coated magnetic beads, and 5 x 107 copies 
of the mouse GAPDH positive extraction control sequence into the bulb of a 15 mL, 
narrow stemmed transfer pipette (Fisher Scientific, catalog # 13-711-36).  The contents 
of the transfer pipettes were frozen at -80°C for 2 hours, after which the pipettes were 
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transferred to a Labconco bulk tray dryer and lyophilized for ~36 hours.  Following 
lyophilization, the transfer pipettes were packaged in plastic zip top bags and shipped to 
South Africa, where they were stored at room temperature for 1-2 weeks prior to use. 
 
Detection of TB IS6110 and mouse GAPDH by PCR. 
A 67 bp amplicon of the IS6110 sequence was amplified using forward primer 5’-
ACCAGCACCTAACCGGCTGTGG-3’ and reverse primer 5’-
GTAGGCGAACCCTGCCCAGGTC-3’ [1].  A 95 bp amplicon of the mouse GAPDH 
sequence was amplified using forward primer 5’-AGGTCGGTGTGAACGGATTTG-3’ 
and reverse primer 5’-GGGGTCGTTGATGGCAACA-3’ (PrimerBank ID 126012538c1) 
[2].  The TB IS6110 and mouse GAPDH sequences were amplified in separate tubes 
during the same PCR reaction.   
For analyzing the Peruvian samples, amplification reactions were performed in a 
25 uL volume using 5 uL of DNA template and the Qiagen QuantiTect SYBR Green PCR 
kit according to manufacturer’s instructions.  Reactions were prepared in 200 uL PCR 
tubes (Thermo Scientific).  Thermal cycling consisted of 95°C for 15 min to activate the 
Taq DNA polymerase and 35 cycles of 95°C for 30 s, 62°C for 30 s, and 72°C for 60 s 
using a Rotor-Gene Q thermal cycler.  Reaction Ct values were recorded by Rotor-Gene 
Q software. 
For analyzing the South African samples, amplification reactions were performed 
in a 25 uL volume using 5 uL of DNA template and the Maxima SYBR Green qPCR 
Master Mix (Thermo Scientific) according to manufacturer’s instructions.  Reactions were 
prepared in LightCycler 480 Multiwell Plate 96 white plates (Roche).  Thermal cycling 
consisted of 95°C for 15 min to activate the Taq DNA polymerase and 35 cycles of 95°C 
for 30 s, 62°C for 30 s, and 72°C for 60 s using a Roche LightCycler 480.  Reaction Ct 
values were recorded by LightCycler software. 
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Processing of 1 mL Peru samples. 
All 40 Peru samples were processed over 4 days.  Urine was removed from 
freezer and thawed over ice immediately prior to use.  Once samples were thawed, a 30 
cm length of 2.36 mm inner diameter FEP tubing was prepared by preloading DNA 
eluent (50 uL nuclease free water), DNA wash solution (300 uL 70% ethanol), and DNA 
precipitation buffer (300 uL 80% ethanol, 5 mM potassium phosphate, pH 8.5).  Each 
solution was pipetted sequentially into the tubing and separated from the next by an 8 uL 
air valve (4 mm in length).   
The 1 mL urine samples were drawn into the bulb of the urine collection pipette, 
which was shaken vigorously by hand for 30 s to dissolve the lyophilized salts, then 
gently for 30 s to allow DNA adsorption to the silica surfaces of the beads.  After mixing, 
the transfer pipette was squeezed to transfer the sample from the bulb to the tip of the 
pipette.  The end of the pipette was then inserted into the preloaded small diameter 
tubing and the sample was transferred into the tubing.  Both ends of the tubing were 
sealed using Hemato-Seal Tube Sealing Compound (Fisher Scientific).  The sealed 
tubing was wrapped around the plastic cassette, which was inserted into the automated 
processor.  The extraction program was run until the magnetic beads exited the elution 
chamber, at which point the tubing was removed from the plastic cassette, and the 
eluent was collected in a 0.5 mL microcentrifuge tube.  Extracted TB and mouse DNA 
was detected using the PCR protocol described above. 
 
Preparation of preloaded small diameter tubing for processing Cape Town samples. 
A 10 cm length of 2.36 mm inner diameter FEP tubing was prepared by 
preloading DNA eluent (50 uL nuclease free water), DNA wash solution (300 uL 70% 
ethanol), and DNA precipitation buffer (300 uL 80% ethanol, 5 mM potassium 
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phosphate, pH 8.5).  Each solution was pipetted sequentially into the tubing and 
separated from the next by an 8 uL air valve (4 mm in length).  Both ends of the tubing 
were sealed using Hemato-Seal Tube Sealing Compound to prevent liquid evaporation 
and stored at room temperature until needed.  Immediately prior to use, the front end of 
the tubing (near the DNA precipitation buffer) was opened by cutting off the sealed end 
with a razor blade. 
 
Processing of 5 mL Cape Town samples. 
On the morning of processing, urine samples were removed from the -20°C 
freezer and thawed at room temperature.  Prior to use, the volume of any urine sample 
less than 5 mL was raised to 5 mL using nuclease free water.  Nine samples were 
prepared and processed simultaneously.  First, the 5 mL urine samples were drawn into 
the bulb of the urine collection pipette, which was shaken vigorously by hand for 30 s to 
dissolve the lyophilized salts, then allowed to sit for ~2 minutes with intermittent shaking 
by hand to allow DNA adsorption to the silica surfaces of the beads.  Next, the tip of the 
transfer pipette was inserted into the end of the preloaded small diameter tubing and a 
2.5 cm cubic neodymium magnet was used to collect the magnetic beads and transfer 
them through the pipette stem and into the DNA precipitation buffer.  Once the beads 
were loaded into the small diameter tubing, the transfer pipette was removed and the 
end sealed with tube sealing compound.   
After 9 samples were ready for processing, three sealed tubes were wrapped 
around each of three extraction cassettes, which were inserted simultaneously into the 
automated processor.  The extraction program was run until the magnetic beads 
reached the elution chamber, at which point the cassettes were removed from the 
processor and allowed to rest at room temperature for 2 min.  The magnetic beads were 
removed from the elution chambers using the neodymium magnet, and the eluent was 
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collected in a 0.5 mL microcentrifuge tube.  Extracted TB and mouse DNA was detected 
using the PCR protocol described above.  
 
Assessing DNase activity of Cape Town urine samples. 
The relative DNase activity of all 144 urine samples was determined using the 
DNaseAlert QC System (Life Technologies Corporation) according to manufacturer’s 
instructions.  Due to the inability to obtain this kit in South Africa, it was transported at 
room temperature, lyophilized, by plane.  Briefly, the lyophilized DNaseAlert substrate 
containing fluorescent DNA probes was resuspended in 1 mL TE buffer.  Ten microliters 
of the DNaseAlert substrate was added to each of the wells of a 96-well plate and mixed 
with 10 uL of 10X NucleaseAlert Buffer.  Finally, 40 uL of urine sample was diluted to 80 
uL using nuclease free water and added to each well.  Urine samples were prepared and 
measured in duplicate.  The plate was incubated at room temperature for 18 h prior to 
measuring fluorescence on a Cary Eclipse Fluorescent Spectrometer (Agilent 
Technologies) using 535/556 nm excitation/emission wavelengths with excitation and 
emission slit widths of 10 and 5 nm, respectively.  Urine sample fluorescent values were 
compared to a DNase negative control by T-test to confirm the presence of DNase 
activity. 
 
Gel electrophoresis on selected extracted samples following PCR amplification. 
After amplification, all PCR plates were kept at 4°C for up to 48 h prior to 
polyacrylamide gel electrophoresis (PAGE).  Four PAGE gels were prepared in the Mini-
PROTEAN Tetra Cell (Bio-Rad Laboratories, Inc.) using 10% acrylamide according to 
manufacturer’s protocol.  Prepared gels were allowed to polymerize for 45 minutes prior 
to use.  The Tetra Cell tank was filled with 1X tris-borate-EDTA (TBE) buffer.  Four 
microliters of 6x Orange DNA Loading Dye (Thermo Scientific) was added to the 
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selected PCR reactions directly into the wells of the PCR plates and mixed well by 
pipetting.  Each reaction was then loaded into the prepared PAGE gels.  One lane on 
each gel was reserved for the O’GeneRuler 50 bp DNA ladder (Thermo Scientific).  The 
gels were then run at 200 V for 90 minutes.  The electrophoresed gels were removed 
from the Tetra Cell tank and incubated for 10 minutes in a 1:10,000 dilution of GrGreen 
nucleic acid staining solution diluted into 1X TBE buffer.  Finally, the gels were visualized 
using the SynGene GeneSnap UV gel document system. 
 
Results 
 
Peru sample PCR analysis. 
The TB IS6110 Ct values were compared for the TB positive and TB negative 
urine samples.  The average Ct value for TB positive urine samples obtained from Peru 
was 32.3 ± 3.2, while the average Ct value for TB negative samples was 30.4 ± 4.7 
(Figure 28).  There was no significant difference between the two populations.   
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The mouse extraction control was detected in 39 of the 40 samples tested.  The 
trend was similar for TB positive and negative samples whose TB IS6110 Ct values were 
compared to the corresponding mouse extraction control Ct value (Figure 29). 
 
 
Figure 28.  There is no difference in average Ct values for PCR 
amplified IS6110 in TB positive and negative extracted urine samples 
(mean ± s.d., n=20). 
 
 
149 
 
 
 
South Africa sample PCR analysis. 
The TB IS6110 Ct values were compared for the TB positive and TB negative 
urine samples processed in South Africa.  A total of 67 urine samples (30 TB+; 37 TB-) 
had no detectable amplification after 35 PCR cycles.  The average Ct value for TB 
positive urine samples was 31.1 ± 3.2, while the average Ct value for TB negative 
samples was 32.3 ± 2.5 (Figure 30).  There was no significant difference between the 
two populations.   
 
 
Figure 29.  There is no trend difference between TB positive (red 
circles) and TB negative (blue circles) samples when the TB IS6110 
and mouse extraction control Ct values were compared (n=20). 
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The mouse extraction control was detected in 92 of the 144 urine samples 
tested.  Of the 92 samples, the TB IS6110 gene was detected in 66 samples (34 TB+, 
32 TB-).  The trend was similar for TB positive and negative samples whose TB IS6110 
Ct values were compared to the corresponding mouse extraction control Ct value. 
 
 
Figure 30.  There is no difference in average Ct values for PCR amplified 
IS6110 in TB positive and negative extracted urine samples (mean ± s.d., 
n=40 TB+ and 46 TB-). 
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The 52 urine samples whose mouse extraction control did not amplify were 
eliminated from further analysis.  Those urine samples whose TB and HIV status was 
known were divided into four categories:  TB positive/HIV positive, TB positive/HIV 
negative, TB negative/HIV positive, and TB negative/HIV negative.  As shown in Figure 
32, the average Ct value for each group was 31.5 ± 2.5, 31.8 ± 3.1, 33.6 ± 1.3, and 31.4 
± 3.3, respectively.  There was no significant difference among the four populations.   
 
 
Figure 31. There is no trend difference between TB positive (red circles) 
and TB negative (blue circles) samples when the TB IS6110 and mouse 
extraction control Ct values were compared (n=33 TB+ and 31 TB-). 
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The samples with the lowest Ct values for the mouse extraction control recovered 
the highest quantity of spiked GAPDH DNA, and as a result likely obtained the most 
DNA from the sample.  Of the 66 urine samples in which the mouse extraction control 
and TB IS6110 gene were detected, those with the 33 lowest Ct values were divided into 
4 categories and their Ct values averaged.  As shown in Figure 33, the average Ct 
values for 5 TB positive/HIV positive, 17 TB positive/HIV negative, 7 TB negative/HIV 
positive, and 17 TB negative/HIV negative were 29.3 ± 2.7, 31.8 ± 2.8, 33.7 ± 1.7, and 
30.9 ± 3.4, respectively.  There was no significant difference among the four populations.   
 
 
Figure 32.  There is no difference in average Ct values for amplified TB 
IS6110 between TB+/HIV+, TB+/HIV-, TB-/HIV+, and TB-/HIV- extracted 
urine samples when samples with no detectable mouse extraction control 
were eliminated from analysis (mean ± s.d., n = 9 TB+/HIV+, 10 TB+/HIV-, 
9 TB-/HIV+, and 18 TB-/HIV-). 
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Surprisingly, the mouse extraction control was not consistently amplified in the 1 
mL urine and serum samples received from the Dheda Lab.  These samples were less 
than 7 days old and had been stored at -80°C since collection.  Of the 34 urine samples, 
the mouse extraction control was detected in only 7, and no TB IS6110 DNA was 
detected in any of these 7 samples.  Of the 14 serum samples, the mouse extraction 
control was detected in only 9.  Of these 9, the TB IS6110 DNA sequence was detected 
in 2 (one TB positive and one TB negative). 
 
Cape Town urine DNase activity. 
DNase activity in the Cape Town urine samples was confirmed by measuring the 
fluorescence of a DNase-cleavable fluorescent probe that was introduced into each 
sample.  DNase activity was confirmed in 95% of the samples tested (137 out of 144).  
 
Figure 33.  There is no difference in average Ct values for amplified TB 
IS6110 between TB+/HIV+, TB+/HIV-, TB-/HIV+, and TB-/HIV- extracted 
urine samples when samples with highest detectable quantities of mouse 
extraction control were analyzed (mean ± s.d., n = 5 TB+/HIV+, 14 
TB+/HIV-, 7 TB-/HIV+, and 17 TB-/HIV-). 
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The relative DNase activity was 0.295 ± 0.12 for TB positive samples and 0.326 ± 0.20 
for TB negative samples (Figure 34).  There was no significant difference between the 
two populations. 
 
 
 
To determine whether there was a potential trend between low recovery of the 
mouse extraction control and sample DNase activity, the relative DNase activity for each 
sample was compared to the Ct value of the corresponding mouse extraction control 
(Figure 35).  There was no trend between TB positive or negative samples. 
 
 
Figure 34.  There was no difference in DNase activity between TB 
positive and TB negative urine samples (mean ± s.d., n = 64 TB+ and 
74 TB-). 
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Polyacrylamide gel electrophoresis on selected PCR products. 
The PCR products from 26 randomly selected extracted urine samples were 
visualized on PAGE gels.  The resulting bands from these 26 samples are shown on the 
four gels in Figure 36A-D.  There are 3 notable patterns in these samples:  1) a 68 bp 
band indicating amplification of the IS6110 gene, 2) no visible bands, and 3) 2-6 
individual bands indicating the formation of multiple nonspecific products.  For example, 
in Figure 36A lane 6, Figure 36B lane 5, and Figure 36C lane 9, there is a single 68 bp 
band indicating the presence of TB IS6110 amplicon.  These samples are all TB 
positive.  However, in Figure 36A lane 5 there is also a single 68 bp band from a TB 
negative sample.  As expected, in some TB negative samples there is no visible product 
(Figure 36B lane 2, Figure 36C lane1).  However, in others there are multiple bands 
(Figure 36A lane 3, Figure 36C lane 6) indicating the presence of nonspecific 
amplification. 
 
Figure 35.  There is no trend difference between TB positive (red circles) 
and TB negative (blue circles) when the relative DNase activity and 
mouse extraction control Ct values were compared (n=45 TB+ and 46 
TB-). 
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Discussion 
Using the automated biomarker extraction processor followed by PCR, TB 
IS6110 was not reliably detectable in the 40 samples obtained from Peru.  The IS6110 
gene was detected at approximately equivalent Ct values for the TB positive and 
negative urine samples (Figure 28).  Despite these results, the positive extraction 
control was detectable in 39 of the samples, indicating a successful extraction was 
completed for each of these samples (Figure 29).  Though the results of this initial study 
were not as expected, we identified several possible reasons why these results were not 
 
Figure 36.  The IS6110 PCR products for 26 extracted urine samples were visualized by 
polyacrylamide gel electrophoresis.  A). Lane 1 – 50 bp DNA ladder; Lane 2 – TB+/HIV-; 
Lane 3 – TB+/HIV+; Lane 4 – TB-; Lane 5 – TB-/HIV-; Lane 6 – TB-/HIV-; Lane 7 – 
TB+/HIV-; Lane 8 – TB-/HIV-; Lane 9 – No TB status provided; Lane 10 – No TB status 
provided.  B). Lane 1 – TB-/HIV-; Lane 2 – TB+/HIV-; Lane 3 – TB+; Lane 4 – TB+; Lane 
5 – TB+/HIV+; Lane 6 – TB-/HIV-; Lane 7 – TB+; Lane 8 – 50 bp DNA ladder.  C). Lane 1 
– TB-/HIV-; Lane 2 – TB-/HIV-; Lane 3 – TB+/HIV+; Lane 4 – TB+ control; Lane 5 – 
TB+/HIV+; Lane 6 – TB-; Lane 7 – TB+/HIV-; Lane 8 – TB-; Lane 9 – TB+/HIV-; Lane 10 – 
50 bp DNA ladder.  D). Lane 1 – TB+/HIV-; Lane 2 – TB-; Lane 3 – TB-/HIV-, Lane 4 – 50 
bp DNA ladder. 
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ideal.  Due to the random cleavage of DNA, it is reasonable to expect that there will be a 
relatively small number of IS6110 segments that are amplifiable by the PCR primers 
being used in this study.  As a result, it would be ideal to perform the extraction and 
subsequent amplification on a larger urine volume to increase the total number of 
biomarkers available for detection.  In this study, we were limited to 1 mL urine samples 
provided by the University of Cayetano.   
Additionally, we expect that patients with both active TB and a weakened 
immune system (i.e. HIV positive patients), or those whose TB has disseminated into the 
blood stream will have a higher instance of Tr-DNA biomarkers because there are more 
active organisms throughout the body.  The patients in this 40 sample study were all HIV 
negative, and none had disseminated TB.  A larger study that included large urine 
samples volumes and a wider variety of TB positive patients may improve upon the 
results obtained in this study. 
Repeating the Tr-DNA study on the urine samples stored at UCT provided the 
opportunity to work with a larger group of samples collected from a broad range of 
patients including those with TB/HIV coinfections as well as a small group of relatively 
fresh urine samples that had undergone no freeze-thaw cycles prior to our arrival.  
However, the majority of the samples had undergone an unknown number of freeze-
thaw cycles and their storage conditions were not well documented.  Despite these 
limitations, 104 samples were provided in large enough quantities to work with 5 mL, 
rather than 1 mL, urine samples.  This larger volume would, in theory, contain 5 times 
more IS6110 biomarkers than similar 1 mL samples.   Following extraction and PCR 
amplification of each urine sample, the IS6110 gene was detected at approximately 
equivalent Ct values for TB positive and TB negative urine samples (Figure 30).   
Detection of the mouse extraction control was considered an indication of a 
successful nucleic acid extraction.  Of the 144 processed urine samples, 92 had 
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detectable quantities of mouse extraction control DNA.  Based on these results, we were 
forced to eliminate 52 samples from analysis (including 36 of the 48 “fresh” urine and 
serum samples obtained from the Dheda Lab), effectively reducing the pool of samples 
by 36% and leaving 49 TB+ and 51 TB- samples for analysis.  The presence of TB 
infection did not appear to affect the detection of the mouse extraction control, as there 
was no difference between the pool of TB positive and TB negative samples when 
mouse extraction control Ct values were compared to TB IS6110 Ct values (Figure 31).  
Additionally, there is no difference between TB IS6110 Ct values (regardless of HIV 
coinfection) for TB positive and TB negative samples (Figure 32), even when only the 
samples with the highest mouse extraction control recovery were analyzed (Figure 33).  
Based on these results, the TB IS6110 biomarker was not reliably detected in TB 
positive samples processed in South Africa.   
The presence of DNase in human urine is a significant barrier to detecting 
partially-degraded DNA biomarkers in a urine sample.  Previous studies have suggested 
that the metal chelator EDTA could be added to urine samples at a concentration 
ranging from 10-40 mM to inhibit DNase activity immediately upon sample collection [3], 
however, only 18 of the 144 urine samples had been supplemented with EDTA (after 
multiple freeze-thaw cycles and long term storage).  We confirmed DNase activity in 137 
of 144 urine samples processed at UCT, including all 18 which had been previously 
supplemented with EDTA, and the relative DNase activity was independent of TB 
infection status (Figure 34).   
Comparatively higher DNase activity did not appear to affect the recovery of 
mouse extraction control DNA (Figure 35), which suggests the DNA-silica binding 
buffer, specifically GuSCN, effectively eliminates DNase degradation of nucleic acids 
once it is added to the sample.  This promising result indicates the immediate addition of 
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a GuSCN-containing buffer upon sample collection may be an effective biomarker 
preservation strategy in addition to or in place of supplementation with EDTA. 
In addition to nucleases potentially reducing available TB biomarkers, an 
inconsistent PCR reaction may also inhibit reliable biomarker detection.  PAGE on 26 
amplified PCR products provided some insight into deficiencies in the PCR reaction 
employed in this study.  As shown in Figure 36, there are TB positive samples with 
amplified IS6110 DNA, as well as TB positive and negative samples with no detectable 
IS6110 DNA.  These particular results suggest the PCR reaction amplified IS6110 DNA 
when present in detectable quantities and did not amplify any product when IS6110 DNA 
was not present.  However, there are also both TB positive and TB negative samples 
with 1 or more nonspecific bands, indicating the formation of nonspecific PCR products.  
This inconsistency would likely result in high numbers of false positives for those 
samples with nonspsecific product amplification and interfere with the identification of 
true positives. 
 
Future Directions 
 The problems encountered with these studies clearly demonstrate the limitations 
posed when performing a retrospective patient sample study.  Though we were able to 
obtain nearly 200 urine samples between collaborators in Peru and South Africa, there 
was no way to control how those samples had been stored or treated prior to our 
studies.  In fact, with the exception of 34 urine samples received from the Dheda Lab, 
we did not know how many freeze-thaws the samples had undergone to date.   
 To further explore the Tr-DNA hypothesis and whether our automated DNA 
extraction cassette processor is a suitable device for preparing urine samples for Tr-
DNA analysis, a prospective study must be completed.  Through a prospective study, all 
aspects of sample analysis can be controlled.  This includes the collection, treatment, 
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and storage of urine samples prior to processing.  Preserving any TB biomarkers should 
begin immediately upon urine collection by inhibiting nuclease activity and properly 
storing collected samples.  Prior studies have demonstrated that the addition of EDTA 
significantly slows DNA degradation in patient urine, especially when treated samples 
are stored at -80ºC until needed.  A prospective study would test this preservation 
strategy by adding EDTA immediately to half of a patient sample, while leaving the other 
half untreated.  Both samples could then be extraction and analyzed for the presence of 
TB biomarkers.  With this design, the effects of nuclease inhibition could be compared 
by examining differences in the frequency of biomarker detection between the treated 
and untreated samples.   
 The biomarker detection strategy must also be optimized to ensure a prospective 
study.  In our studies, we utilized primers designed for a 68 bp amplicon and a SYBR 
green detection scheme.  Though short amplicons are desired to increase the chances 
for detecting extracted Tr-DNA fragments, this also increases the potential for false 
positives due to nonspecific product formation during the PCR reaction.  Additionally, 
SYBR green is a nonspecific intercalating dye that fluoresces in the presence of any 
double stranded DNA, regardless of its sequence.  Alternatively, a short amplicon 
coupled with a sequence specific probe, such as a TaqMan probe, could improve both 
the sensitivity and specificity of the PCR reaction, thus increasing the likelihood for 
detecting extracted TB biomarkers.   
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